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Chemotherapy treatment in premenopausal women has been linked to premature 
ovarian failure (POF), and hence infertility, through ovarian follicle loss. The exact 
mechanisms that lie behind this loss are unclear and so the action of two commonly 
used chemotherapeutic agents were compared here. Cisplatin is a DNA cross-linking 
agent commonly used in the treatment of ovarian, lung and bladder cancers, while 
the anthracycline doxorubicin is commonly used to treat leukaemia and breast 
cancer. Neonatal mouse ovaries were cultured in vitro and exposed to cisplatin or 
doxorubicin in order to determine their effects on primordial and early growing 
follicles. Both drugs caused a dose dependant follicle loss but targeted different cell 
types. Cisplatin caused a significant increase in follicles with unhealthy oocytes; 
furthermore primary stage follicles were the follicle class most affected (up to 98% 
classified as unhealthy compared with 13% in control, p<0.001). In contrast, 
doxorubicin caused a significant increase in follicles with unhealthy granulosa cells 
and affected all follicle stages present. When the mechanism of cell death was further 
investigated, apoptosis was the main pathway through which these drugs cause 
ovarian cell death. Doxorubicin in particular caused a significant increase in 
apoptosis of ovarian somatic cells including the granulosa cells and stroma. Imatinib 
mesylate, a tyrosine kinase inhibitor which is also used as a chemotherapeutic agent, 
has been implicated as a potential therapy to block the ovotoxic effects of cisplatin. 
Results here confirm this finding (29% of follicles classified as unhealthy in the 
cisplatin only group compared to 8% in the cisplatin and imatinib co-treatment 
group, p<0.001) and found further, that imatinib was unable to protect against 
doxorubicin-induced damage (28% of follicles classified as unhealthy in the 
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doxorubicin treated group compared to 19% in the doxorubicin and imatinib co-
treatment group). Imatinib treatment alone in newborn ovaries caused a significant 
increase in the number of follicles present at the end of culture compared to control 
(402±43 in the imatinib group compared to 188±34 in control, p<0.001), which is 
likely due to an effect on follicle formation. In conclusion, the work presented in this 
thesis demonstrates drug specific actions of cisplatin and doxorubicin on the mouse 
ovary. This suggests that any therapy designed to confer ovarian protection in the 
future may have to be tailored to be drug specific. 
 
 v 
Publications arising from this work 
 
Morgan, S., Anderson, R. A., Gourley, C., Wallace, W. H. B., and Spears, N. (2012). 
How do chemotherapeutic agents damage the ovary? Human Reproduction Update 
18, 525-35. 
 
Morgan, S., Lopes, F., Gourley, C., Anderson, R. A., and Spears, N. (2013). 
Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; 
Imatinib Provides Selective Protection Only against Cisplatin. PloS One 8, e70117.
 vi 
Abstracts for poster presentations 
 
Stephanie Morgan, Richard Anderson and Norah Spears. 
The effect of cisplatin on the ovary 
Fertility 2010 
 
Stephanie Morgan, Richard Anderson and Norah Spears 
The effect of cisplatin and doxorubicin on the ovary. 
Reproductive Function and Dysfunction, 2011. 
 
Stephanie Morgan, Richard Anderson and Norah Spears. 
Cisplatin and doxorubicin cause ovarian cell death through apoptosis not 
autophagy.  
Society for the Study of Reproduction, 2013. 
 vii 
Assistance given throughout this investigation 
All work detailed throughout this thesis was conducted by myself with the following 
exceptions: 
Chapter 3: Assessment of follicle distribution over the 6 day newborn mouse ovary 
culture was done by Federica Lopes. I was helped in the setting up of the bovine 
cultures by Marie McLaughlin. 
Chapter 4. TUNEL experiments and analysis conducted by Federica Lopes. 
Chapter 5. Slides from etoposide-treated ovaries donated by Agnes Stefansdottir. 
Chapter 6. Preliminary imatinib dose response experiment was done by Sampurna 
Ghosh. Victoria Conrath (undergraduate student) under my supervision assisted in 
initial imatinib newborn cultures. 
Histology: Processing of mouse ovarian tissue after fixation and embedding into 
paraffin was conducted by Vivian Allison or Louise Dunn.  
 viii 
Acknowledgements 
First and foremost, I would like to thank my supervisor Norah Spears whose support, 
kindness and approachability has made this whole process so much easier. Also, 
thank you to Richard Anderson, who has been so supportive and encouraging 
throughout. A massive thank you to Alison Murray, who took me under her wing 
within the first few days and pretty much taught me everything I know. Thank you to 
Evelyn Telfer for all her support and advice, especially about the dissociation 
experiments. A big thank you to Marie McLaughlin, for being so kind, encouraging 
and always being willing to offer advice, support and cake. Thanks to Federica for 
sharing the load! Agnes, thank you for being so understanding of my constant 
encroaching on both your lab and desk space and for providing friendship and chat 
throughout. Mike Molinek, Rowena Smith and rest of the Coffee Club, for all your 
advice over the years, your friendship and for so often providing an ear to vent my 
frustrations into.  
Thankyou to all who helped and advised me on the various experiments throughout. 
As well as those listed above, I am so grateful to Pan Filis, who very kindly taught 
me how to do Western Blotting and QPCR. To all the students who I have 
supervised- thanks for making it easier! 
A massive thank you to my family and friends for putting up with me, especially the 
flatmates for allowing me to so often shirk cleaning duties in the final stretch and 
always having a glass of wine handy! On that note, I must also thank the 
manufacturers of Bombay Sapphire gin, Butterkist popcorn and the makers of 
Breaking Bad for getting me through the write up. 
 ix 
Table of Contents 
Abstract                   iii 
Publications arising from this work                v 
Abstracts for Poster presentations                vi 
Assistance given throughout this investigation              vii 
Acknowledgements                  viii 
Table of Contents                     ix 
List of Figures                  xvi 
List of Tables                   xix 
Abbreviations                  xx 
 
Chapter 1. Introduction        pg 
1.1. General overview of the ovary     
 2 
1.1.1. Follicle Formation      2 
1.1.2. Follicle Activation      4 
1.1.3. Ovarian Reserve      5 
1.1.4. Early Folliculogenesis     8 
1.1.5. Late Folliculogenesis      9 
1.1.6. Apoptosis       12 
1.1.7. Ovulation       15 
1.1.8. Fertilisation       16 
1.1.9. Preimplantation development     19 
1.2.  In Vitro culture of Ovarian Tissue     20 
 x 
1.3.  Chemotherapy and Premature Ovarian Failure   
 22 
1.3.1. Potential Targets in the ovary     26 
 1.3.1.1. Follicle Class      26 
 1.3.1.2. Germ or Somatic cells    27 
1.3.1.3. Non Ovarian Effects      33 
1.4. Chemotherapy and Male infertility     33 
1.5. Chemotherapeutic agents       35 
 1.5.1. Cyclophosphamide      35 
 1.5.2. Cisplatin       36 
 1.5.3. Doxorubicin        38 
1.6. Hypothesis        42 
 1.7. Aim of this PhD        42 
 
Chapter 2. General Materials and Methods     43 
 
2.1. Newborn Ovary Dissection      44 
 2.1.1. Dissection Medium      44 
 2.1.2. Gross Dissection      44 
 2.1.3. Fine Dissection       45 
2.2. Newborn Ovary Culture       45 
 2.2.1. Newborn Ovary Culture Medium    45 
 2.2.2. Newborn Ovary Culture     46 
2.3. Chemotherapeutic Agent Stock Solutions    46 
 2.3.1. Cisplatin       46 
 2.3.2. Doxorubicin        46 
2.4. Histology         47 
 2.4.1. Fixing and Processing      47 
 2.4.2. Haemotoxylin and Eosin     48 
 xi 
2.5. Follicle Counting        48 
2.6. Statistical analysis       51 
 
Chapter 3. The effect of cisplatin and doxorubicin on the ovarian follicle 
population          52 
3.1. Introduction        53 
3.1.1. Known effects of cisplatin on follicles    53 
3.1.2. Known effects of doxorubicin on follicles   53 
3.1.3. The mouse ovary as an in vitro model    54 
3.1.4. The bovine ovary as an in vitro model    56 
3.1.5. Aims        57 
3.2. Materials and Methods       58 
3.2.1. Animals        58 
3.2.2. Experiment 3.1. Preliminary mouse cultures   58 
3.2.3. Experiment 3.2. Preliminary bovine cultures   58 
3.2.4. Experiment 3.3.       59 
3.2.5. Histology       60 
3.2.6. Statistical analysis      61 
3.3. Results         62 
3.3.1. Comparison of mouse and cow as model species  62 
3.3.2. The effect of cisplatin and doxorubicin   64 
3.4. Discussion        83 
3.4.1. Comparison of mouse and cow as model species  83 
3.4.2. Comparison of cisplatin and doxorubicin   84 
3.4.2.1. The effect of cisplatin    85 
3.4.2.2. The effect of doxorubicin    86 
3.4.3. Stromal effects       87 
 xii 
3.4.4. Conclusions       88 
 
Chapter 4. Molecular mechanisms by which cisplatin and doxorubicin induce 
cell death          89 
4.1. Introduction        90 
4.1.1. Apoptosis       90 
4.1.1.2. Markers of apoptosis     91 
4.1.2. Autophagy       95 
4.1.3. Necrosis       97 
4.1.4. Aims        98 
4.2. Materials and Methods                100 
4.2.1. Animals                 100 
4.2.2. Newborn ovary culture               100 
4.2.3. RNA extraction                101 
4.2.4. RNA gel                103 
4.2.5. cDNA synthesis               103 
4.2.6. Primer design                104 
4.2.7. Quantitative PCR               106 
4.2.8. qPCR analysis                107 
4.2.9. Protein extraction               107 
4.2.10. Western blotting               108 
4.2.11. Statistical analysis               109 
4.3. Results                  110 
4.3.1. Expression of autophagy-associated genes            110 
4.3.2. Cleaved PARP protein expression             110 
4.4. Discussion                 116 
4.4.1. Cell death is unlikely to occur via autophagy            116 
 xiii 
4.4.2. Apoptosis is likely to be involved in cell death           117 
4.4.3. Conclusion               119 
  
Chapter 5. Cell localisation of apoptosis              120 
 
5.1. Introduction                 121 
5.1.1. Cleaved PARP                121 
5.1.2. Caspase-3                122 
5.1.3. γH2AX                 123 
5.1.4. Aims                          124 
5.2. Materials and Methods                125 
5.2.1. Animals                 125 
5.2.2. Newborn ovary culture               125 
5.2.3. Histology                125 
5.2.4. Immunohistochemistry using DAB staining            126 
5.2.4.1. Counting and analysis             127 
5.2.5. Immunofluorescence               128 
5.2.6. Statistical analysis               129 
5.3. Results                  130 
5.3.1. Cleaved PARP                130 
5.3.2. Cleaved Caspase-3               130 
5.3.3. γH2AX                 131 
5.4. Discussion                 141 
5.4.1. Cisplatin                141 
5.4.2. Doxorubicin                142 
5.4.3. γH2AX                 144 
5.4.4. Future work                145 
5.4.5. Conclusion                146 
 xiv 
 
Chapter 6. The ability of imatinib mesylate to protect the ovary from cisplatin- 
and doxorubicin- induced damage                147 
 
6.1. Introduction                 148 
6.1.1 Current options to protect fertility             148 
6.1.1.1. Cryopreservation             148 
6.1.1.2. GnRH agonists/antagonists            149 
6.1.2. Potential protective treatments             151 
6.1.2.1. Ceramide              151 
6.1.2.2. AS101              152 
6.1.2.3. Dexrazoxane              153 
6.1.2.4. Tamoxifen                                    154 
6.1.2.5. Amifostine              155 
6.1.2.6. Antioxidants              156 
6.1.2.7. Imatinib              157 
6.1.3. Aims                158 
6.2. Materials and Methods               159 
6.2.1. Animals                159 
6.2.2. Imatinib stock solution              159 
6.2.3. Newborn ovary culture              159 
6.2.4. P4 ovary culture              160 
6.2.5. Histology               160 
6.2.6. Statistical analysis              160 
6.3. Results                 161 
6.3.1. Newborn ovary cultures             161 
6.3.2. P4 cultures               162 
 xv 
6.4. Discussion                171 
6.4.1. Imatinib’s protective effect             171 
6.4.2. Imatinib and follicle formation             172 
6.4.3. Imatinib and follicle recruitment            173 
6.4.4. Imatinib as a clinical treatment             174 
6.4.5. Conclusion               175 
 
 
Chapter 7. Discussion               176 
 
7.1. Summary of results              177 
7.2. Future work and considerations             182 
7.2.1. Extending the mouse in vitro model           182 
7.2.2. Protective treatments             184 
7.2.3. Mutagenesis, epigenetics and transgenerational changes    185 
 7.2.3.1. Cisplatin and doxorubicin as mutagens        187 
 7.2.3.2. Protective treatments and mutagenesis        188 
 7.2.3.3. Epigenetic modifications          188 
 7.2.3.4. Transgenerational changes          189 
 7.2.3.5. Proposed experimental model         190 
7.2.4. Targeted chemotherapy treatments and personalized medicine  
                 192 
References                193 
Appendix A. List of suppliers             226 
Appendix B. Published work              227 
 xvi 
List of Figures 
1.1 Summary of Folliculogenesis       11 
1.2 Summary of major factors involved in apoptosis in the ovary   14 
1.3 Possible targets in the ovary       29 
1.4 Potential mechanisms by which chemotherapy may cause cell death  41 
2.1. Examples of follicles classified due to their morphology   50 
3.1. Change in follicle distribution over a six day newborn ovary culture  56 
3.2. Percentage of follicle following cisplatin exposure in newborn ovaries  68 
3.3. Percentage of transitional and primary follicle classified as unhealthy  69 
3.4. Representative histological pictures of bovine cortical strips   70 
3.5. Percentage of unhealthy follicles in bovine cortical strips exposed to cisplatin 72 
3.6. Comparison of follicle distribution in mouse and bovine cultures  73 
3.7. Representative histological pictures of newborn mouse ovaries   75 
3.8. Cisplatin and doxorubicin lead to loss of follicle health and follicle number 77 
3.9. Number of remaining primordial follicles     78 
3.10. Unhealthy follicles classified into follicle type     79 
3.11. Unhealthy follicles classified according to follicle cell type   81 
3.12. Oocyte and follicle size        82 
4.1. TUNEL analysis in primordial follicles      94 
4.2. Brief summary of autophagy       97 
4.3. Summary of RNA extraction                 102 
4.4. cDNA synthesis protocol                  104 
 xvii 
4.5. mRNA expression of Becn1 relative to Gapdh               112 
4.6. Representative Western blots for Cleaved PARP and β actin             113 
4.7. Protein expression of Cleaved PARP following cisplatin over 24 hours          114 
4.8. Protein expression of Cleaved PARP following cisplatin and doxorubicin 
treatment                   115 
5.1. Example of section analysis                         128 
5.2. Representative immunohistochemistry images for cleaved PARP           133 
5.3. Number of cleaved PARP cells, oocytes and somatic cells            134 
5.4. Number of cleaved PARP granulosa and stromal cells             135  
5.5. Representative immunohistochemistry images for cleaved caspase-3           136 
5.6. Number of cleaved caspase-3 positive cells, oocytes and somatic cells           137 
5.7. Number of cleaved caspase-3 positive granulosa and stromal cells          138 
5.8. Expression of cleaved caspase-3 in the stroma resembling blood vessels       139 
5.9. Expression of γH2AX                140 
6.1. Representative histological sections of treated newborn ovaries           164 
6.2. Percentage of unhealthy follicles and total follicle number in treated newborn 
ovaries                  166 
6.3. Representative histological sections of treated P4 ovaries           167 
6.4. Percentage of unhealthy follicles and total follicle number in P4 ovaries     169 
6.5. Follicle distribution in P0 and P4 ovaries           170 
7.1. Summary of the different mechanisms through which cisplatin and doxorubicin 
cause follicle loss.                              178 
 xviii 
Fig 7.2. Potential mechanism by which cisplatin and doxorubicin could cause ovarian 
cell death                 180 
 xix 
 
List of Tables 
Table 1.1. Summary of major factors involved in the maintenance of the ovarian 
reserve.          7 
Table 1.2. Summary of the major factors involved in apoptosis and their role in the 
ovary.           13 
Table 1.3. Major risk factors associated with diminished ovarian reserve and POF 23 
Table 1.4. Summary of literature which examines direct action of chemotherapy on 
the ovary          31 
Table 3.1. Total number of follicles counted in newborn mouse ovaries treated with 
cisplatin          67 
Table 3.2. Total number of bovine follicles counted in cortical strips treated with 
cisplatin          71 
Table 3.3. Total number of mouse follicles counted in each treatment group in 
Experiment 3.3         76 
Table 4.1. Primer sequences designed for qPCR analysis              106 
Table 4.2. Reaction mix for qPCR analysis                106 
Table 6.1. Total number of follicles counted in newborn mouse ovaries cultured in 
the presence or absence of imatinib                165 
Table 6.2. Total number of follicles counted in P4 mouse ovaries cultured in the 







ABL. Abelson murine leukemia viral oncogene homolog 
ABVD. Adriamycin, bleomycin, vinblastin, dacarbazine 
ABVE. Adriamycin, bleomycin, vinblastine, etoposide 
AC. Adriamycin, cyclophosphamide 
ACTD. Adriamycin, cyclophosphamide, actinomycin D 
ADE-GMTZ. Arabinoside-C, Daunorubicin, Etoposide, Gemtuzumab 
ozogamicin 
ADP. Adenosine Diphosphate 
AI. Arabinoside cytoside, idarubicin 
AIE. Arabinoside cytosine, idarubucin, etoposide 
AMH. Anti Müllerian Hormone 
AMP. Adenosine Monophosphate 
APAF-1. Apoptotic protease activating factor 1 
AS101. Ammonium tri-chloro(dioxoethylene-O,O’-)tellurate 
 xxi 
ATG7. Autophagy-related protein 7 
ATG13. Autophagy-related protein 13 
ATP. Adenosine Triphosphate 
BCL2. B-cell lymphoma 2 
BEA. Bleomycin, etoposide, adriamycin 
BEACOPP. Bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, prednisone. 
BMP-15. Bone Morphogenetic Protein-15 
BSA. Bovine Serum Albumin 
CAF. Cyclophosphamide, adriamycin, 5-flourouracil  
CC3. Cleaved Caspase 3 
cDNA. Complementary Deoxyribonucleic Acid 
CHOP. Cyclophosphamide, doxorubicin, vincristine, prednisone 
CMF. Cyclophosphamide, Methotrexate and 5-fluouracil 
COAP. Cyclophosphamide, vincristine, cytosine arabinoside, prednisone 
COPP. Cyclophosphamide, oncovin, procarbazine, prednisone 




DNA. Deoxyribonucleic Acid 
DNR. Daunorubicin 
E. Embryonic Day 
E-PIE. Etoposide, cisplatin, I-fosphamide 
FBS. Foetal Bovine Serum 
FOXO3a. Forkhead box O3 
FSH. Follicle Stimulating Hormone 
GAPDH. Glyceraldehyde 3-phosphate dehydrogenase 
GDF-9. Growth Differentiation Factor-9 
GMALL. Methotrexate, cyclophosphamide, vincristine, daunorubicin, 
asparginase, cytarabine, 6-mercapto-purine, etoposide 
GMP. Guanosine Monophosphate 
GnRH- Gonadotrophin Releasing Hormone 
GVBD. Germinal Vesicle Breakdown 
HAM. High dose arabinoside cytosine, mitoxantrone 
hCG. Human Chorionic Gonadotrophin 
I-Fos. I-fosfamide 
ICM. Inner Cell Mass 
 xxiii 
IL. Interleukin 
IVF. In vitro Fertilisation 
IVM. In Vitro Maturation 
JET. Carboplatin, etoposide 
LH. Luteinizing Hormone 
MECC. Melphalan, etoposide, citarabin, carmustine 
MII. Meiotic arrest, stage two 
MINE EASHAP. Mesna, ifosfamide, mitoxantrone, etoposide, cytosine 
arabinoside, cis-platinum and steroids 
MPF. Maturation Promoting Factor 
mRNA. Messenger Ribonucleic Acid 
MTX. Methotrexate 
MVH. Mammalian Vasa Homolog 
NAD. Nicotinamide Adenine Dinucleotide 
NER. Nucleotide Excision Repair 
P. Postnatal day 
P. Procarbazine 
PBS. Phosphate Buffered Saline 
 xxiv 
PCR. Polymerase Chain Reaction 
PDGF. Platelet Derived Growth Factor 
PMF. Primordial Follicles 
PMSG. Pregnant Mare Serum Gonadotrophin 
PND. Postnatal Day  
POF. Premature Ovarian Failure 
Pr. Prednisone 
PTEN. Phosphatase and Tensin Homolog 
PVD. Prednisone, vincristine, doxorubicin 
RNA. Ribonucleic acid 
RT. Reverse Transcriptase 
S1P. Sphingosine-1-phosphate 
SDS. Sodium dodecyl sulphate 
SEM. Standard error of the mean 
SCF. Stem Cell Factor 




TNF. Tumour necrosis factor 
TSC-2. Tuberous Sclerosis 2 
TUNEL. Terminal deoxynucleotidal transferase dUTP nick end labelling 
ULK1. Unc-51 like autophagy activating kinase 1 
V. Vincristine 
VACOP-B. Doxorubicin, cyclophosphamide, vincristine, bleomycin, 
etoposide 
 VC. Vincristine, cyclophosphamide 
 VCAIE. Vincristine, cyclophosphamide, arabinosidecytosine, idarubicin, 
etoposide 
 VMTX. Vincristine, methotrexate 















1.1 General Overview of the Ovary 
By the time of birth in humans, the ovary contains all the germ cells required for the 
reproductive lifespan of the female. These germ cells are maintained within 
primordial follicles, a functional unit which consists of a germ cell, oocyte, 
surrounded by a few flattened pregranulosa cells. At birth, there are approximately 1-
2 million primordial follicles within the ovary, by the onset of puberty there are 
300,000 remaining. These primordial follicles can remain in a dormant state for the 
full reproductive lifespan before being activated to grow. At any one time, small 
cohorts of these follicles are recruited out of the resting primordial pool and are 
activated to grow. This process is continuous until there are no follicles remaining; 
when fewer than a thousand remain, this is defined as the onset of the menopause 
(Wallace and Kelsey, 2010). In this thesis, the mouse was used as a model and so is 
the species that will be referred to throughout. 
1.1.1 Follicle Formation 
Primordial germ cells (oocyte precursors) arise during embryonic gastrulation and 
actively migrate through the hindgut epithelium and dorsal mesentery to the site of 
the genital ridge, arriving there around embryonic day (E) 11.5 (Molyneaux et al, 
2001). The primordial germ cells are then referred to as oogonia and undergo mitotic 
divisions, forming germ cell nests (also called cysts) in which the cells are connected 
through intercellular bridges (Pepling, 2012). These germ cell nests are surrounded 
by somatic cells which invade the ovary and are generally thought to be derived from 
the ovarian surface epithelium (Sawyer et al, 2002). The oogonia divide mitotically 
until around E13.5 (in humans this corresponds to around week 13 of gestation), after 
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which they enter prophase 1 of meiosis, arrest in the diplotene phase and enlarge; 
thereafter they are referred to as oocytes. The somatic cells surrounding the nests 
closely associate with the oocytes and differentiate into follicular granulosa cells. 
Germ cell nest breakdown occurs around the time of birth in mice during which 
oocytes separate and are surrounded by pregranulosa cells to form primordial 
follicles. In humans, primordial follicles are first seen between 16 and 21 weeks of 
gestation (Konishi et al, 1986). Only a third of the oocytes which undergo cyst 
breakdown survive; the rest die through a process of programmed cell death. Once 
granulosa cells have surrounded the oocyte, the follicle is encompassed by a 
basement membrane. 
Oocyte loss during germ cell nest breakdown is substantial and postulated to be a 
quality control mechanism whereby the ‘best’ oocytes are preferentially selected to 
become primordial follicles (Tingen et al, 2009). The mechanism by which so many 
oocytes are lost is likely to be apoptosis with the bulk of evidence implicating the 
Bcl2 (B-cell lymphoma 2) family as being key regulators of this process (De Felici et 
al, 1999). However recent evidence has also implicated autophagy as an important 
cell death mechanism in cyst breakdown (De Felici et al, 2008).  
Due to the fact that the oocytes have entered meiosis, the population of primordial 
follicles is fixed by the time of birth and will be continuously depleted over the 
reproductive lifespan. Although this has been recently challenged with studies 
suggesting the existence of female germline stem cells (Johnson et al, 2004; White et 
al, 2012; Zou et al, 2009), the conventional view is that the primordial follicle 
reserve is finite, meaning that any toxic insult to this pool is likely irrevocable. The 
existence of these stem cells is still controversial and in my opinion, there is 
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currently no robust evidence for the existence of germ stem cells in the postnatal 
ovary which function in vivo.  
1.1.2 Follicle Activation  
The mechanism by which primordial follicles activate, while still not fully 
understood, has been largely elucidated following in vitro work which demonstrated 
widespread activation of bovine primordial follicles in culture due to the removal of 
inhibitory signals (Wandji et al, 1996) and several rodent gene knockout models. The 
activation of primordial follicles is orchestrated through a variety of local paracrine 
factors including several inhibitory signals such as Foxo3a (Forkhead box O3, 
Castrillon et al, 2003), Tsc-2 (Tuberous sclerosis 2, Adhikari et al, 2009), p27 
(Rajareddy et al, 2007) and PTEN (Phosphatase and tensin homolog, Reddy et al, 
2008). As primordial follicles activate, the flattened pre-granulosa cells that surround 
the oocyte proliferate and become cuboidal to form a single layer; this is defined as a 
primary follicle. During this transition, the oocyte increases in size and the zona 
pellucida forms. The zona pellucida is a matrix composed of four glycoproteins, ZP1, 
2, 3, and 4 which envelops the oocyte (Rankin et al, 2000), with the granulosa cells 
maintaining their close association with the oocyte through gap junctions which 
penetrate the zona (Carabatsos et al, 2000). In the mouse only ZP1, 2, and 3 are 
expressed in the zona pellucida (Bleil and Wassarman, 1980). 
The growth of primary follicles is largely gonadotrophin-independent and is likely 
reliant on a variety of paracrine and autocrine signals. When isolated, primary 
follicles degenerate rapidly in culture, indicating a reliance on the other cell types in 
the ovary including stromal cells as well as other follicles (Hornick et al, 2013). 
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Follicles which are growing are often surrounded by other growing follicles, perhaps 
indicating that they have a stimulatory effect upon each other’s growth (Da Silva-
Buttkus et al, 2009).  
1.1.3 Ovarian Reserve 
The ovarian reserve describes the population of primordial follicles remaining in the 
ovary. The conventional view is that this reserve is finite once established, and is 
depleted over time by both degeneration and the activation of follicles into the 
growing population. The factors that govern these processes therefore are vital to the 
maintenance of the primordial follicle reserve and hence a females reproductive 
lifespan (Kerr et al 2013). Major factors which are known to be involved in these 
processes are listed below (Table 1.1). 
 6 
Table 1.1. Summary of the major factors involved in the maintenance of the ovarian 
reserve. This involves factors/pathways which regulate primordial germ cell number, 
primordial follicle formation and follicle activation. 
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FIGα x Required for x Soyal et al 2000 
Dazla  Increases/is 
necessary for 
maintenance of 
x x Ruggiu et al 1997 
Grem1  Increases Accelerates x Myers et al 2011 
Bax Reduces x x Greenfeld et al 
2007 
Bcl2 Increases x x Flaws et al 2001 
Activin A Increased 
survival  
x x Martins da Silva et 
al 2004 
Neurotrophins Reduces x x Spears et al 2003 
Pten x x Suppressor Reddy et al 2008 
Foxo3a x x Suppressor Castrillon et al 
2003 
Tsc1 x x Suppressor Adhikari et al 2010 
Tsc2 x x Suppressor Adhikari et al 2009 
p27 x x Suppressor Rajareddy et al 
2007 
AMH x Suppressor Suppressor Durlinger et al 
1999, Nilsson et al 
2011 
Kit ligand  x ? Activator Nilsson and 
Skinner 2004 
PDGF x ? Activator Nilsson et al 2006 
GDF9 x x Activator Dong et al 1996 





1.1.4 Early folliculogenesis 
As the follicle progresses from the primary stage, the granulosa cells continue to 
proliferate and form multiple layers, the oocyte continues to grow and a thecal cell 
layer is recruited. The thecal layer becomes heavily vascularized, reflecting the 
dependence of the preantral follicle on endocrine support. Fluid filled patches then 
form in the granulosa cell layers, which coalesce to form an antral cavity (Fig 1.1.). 
The exact function of the antral cavity is unclear but is considered to be a nutrient 
store as well as potentially aiding in the maintenance of the correct pH and as a sink 
for oocyte and granulosa cell waste products.  
The cells of the follicle are interdependent on each other for the correct growth and 
development, with the oocyte considered to be the driving force behind overall 
follicle development (Eppig et al, 2002). Bidirectional communication between the 
oocyte and somatic cells of the follicle is essential and so must be tightly 
coordinated. The oocyte interacts with the granulosa cells through gap junctions 
which are channels formed from connexin proteins. The importance of these to 
oocyte growth and development is highlighted by mice lacking the connexin-37 
gene, which fail to exhibit mature Graffian follicles, ovulate, have premature 
luteinization and do not show meiotic competence (Simon et al, 1997). The oocyte 
produces factors such as GDF-9 (Growth Differentiation Factor-9, McGrath et al, 
1995) and BMP-15 (Bone Morphogenetic Protein-15, Dube et al, 1998), which 
promote the proliferation and differentiation of the granulosa cells. In turn, the 
granulosa cells support oocyte growth and regulate its progression through meiosis. 
The oocyte increases in size, at least in part due to an increase in protein content, as 
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proteins essential for further development, maturation and preimplantation embryo 
development are synthesised.  
During gamete formation, epigenetic reprogramming occurs in a process including 
widespread demethylation and histone modifications (Seisenberger et al, 2013). This 
means that sex-specific imprinting needs to be established in the gametes and so 
another important part of oocyte development is epigenetic reprogramming, with 
maternal gene imprinting occurring as the oocyte grows (Lucifero et al, 2002). This 
is likely to occur through DNA methylation, with specific gene imprints established 
throughout primary to antral oocyte growth (Obata and Kono, 2002). This process is 
essential, as parthenogenetic embryos which express double copies of either the 
paternal or maternal genome arrest in early development (Surani et al, 1984).  
1.1.5. Late folliculogenesis 
Around the time the antral cavity develops, the oocyte stops growing but continues 
the process of nuclear maturation, developing the ability to resume meiosis, undergo 
fertilisation and support embryonic development. This process occurs whilst the 
oocyte is maintained in meiotic arrest, achieved through the interaction of the oocyte 
with its surrounding granulosa cells. It is thought that oocyte meiotic maturation is 
inhibited through a cyclic-AMP (Adenosine Monophosphate) dependant process 
(Eppig et al, 1983), levels of which are regulated by cyclic-GMP (Guanosine 
Monophosphate) produced by the granulosa cells and passed to the oocyte through 
gap junctions (Norris et al, 2009). High levels of cyclic-AMP suppress MPF 
(Maturation Promoting Factor, a complex of cyclin B and Cdc-2), maintaining 
meiotic arrest. 
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The early antral follicle is also dependant on the presence of follicle stimulating 
hormone (FSH) from the pituitary gland, which it is increasingly exposed to through 
the increased vasculature in the thecal cell layer. As well as inducing the 
proliferation of granulosa cells at this follicle stage, FSH also drives the expression 
of lutenising hormone (LH) receptors on the granulosa cells which are essential for 
ovulation and corpus luteum formation (Erickson et al, 1979). FSH also plays a key 
role in steroidogenesis, driving the production of oestradiol-17β in the granulosa 
cells. Aromatase, the enzyme crucial for oestradiol synthesis is expressed only in the 
granulosa cells in mice (Gray et al, 1995). To synthesise oestradiol, aromatase 
requires androgens as a substrate. The granulosa cells do not have the enzymes 
required for androgen production and so are reliant on androstenedione produced by 
the surrounding thecal cells. This is known as the 2 cell/2gondaotrophin model of 
steroidogenesis (Hillier et al, 1994). 
As the antral cavity forms, the granulosa cells differentiate to become two distinct 
populations (Telfer et al, 1988). Those adjacent to the oocyte differentiate to become 
the cumulus cells, which remain attached to the oocyte and are ovulated with it. The 
oocyte retains contact with these cells through gap junctions, allowing for the 
cumulus cells to supply nutrients that allow for further development as well as 
keeping the oocyte in meiotic arrest (Eppig and Downs, 1984). Those closest to the 
follicle wall become the mural granulosa cells, which remain behind following 
ovulation and regress to form the corpus luteum. The final phase of preovulatory 
development involves a massive increase in follicle size, due to the increase in the 
volume of follicular fluid. 
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Fig 1.1. Diagrammatic illustration of Folliculogenesis. At any one time, a small 
cohort of primordial follicles are recruited out of the resting pool and activated to 
grow. Of the follicles that are activated, only one will make it to the preovulatory 
stage and be ovulated; the others will die from follicle atresia. Although the majority 
of follicles which are lost from atresia are from the antral stage (indicated by the 
solid lines), follicles can be lost from any stage of folliculogenesis (indicated by the 
dashed lines). Adapted from Morgan et al, 2012. 
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1.1.6. Apoptosis  
The ovary is the site of a large amount of cell death physiologically, the majority of 
which appears to occur through apoptosis. Apoptosis has been shown to have an 
important role in establishing the primordial germ cell population, follicle atresia as 
well as corpus luteum regression (evidence summarised in Table 1.2). Apoptosis is a 
well-defined mechanism of programmed cell death which is characterised by distinct 
morphological changes including cell shrinkage, membrane blebbing and DNA 
fragmentation. The canonical apoptosis pathway is an energy-dependant molecular 
cascade, which can be activated by intrinsic factors or extrinsic stimuli (e.g. Tumour 
necrosis factor [TNF]). The disruption of mitochondrial function plays a key role, 
including loss of transmembrane potential and release of cytochrome c into the 
cytosol. From there, cleavage/activation of caspase-9 allows for the 
cleavage/activation of other downstream members of the caspase family which 
subsequently cleave target proteins including PARP-1 (poly[ADP-ribose] 
polymerase 1) (Fig 1.2.).   
 13 
 
Gene Action Ovarian Phenotype/Role in the 
ovary  
Reference 
Bax Pro-apoptotic Increased germ cell numbers (-/-) Greenfeld et al 
2007 
Bcl2 Pro-survival Increased primordial follicle 
numbers at birth (overexpressed) 
Flaws et al 2001 
Protected from normal and 
chemotherapy induced apoptosis 
(oocyte specific expression) 
Morita et al 1999 
Bid Pro-apoptotic Involved in granulosa cell apoptosis Sai et al 2011 
Caspase-2 Pro-apoptotic Involved in radiation-induced 
oocyte death  
Hanoux et al 2007 
Caspase-3 Pro-apoptotic Required for granulosa cell 
apoptosis 
Matikainen et al 
2001 
Expressed in corpus luteum Carambula et al 
2002 
Caspase-9 Pro-apoptotic Involved in neonatal oocyte loss Ene et al 2013 




p53 Pro-apoptotic Granulosa cell apoptosis Tilly et al 1995 
TAp63 Pro-apoptotic Oocyte specific death Gonfloni et al 
2009 
Fas ligand Pro-apoptotic Granulosa cell apoptosis Yang et al 2012 




c-KIT Pro-survival Improved oocyte survival De Felici et al 
1999 
 
Table 1.2. Summary of some of the major factors involved in apoptosis and their 
role in the ovary. 
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Fig 1.2. Summary of some of the major factors involved in the canonical apoptotic 
pathway and how they interact with each other. Black arrows indicate activation, flat 
ended arrows indicate repression and red arrows indicate cleavage/activation. 
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1.1.7 Ovulation 
Ovulation is dependent on a massive surge in LH released from the pituitary gland, 
receptors for which are expressed on the granulosa and theca cells (Jeppesen et al, 
2012). Within a few hours of this surge, germinal vesicle breakdown (GVBD) 
occurs, signalling the resumption of meiosis in the oocyte. This will continue until 
the first meiotic cell division, an asynchronous division in which half of the 
chromosomes are ejected from the oocyte but with little cytoplasm (Maro and 
Verlhac, 2002). This forms the first polar body which sits under the zona pellucida 
layer. The oocyte continues into the second phase of meiosis until the chromosomes 
are aligned on the spindle in metaphase (MII oocytes). Meiotic arrest then resumes 
until fertilisation occurs. 
The LH surge induces the expression of genes crucial to ovulation in the granulosa 
cells of the preovulatory follicle, including progesterone receptors and prostaglandins 
(Richards et al, 1998). Morphologically, the ovary becomes swollen and red which 
are characteristics of an inflammatory response. Leukocytes and macrophages are 
recruited to the site as well as factors including cytokines, histamine and 
prostaglandins (Espey, 1994).  At the apex of the follicle, the basement membrane 
degrades (Reich et al, 1985) and so the follicle ruptures, releasing the oocyte with its 
attached cumulus cells and some follicular fluid adjacent to the fimbriae of the 
infundibulum of the oviduct. The infundibulum has cilia which help collect the 
oocyte-cumulus complex and guide it into the oviduct (Hunter, 1998).  
The mural granulosa cells which remain behind divide rapidly and then hypertrophy 
to form large luteal cells which produce increasing quantities of progestagens. 
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Remaining thecal cells also form luteal cells, which produce progestagens as well as 
androgens. The whole structure becomes heavily vascularized and is referred to as 
the corpus luteum.   
1.1.8 Fertilisation 
The oocyte is conveyed along the oviduct to the ampulla region, a process which is 
classically attributed to a combination of cilia beating and smooth muscle 
contractions. Cilia beating is potentially mediated through the progesterone receptor, 
which is expressed in the cilia of the oviducts epithelial cells (Teilmann et al, 2006). 
The oviduct is lined with smooth muscle, slow wave contractions of which also 
contribute to oocyte transport (Dixon et al, 2011). Once the oocyte arrives in the 
ampulla, it attaches to the oviductal epithelium through the cumulus cells (Kolle et 
al, 2009)  
Spermatozoa enter the female reproductive tract where they capacitate. Capacitation 
involves the spermatozoa becoming hyperactive, with the flagella beating 
asymmetrically allowing for progressive motility (Chang and Suarez, 2010). This 
process also involves changes in membrane organisation and ion permeability 
(Visconti et al, 2011). The changes in the head of the spermatozoa make the 
acrosome cap unstable, allowing for the acrosome reaction to occur in response to 
the presence of the oocyte-cumulus cell complex (Zaneveld et al, 1991). Capacitation 
is essential, made clear by early experiments which demonstrated that sperm have to 
reside in the female reproductive tract before fertilisation can occur (Austin, 1952; 
Chang, 1951). Sperm bind the oviduct to form a sperm reservoir, seemingly allowing 
for the release of small quantities of them at a time, possibly as an additional control 
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to prevent polyspermy. The exact mechanism by which the sperm then detach from 
the oviduct is unclear but maybe due to their hyperactivity. Once they have detached, 
they have to recognize the correct direction to travel in order to approach the oocyte- 
cumulus complex. In mammals this has been attributed to chemotaxis, which is a 
crucial mechanism in invertebrates (Chang et al, 2013) and/or temperature gradients, 
whereby the sperm move towards increasing temperatures (Bahat et al, 2003). 
The spermatozoa approach the oocyte cumulus complexes which are in the ampulla 
region of the fallopian tube and penetrate through the cumulus cell layer to reach the 
zona. The cumulus cells are embedded in an extracellular matrix rich in hyaluron 
(Kim et al, 2008), therefore the sperm utilise hyaluronidase enzyme which digests a 
path through the cumulus cells, as well as their own motility. Spermatazoa then bind 
to the zona pellucida, the exact process of which remains somewhat controversial. In 
mice, initial experiments indicated that sperm binding is mediated through the ZP3 
protein (Bleil and Wassarman, 1983). Recent evidence suggests that in humans, ZP2 
is the key to this process as human sperm only binds to zona pellucidae expressing 
ZP2, either alone or co-expressed with the other ZP (Baibakov et al, 2012). It is 
generally assumed that this binding induces exocytosis of the contents of the 
acrosomal cavity; also known as the acrosome reaction. Recent evidence has 
suggested however that in mice, many spermatozoa begin the acrosome reaction 
before contact with the zona pellucida, suggesting that the cumulus cells may play a 
role in triggering this reaction (Jin et al, 2011). The acrosome reaction is essential for 
the sperm to penetrate the zona and fuse with the plasma membrane. As it is only 
acrosome reacted sperm which are capable of fusing to the oocyte membrane, it is 
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thought that the acrosome reaction allows the release of proteases such as acrosin 
which aid this binding (Howes and Jones, 2002).  
The plasma membrane of the oocyte is then modified to prevent any additional sperm 
from binding to the egg. This is a rapid process, occurring within minutes, but unlike 
other species, in humans it does not appear to be associated with changes in electrical 
potential (Jaffe et al, 1983) and the exact mechanism is unclear. In the mouse, fusion 
of the sperm head with the oocyte causes a calcium-dependant exocytosis of cortical 
granules, which contain enzymes that modify the plasma membrane (Ducibella et al, 
1994). A further block to polyspermy in most species occurs as ZP2 is cleaved to 
prevent more sperm binding (Burkart et al, 2012).  
The oocyte at this stage is still in meiotic arrest and so must undergo a further 
cleavage to complete MII. Fertilisation induces the second meiotic division, leading 
to the extrusion of a second polar body. This occurs due to the increase in 
intracellular calcium, which inhibits expression of MPF, the factor which maintains 
meiotic arrest. The paternal genome is decondensed, protamines are removed and the 
DNA is demethylated (Mayer et al, 2000). Shortly after fertilisation, nuclear 
membranes form around the maternal and paternal chromosomes, which become 
identifiable as two distinct pronuclei in the centre of the zygote. DNA replication 
occurs here before the nuclear membranes breakdown and the chromosomes 
assemble on the mitotic spindle (Bouniol et al, 1995). Cell division then occurs and 
the one cell zygote becomes a two-cell embryo, approximately 24 hours after 
fertilisation. The embryo at this stage is reliant on RNA and proteins which were 
present in the oocyte and synthesised during oogenesis. The zygote genome is 
activated at the late 1-cell to the mid 2-cell stage, allowing the embryo to produce its 
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own RNA and proteins and so most of the maternal mRNAs remaining at this stage 
are degraded (Paynton et al, 1988) 
1.1.9 Preimplantation Development 
Preimplantation development of the embryo is defined as the period in which the two 
cell embryo becomes a multicellular expanded blastocyst and implants into the 
endometrial lining of the uterus.    
Cell cleavages beyond the 2-cell stage occur as the embryo moves along the oviduct, 
with the embryo comprising 4 and then 8-cells, with individual cells called 
blastomeres. Following these 3 cell divisions, the embryo compacts to form a 
morula. The blastomeres become smooth and flattened and cell adhesions increase 
due to the formation of intracellular junctions meaning that cell boundaries are less 
distinct (Reima, 1990). The blastomeres also become polarized, with a dense 
population of microvilli appearing on their apical surface (Johnson and McConnell, 
2004). The blastomeres then specify into two distinct lineages. The trophectoderm 
(TE) forms as the outer epithelial layer of the blastocyst and will develop into the 
extraembryonic tissue including the placenta (Sasaki, 2010). The inner cells form the 
inner cell mass (ICM) which develops eccentrically with a fluid filled cavity 
(blastocoel) forming at the 32 cell stage. The blastocyst then hatches out from the 
zona pellucida and implants into the uterine endometrium. 
The environment of the oviduct and uterus needs to support the development of the 
zygote through to the blastocyst stage. Development to the blastocyst stage can be 
achieved in vitro, so much of our knowledge of the factors required in vivo has been 
derived from such experiments. An appropriate energy source is essential and whilst 
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the zygote preferentially metabolises pyruvate, the compacted morula and blastocyst 
utilise glucose as their main energy source (Hardy et al, 1989). Within the female 
reproductive tract, there is a carbohydrate gradient which reflects the needs of the 
embryo as it moves through and develops. This is why many in vitro fertilisation 
protocols utilise sequential media which are designed to support different stages of 
embryo development. Amino acids are also important and their addition to culture 
improves embryo viability (Gardner et al, 2002).  
Epigenetic reprogramming is a key event in early embryo development. The paternal 
genome is actively demethylated in the zygote, with a more passive demethylation of 
the maternal genome occurring through to the morula stage. At the blastocyst stage, 
de novo methylation of DNA occurs in the inner cell mass (Santos et al, 2002).  
1.2 In vitro culture of ovarian tissue 
In vitro culture of ovarian tissue has been a useful experimental tool to elucidate key 
events and regulators in the process of folliculogenesis. In the mouse, maturation 
from primordial follicles through to live young has been achieved in culture, 
indicating that in vitro conditions are highly physiological (O'Brien et al, 2003). Full 
maturation from primordial follicles to fertilisable oocytes in vitro has not yet been 
achieved in humans, although great strides forward have been made (Telfer and 
Zelinski, 2013). The large number of primordial follicles present in ovaries/ovarian 
biopsies makes them an attractive prospect for fertility preservation, as a system to 
achieve full maturation in vitro could have far reaching benefits for assisted 
reproduction, particularly for patients following chemotherapy treatment. Culture of 
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ovarian tissue also provides a useful research tool for toxicology testing of agents 
including chemotherapy. 
There are many challenges involved in the successful culture of ovarian material in 
vitro.  Optimisation of the culture medium is necessary if it is to adequately support 
the physiological needs of each cell type as well as the follicle as a unit. The base 
medium used varies and includes minimum essential medium (Spears, 1994), 
McCoys 5a (Telfer et al, 2008) and Waymouths (Eppig and O'Brien, 1996). The base 
medium is then often supplemented. Serum is a heavily debated additive, as it has a 
highly variable composition of substrates including hormones, proteins, 
carbohydrates and growth factors (Picton et al, 2008). Its addition is usually 
necessary as it acts to balance the osmolarity and can provide substrates for steroid 
biosynthesis. Serum is often replaced therefore with bovine serum albumin (BSA) or 
serum substitutes, which can successfully support follicle development (Telfer et al, 
2008). Other common additives include antibiotics, FSH, insulin, selenium, 
transferrin, ascorbic acid (Murray et al, 2001) and activin (Telfer et al, 2008). The 
differences in additives reflect the different species used and the changing 
requirements of each stage of follicle development.  
Rodent follicle culture is much further advanced than in other species, with such 
successes difficult to replicate in humans and other large ruminants. It is technically 
challenging to retrieve follicles from the ovarian cortex of these animals, due to the 
fibrous stroma (Telfer, 1996). Primordial follicles when isolated degenerate rapidly 
in culture, indicating that they require the support of other cells of the ovary (Hornick 
et al, 2013).  Primordial follicles can therefore be cultured successfully within pieces 
of ovarian cortex which provides them with the support of their surrounding cells, 
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maintains the three-dimensional structure of the tissue and can avoid damage from 
enzymatic retrieval procedures. 
For follicles to develop further, they must be isolated from the tissue at around the 
secondary stage, either mechanically or with enzymatic digestion although the use of 
enzymes can cause a loss of follicular integrity. Murine preantral follicles can be 
cultured in microdrops of culture medium overlayed with mineral oil, which support 
development from the mid-preantral stage to the Graffian stage. These follicles 
contain oocytes which are healthy and can be fertilised to produce live offspring 
(Spears et al, 1994). Other approaches for preantral culture include encapsulating the 
follicle in a matrix of collagen or alginate (Carroll et al, 1991; Xu et al, 2006). The 
final stage is in vitro maturation (IVM) of oocytes, which will support the maturation 
of oocytes through further meiotic progression to the MII stage. Whilst it still can be 
considered fairly experimental, IVM using human oocytes has been achieved 
clinically (Ferraretti et al, 2013).    
In vitro fertilisation of oocytes once matured is a well-established clinical technique 
to treat problems with fertility. It is estimated that 1-2% of births worldwide can be 
attributed to IVF technologies (Fortunato and Tosti, 2011). IVF has also greatly 
increased our understanding of the key events and factors required during early 
embryo development.  
1.3 Chemotherapy and Premature Ovarian Failure 
Advances in chemotherapy treatment are leading to increased survival rates among 
cancer patients. In premenopausal women, chemotherapy treatment has been linked 
to premature ovarian failure (POF) due to accelerated follicle loss. As well as its 
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detrimental effect on fertility, POF has a number of associated side effects including 
an increased risk of cardiovascular disease (Jeanes et al, 2007), osteoporosis 
(Bruning et al, 1990) and psychosocial problems such as depression (Carter et al, 
2005). Chemotherapy is not the only risk factor for the development of POF in 
premenopausal women; other major risk factors are summarised below (Table 1.3.).   
Genetic Reference 
Fragile X syndrome (e.g. FMR1 mutation carriers) De Caro et al 2008 
Turners syndrome and haploinsufficiency of X-linked genes  Goswami and Conway 
2005 
Autosomal gene deletion/mutations (e.g. GDF9, FOXL2, FSHR)  Jin et al 2012 
Family history of POF Van Kasteren et al 
1999 
Other risk factors  
Autoimmune disease Dragojević-Dikić et al 
2010 
Metabolic disease (e.g. galactosaemia) Fridovich-Keil et al 
2011 
Environmental/lifestyle toxins (e.g. 4-vinylcyclohexane diepoxide 
and cigarette smoke) 
Hoyer et al 2001 
Chemotherapy exposure Morgan et al 2012 
Radiotherapy Wo and Viswanathan 
2009 
 
Table 1.3. Major risk factors associated with diminished ovarian reserve and POF. 
The risk of developing POF following chemotherapy treatment is dependent on 
several factors. The chemotherapeutic regimen used is important, with data 
suggesting that some treatments, such as alkylating agents, are more gonadotoxic 
than others. Following treatment with alkylating agents, 42% of women developed 
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premature ovarian failure whilst those exposed to plant alkaloids or platinum agents 
had no significant increase in POF risk (Meirow, 2000). It has been estimated that 
60-80% of women who are treated with CMF (cyclophosphamide, methotrexate and 
5-fluouracil) will develop premature ovarian failure (Byrne et al, 1992). In women 
under the age of 20, those treated with alkylating agents were nine times more likely 
to develop premature ovarian failure than control patients (Bines et al, 1996; Lower 
et al, 1999). Dosage of treatment is another important factor as several studies have 
shown premature menopause to occur in a dose dependant manner (Chiarelli et al, 
1999). In mice, there was an increase in primordial follicle loss following increasing 
doses of cyclophosphamide (Meirow et al, 1999). 
Another crucial risk factor is the age of the patient, with an increased incidence in 
POF reported in older patients (Petrek et al, 2006). Older women have a smaller 
primordial follicle pool than younger patients at the start of treatment, so it could be 
that follicle loss from this smaller pool is more likely to induce POF by the end of 
treatment (Meirow, 2000).    
One of the major issues with studies designed to assess the risk of a patient 
developing POF following chemotherapy treatment, is the reliability and 
heterogeneity of methods used to assess the remaining follicle pool. One commonly 
used endpoint is amenorrhea but this can be a temporary effect as patients often 
resume menstruation in the months following treatment. This is clearly demonstrated 
in a prospective study which found that, although 84% of women treated with 
doxorubicin and cyclophosphamide became amenorrhoeic during treatment, almost 
half had resumed menstruating nine months later (Petrek et al, 2006). This 
resumption can, however, be shortlived before permanent amenorrhoea occurs (Sklar 
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et al, 2006). Amenorrhea is also an unreliable output measure as it is often self-
reported. Other measures which are being used increasingly frequently are ultrasound 
antral follicle counts and hormonal indicators including oestradiol, FSH, inhibin B 
and AMH. AMH is produced by the granulosa cells of growing follicles and so 
serum levels can be used to infer the number of small growing follicles present. From 
this, the number of remaining primordial follicles can be extrapolated (Kelsey et al, 
2011). 
What is missing from the vast majority of publications are the long-term follow up 
data which is needed to establish if women who resume menstrual cycles 
subsequently undergo POF (Bines et al, 1996; Letourneau et al, 2012; Partridge and 
Ruddy, 2007). The major difficulty with these studies is that they would need to 
follow women for decades. To date, this has been done in two studies of childhood 
cancer survivors. The reproductive outcomes for 830 cancer survivors were analysed 
in one study to determine the risk of developing POF following either chemotherapy 
or irradiation (Chiarelli et al, 1999). The long term follow up was between 5 and 30 
years and showed that there was no increase in risk of POF in chemotherapy treated 
patients. However the patients who were treated only with chemotherapy were the 
patients that had the fewest years of follow up (45% had less than 10 years follow up 
and so were younger than 30 when the study was conducted) and so perhaps any 
POF may not have become evident yet. Another study, which followed a large 
number of patients diagnosed between 1970 and 1986, demonstrated that there was a 
significantly increased risk of developing POF immediately following 
cyclophosphamide treatment (Sklar et al, 2006). 
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1.3.1 Potential targets in the ovary 
1.3.1.1. Follicle class 
A womens reproductive lifespan is determined by the number of primordial follicles 
present in her ovaries, with the loss of this reserve resulting in POF. This could occur 
due to a direct effect, with chemotherapy directly targeting the primordial follicle 
reserve. However, this could also be attributed to an indirect effect, with the death of 
large activated follicles leading to an increase in primordial follicle recruitment and 
hence primordial follicle loss (Fig 1.3.A). Growing follicles inhibit primordial 
follicle activation through factors including AMH (Durlinger et al, 1999) and so 
acute loss of growing follicles could lead to increased recruitment of primordial 
follicles. Over repeated cycles of chemotherapy treatment, this could lead to a 
marked effect on the number of primordial follicles remaining in reserve (Morgan et 
al, 2012). In a recent study, cyclophosphamide has been shown to cause increased 
recruitment of primordial follicles which could occur either through direct action on 
the primordial follicles themselves, or indirectly through loss of inhibition from 
growing follicles (Kalich-Philosph et al, 2013). 
The follicle population in the ovary is heterogeneous and each follicle class could 
have a different vulnerability to chemotherapy-induced toxic effects. Currently, there 
is relatively little data available on this, as most studies examine the primordial 
follicle reserve, as it is this reserve which determines a womens reproductive 
lifespan. When human ovarian biopsies are treated with cyclophosphamide, 
significantly fewer primordial follicles remain when compared to untreated controls 
(Oktem and Oktay, 2007b). Following cisplatin and paclitaxel exposure to rats in 
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vivo, primordial follicle counts decrease (Yucebilgin et al, 2004). In mouse and rat 
ovaries, cyclophosphamide and its metabolites cause a decrease in healthy primordial 
and small primary follicles (Desmeules and Devine, 2006; Petrillo et al, 2011).  
Damage to the growing population of follicles could lead indirectly to the loss of the 
primordial follicle reserve. Preantral follicles are highly susceptible to 
chemotherapy-induced damage, with the quality of follicles deteriorating both in vivo 
and in vitro (Abir et al, 2008; Raz et al, 2002). The rapid fall in AMH levels which is 
often seen during chemotherapy treatment also indicates that follicles in the 
preantral/early antral stage are lost (Decanter et al, 2010; Rosendahl et al, 2010a). 
The number of secondary follicles present in mouse ovaries significantly reduces 
following doxorubicin injections (Ben-Aharon et al, 2010). 
1.3.1.2 Germ or somatic cells 
The ovary is populated with several cell types, all of which may be at risk of 
chemotherapy-induced damage and potentially with differing sensitivities. A 
common assumption is that the oocyte is damaged directly by chemotherapy 
treatment, leading to germ cell death and hence follicle loss. There is actually little 
available evidence for this and so an alternative explanation is that chemotherapy 
damages the somatic cells of the ovary. The somatic cells are mitotically dividing, a 
trait which chemotherapy agents are designed to target, and so it could be that 
chemotherapy causes follicle loss indirectly (Fig 1.3.B). For example, the oocyte and 
the granulosa cells are interdependent on each other for growth and development and 
so damage to the granulosa cells would lead indirectly to oocyte damage and hence 
follicle loss. This could be a latent effect, only manifesting when the granulosa cells 
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actively divide as the follicle activates. Oocyte damage could also be a latent effect, 
manifesting at later stages of development including late folliculogenesis or even 
post fertilisation. 
Doxorubicin can cause apoptosis in mature ovulated mouse oocytes (Jurisicova et al, 
2006; Perez et al, 1997) but the effect on immature oocytes contained within follicles 
is less clear. In an in vitro study of human primordial follicles, doxorubicin exposure 
caused apoptosis and DNA damage in both oocytes and granulosa cells (Soleimani et 
al, 2011). A xenografting model, which grafted human foetal ovary pieces into mice 
which were then treated with cyclophosphamide, apoptosis was detected in oocytes 
before pregranulosa cells (Oktem and Oktay, 2007a). Whilst this model could 
indicate that the oocyte is more susceptible to damage than the granulosa cells, it 
used foetal tissue which could still contain mitotically active germ cells. When 
human cortical pieces are cultured in the presence of cyclophosphamide and 
examined, there is an increase in damaged granulosa cell nuclei and basement 
membranes after treatment (Raz et al, 2002). Similar results were seen in a follow on 
in vivo study, examining ovarian biopsies from chemotherapy treated women (Abir 
et al, 2008). Finally, in mouse ovaries exposed in vivo to doxorubicin, DNA damage 
(as detected by TUNEL positive staining) was first identified in granulosa cells, with 
expression moving to the oocytes over time (Ben-Aharon et al, 2010).
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Fig 1.3. Chemotherapy treatment has several potential targets in the ovary. A) 
Chemotherapeutic agents could directly damage the primordial follicle pool or 
indirectly, through growing follicle damage. As growing follicles inhibit the 
activation of primordial follicles, loss of the growing population could lead to 
increased recruitment of primordial follicles and so loss of that reserve. B) 
Chemotherapy could be directly damaging the oocyte or be damaging the somatic 
cells, which will lead indirectly to oocyte damage and follicle loss. Adapted from 




Another possibility is that chemotherapy damages the ovarian stroma, which could 
also adversely affect follicle health. In an ultrastructural study of ovarian biopsies 
from girls who underwent treatment for childhood leukaemia, moderate to severe 
signs of stromal damage and capillary changes were found (Marcello et al, 1990). 
Another study has also found evidence of cortical fibrosis and blood vessel damage 
in human ovaries following chemotherapy (Meirow et al, 2007), which suggests that 
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Table 1.4. Summary of literature which examines the direct action of chemotherapy 
on the ovary. ABVD: adriamycin, bleomycin, vinblastin, dacarbazine; ABVE: 
adriamycin, bleomycin, vinblastin, etoposide; AC, adriamycin, cyclophosphamide; 
ACTD: adriamycin, cyclophosphamide, actinomycin D; ADE-GMTZ, Arabinoside-
C, Daunorubicin, Etoposide, and Gemtuzumab ozogamicin; AI: arabinoside cytoside, 
Idarubucin; AIE: arabinoside cytosine, Idarubucin, etopside; BEA: bleomycin, 
etopside, adriamycin; BEACOPP; bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine, prednisone; BECOPP: bleomycin, 
etoposide, cyclophosphamide, oncovin, procarbazine, prednisone; CAF: 
cyclophosphamide, adriamycin, 5-fluorouracil; CHOP, cyclophosphamide, 
doxorubicin, vincristine, prednisone; COAP: cyclophosphamide, vincristine, cytosine 
arabinoside, prednisone; COPP: cyclophosphamide, oncovin, procarbazine, 
prednisone; CVPP: cyclophosphamide, vincristine, procarbazine, prednisone; DNR: 
Daunorubicin; E-PIE: etoposide, cisplatin, I-fosphamide; 5FU: 5-flourouracil; 
GMALL: methotrexate, cyclophosphamide, vincristine, daunorubicine, sparginase, 
cytarabine, 6-mercapto-purine, etoposide; HAM: high dose arabinoside cytosine, 
mitoxantrone; I-Fos: I-fosphamide; JET; carboplatin, etoposide; MECC, melphalan, 
etopuside, citarabin, carmustine; MINE EASHAP, mesna, ifosfamide, mitoxantrone, 
etoposide, cytosine arabinoside, cis-platinum and steroids; 6MP: 6-mercaptopurine; 
MTX, methotrexate; P, procarbazine; Pr: prednisone; PVD: Prednisone, vincristine, 
doxorubicin; 6TG: 6-thioguanine; V, vincristine; VACOP-B, doxorubicin, 
cyclophosphamide, vincristine, bleomycin, etoposide; VC; vincristine, 
cyclophosphamide; VCAIE; vincristine, cyclophosphamide, arabinosidecytosine, 




1.3.1.3 Non ovarian effects 
Chemotherapy could also potentially affect fertility without damaging the ovary by 
causing damage to the structure of the uterus and its ability to support a foetus to 
term. Alterations to the uterine vasculature and musculature could lead to an 
impairment of its function. Data from women treated with abdominal radiation 
suggests that there are uterine changes, including a shortening of uterine length, an 
increase in endometrial thickness and decreased blood flow (Critchley, 1999), all of 
which could compromise implantation and the development of a successful 
pregnancy. Radiotherapy has also been linked to adverse prenatal outcomes 
including preterm birth and small gestational weight (Signorello et al, 2006). For 
women treated only with chemotherapy, results are more encouraging. Pregnancy 
outcome in 44 survivors of acute lymphoblastic leukaemia treated with 
chemotherapy was described and no adverse effects were reported (Green et al, 
1989). It may be therefore that chemotherapeutic agents are less detrimental to the 
uterus than radiotherapy.  
1.4 Chemotherapy and male infertility 
Chemotherapy treatment has also been linked to male infertility, causing 
oligospermia and azoospermia in male survivors of childhood Hodgkins lymphoma 
(van Dorp et al, 2012). As with women, the risk of developing fertility problems are 
related to patient age, dosage of drug used (Strumber et al, 2002) and the type of 
drug (alkylating agents being the most toxic). In the Childhood Cancer Survivor 
study, survivors were approximately half as likely to sire a pregnancy than sibling 
controls, with particularly detrimental effects to fertility noted following high doses 
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of radiotherapy or alkylating agents (Green et al, 2010). Eighty percent of male 
childhood cancer survivors were azoospermic following high dose 
cisplatin/alkylating treatment; when several drug regimes were compared, 10-50% of 
survivors were azoospermic (Romerius et al, 2011). Drug treatments including 
cyclophosphamide, ifosamide and busulfan are considered highly toxic to 
spermatogenesis, with cisplatin and doxorubicin considered medium risk (Dohle, 
2010). Age is a somewhat controversial risk factor in males, with some studies 
showing the testis is susceptible to damage whether exposed pre- or post- pubertally 
(Wallace et al, 2005). 
Whilst chemotherapy is often associated with azoospermia during and immediately 
following treatment, this can be a short term effect with spermatogenesis often 
recovered. The drug treatments could target somatic cells (Sertoli and Leydig cells) 
or the germ cells themselves. Different drug treatments appear to target different cell 
types with most damaging the differentiated spermatogonia (Meistrich et al, 1982). 
There is concern that drug treatment could damage the spermatogonial stem cells, as 
it is these which are responsible for repopulating the testis with germ cells. 
Treatments which do not include cyclophosphamide have been shown to be less 
toxic to the stem cells, with fertility often recovered (Nurmio et al, 2009). In a study 
examining long-term Leydig cell function, there was no negative effect of standard 
cisplatin exposure although high cumulative doses of chemotherapy were linked to 




1.5. Chemotherapeutic Agents 
There are many different chemotherapy agents which are classified according to their 
general drug action. As discussed above, the varying classes of drug each cause 
differing levels of ovotoxicity. Some of the drugs most commonly used in the 
treatment of premenopausal women are discussed below. A summary of potential 
mechanisms of action is presented in Fig 1.4. 
1.5.1. Cyclophosphamide  
Cyclophosphamide is classified as an alkylating agent and is one of the most widely 
used chemotherapy drugs. It was first synthesised in 1958 and approved for use as an 
anticancer agent in 1959 (Emadi et al, 2009). A broad range of cancers can be treated 
with cyclophosphamide, including breast and lymphoid malignancies and it is often 
used in conjunction with other anticancer drugs. It is also used as an 
immunosuppressor for blood and marrow transplantations. Its use clinically is limited 
by its toxicity, with side effects including haematological effects such as neutropenia, 
cardiotoxicity and haemorrhagic cystitis (Lallana and Fadul, 2011; Zver et al, 2007). 
Cyclophosphamide and other alkylating agents such as busulfan are considered to be 
the most ovotoxic chemotherapeutic agents (Meirow, 2000). 
Cyclophosphamide is an inactive pro-drug and so needs to be cleaved to its active 
metabolite phosphoramide mustard. There are other metabolites produced as 
cyclophosphamide is cleaved but work suggests that phosphoramide mustard is the 
most ovotoxic metabolite (Desmeules and Devine, 2006; Plowchalk and Mattison, 
1991). Phosphoramide mustard results in intra-strand and inter-strand crosslinking of 
DNA which can interfere with cell division. Granulosa cells which have been treated 
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with cyclophosphamide exhibit mitochondrial effects, including a reduction in 
mitochondrial transmembrane potential and an accumulation of cytochrome c in the 
cytosol which can lead to a downstream activation of apoptosis through caspase 
signalling (Zhao et al, 2010). During cell death, a protein called Bax which is largely 
found in the cytosol, inserts into the outer membrane of the mitochondria. 
Cyclophosphamide has been shown to cause a large upregulation of Bax expression 
(Barekati et al, 2012) and this could be how the drug mediates the reduction in 
mitochondria transmembrane potential, leading to apoptosis. Oxidative stress, for 
example through increased reactive oxygen species, is another mechanism through 
which cyclophosphamide is thought to cause cell death and has been particularly 
linked to adverse side effects including cardiotoxicity (Schimmel et al, 2004). Mouse 
ovaries which are exposed to cyclophosphamide metabolites in vitro have an 
induction of H2AX expression (Histone H2AX, a marker of double strand DNA 
breaks) predominantly in oocytes but also in the granulosa cells following treatment 
(Petrillo et al, 2011). 
1.5.2 Cisplatin 
Cisplatin, or cis-diamminedichloroplatinum(II), was first identified as an anti-tumour 
agent in the 1970s and was approved for clinical use in 1978. It is used as a therapy 
for various cancers including ovarian, testicular, cervical, bladder and lung cancer. 
Although extensively used, its clinical use has been somewhat limited by side effects 
including ototoxicity, renal damage and neuropathy. Cisplatin’s exact mechanism of 
action is still unclear but it is classified as an alkylating-like agent, causing DNA 
crosslinking and adduct formation. The mechanism by which cisplatin enters cells to 
get to DNA to form adducts is also undefined, although it has been linked to either 
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passive diffusion or the copper transporter CT1 (Ishida et al, 2002), expression of 
which is abundant in the ovarian stroma (Kuo et al, 2001). Its interaction with DNA 
causes intra- and interstrand crosslinks which distort the structure of the DNA. 
The primary target of cisplatin action in cells appears to be the nuclear DNA 
(Akaboshi et al, 1992) with some evidence suggesting an interaction with the 
phospholipids in the cell membrane (Speelmans et al, 1996) as well as interfering 
with the cytoskeleton (Kopf-Maier and Muhlhausen, 1992). There is also the 
possibility that it may interact with the mitochondrial DNA, as evidenced by a study 
in Chinese hamster ovary cells which had a 4 fold increase in mitochondrial DNA 
adduct formation following cisplatin treatment (Olivero et al, 1995).   
DNA adducts could have several different effects on cellular function. They could 
lead to the inhibition of DNA synthesis and thus an inhibition of DNA replication. 
Cisplatin can also cause inhibition of gene expression (Evans and Gralla, 1992) and 
an inhibition of transcription. The ability of a cell to process DNA adducts could 
have a massive effect on the sensitivity of that particular cell to cisplatin induced 
toxicity. E. Coli which are deficient in DNA repair mechanisms are much more 
sensitive to the toxic effects of cisplatin than wild type strains (Beck and Brubaker, 
1973). The mechanism of cisplatin-DNA adduct repair in cells is thought to be 
mainly through the nucleotide excision repair (NER) pathway. This involves the 
recognition of DNA damage, excision of the damaged portion of DNA and then 
repair of the gap by DNA polymerase and ligase enzymes. If there is a failure of the 
cell to repair the DNA adduct or the DNA damage is too overwhelming, this will 
lead to cell death. It is thought that the cell death triggered in this manner is largely 
apoptosis related. 
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Another mechanism by which cisplatin has been implicated to cause cell damage is 
the activation of mitochondrial-related death pathways, leading to the release of 
cytochrome c into the cytosol (Sancho-Martinez et al, 2012). This subsequently leads 
to activation of the caspase family of proteins and hence apoptosis. Cisplatin has also 
been linked to endoplasmic reticulum stress (Mandic et al, 2003), which 
subsequently activates caspase 12 and thus apoptosis. More recently, cisplatin has 
been linked to increased oxidative stress in the testis (Rezvanfar et al, 2013). 
Nonetheless, the primary action of cisplatin on cells appears to be DNA damage 
induction. 
1.5.3 Doxorubicin 
Doxorubicin (also called Adriamycin) is an anthracycline antibiotic which has been 
used to treat Hodgkins lymphoma, breast cancer and soft cell sarcomas since the 
1960’s (Minotti et al, 2004). Although one of the most effective anticancer drugs, its 
use clinically is limited by its detrimental side effects- in particular cardiotoxicity 
leading to congestive heart failure (Lipshultz et al, 2012; Volkova and Russell, 
2011). There also is a link to an increase in secondary malignancies in treated 
patients (Arslan and Uslu, 2013)  
The mechanism by which doxorubicin causes cell death remains unclear despite its 
widespread clinical use, with many different actions being implicated. Doxorubicin 
enters cells through passive diffusion (Decorti et al, 1989; Skovsgaard and Nissen, 
1982), a process which is favoured by high intracellular pH (Swietach et al, 2012). 
The major mechanisms of doxorubicin are postulated to involve inhibition of 
topoisomerase II (Tewey et al, 1984), inhibition of DNA synthesis (Schott and 
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Robert, 1989) as well as DNA intercalation and crosslinking (Chen et al, 2012; 
Cullinane et al, 1994). There is evidence that doxorubicin can also cause the 
generation of free radicals (Bachur et al, 1977) and increased oxidative stress (Lahoti 
et al, 2012). Doxorubicin also has direct membrane effects, interacting with both the 
cells plasma membrane and the mitochondrial membrane (Murphree et al, 1981; 
Praet et al, 1984). However, many studies examining doxorubicins action in vitro use 
concentrations that far exceed serum levels; when this is taken into consideration, the 
major action of doxorubicin appears to be topoisomerase II inhibition (Gewirtz, 
1999). Tumour cells which are resistant to anthracyclines have reduced levels or 
activity of topoisomerase II and thus reduced double strand breaks (Capranico et al, 
1987; Deffie et al, 1989) 
Topoisomerase enzymes allow for the unwinding of DNA by severing the phosphate 
backbone of one (type I) or both (type II) strands of the double helix. There are two 
topoisomerase II enzymes; IIα and IIβ, both of which are inhibited by doxorubicin. 
The anticancer activity of doxorubicin has been linked to its inhibition of 
topoisomerase IIα (Press et al, 2011). In cardiomyocytes, inhibition of topoisomerase 
IIβ appears to be the primary mechanism through which doxorubicin causes 
cardiotoxicity (Zhang et al, 2012). Topoisomerase poisons such as doxorubicin 
stabilise the DNA-topoisomerase complex and thus impede the resealing of DNA 
strand breaks once cut. This means doxorubicin effectively blocks transcription and 
replication. DNA strand breaks are rapidly detected by the cell and if they are too 
extensive to be repaired, cell death pathways such as apoptosis are activated. That 
being said, doxorubicin is associated with a high level of cytotoxicity even with low 
levels of DNA damage (Gewirtz, 1999). The site of the DNA breaks may be of 
 40 
importance here as there is evidence that anthracyclines cause DNA breaks at 
specific gene loci, which are different to that of other topoisomerase inhibitors 




Fig 1.4. Potential mechanisms by which chemotherapy agents may cause cell death. 
Chemotherapeutic drugs may act at the level of the nucleus to cause DNA damage or 
interfere with DNA transcription and replication. They can also act on the 
mitochondria to induce the release of cytochrome c into the cytoplasm. These 
pathways all interconnect and lead to cell death, often through the caspase family of 
proteins which are associated with apoptosis. Adapted from Morgan et al (2012). 
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1.6 Hypothesis  
Chemotherapeutic agents are designed to target rapidly dividing cells. It is likely 
therefore that they will damage the somatic cells of the ovary, such as the granulosa 
cells, thereby causing indirect oocyte loss. The hypothesis of this project therefore 
was that chemotherapeutic agents cause ovotoxicity primarily through the ovarian 
somatic cells.  
1.7 Aim of this PhD. 
With survival rates for cancer patients increasing, more attention needs to be focused 
on the long term adverse effects of their treatment. Whilst the endpoint of POF 
following chemotherapy has been well established, the precise mechanism by which 
this occurs is less clear. Increasing our understanding of the mechanism by which the 
ovarian follicle pool is depleted could lead to new approaches in treatment to 
alleviate POF. 
The aims of this project were to elucidate in detail the mechanism by which 
chemotherapeutic agents directly damage the ovary and to determine which stages of 









GENERAL MATERIALS AND METHODS
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2.1 Newborn Mouse Ovary Dissection 
2.1.1 Dissection medium 
The medium used for dissection in all the methods detailed below was Leibowitz 
L15 (Invitrogen UK, #11415049). Aliquots of 50mls were stored at 4ºC, used within 
6 days once opened and then discarded. The osmolarity of each bottle was measured 
using an osmometer (Camlab, 026461 DBS) and adjusted to 285 mmOsm/kgH2O 
using sterile H2O (Sigma Aldrich, #W1515). This medium was supplemented with 
3mg/ml bovine serum albumin (BSA, #A9418, Sigma Aldrich Ltd) under a laminar 
flow hood and once BSA was dissolved, it was syringe filtered (Filters: Iwaki, 
#2053-025, pore size 0.2µm, Syringes: BD, #301604). It was warmed in an oven at 
37°C for a minimum of 45 minutes prior to use. Once made up, medium was used 
within 24 hours. 
2.1.2 Gross Dissection 
Mice were kept on a 12 hour light/dark cycle with food and water available ad 
libitum. Newborn female mice were culled by decapitation (according to UK Home 
Office Regulations, Project Licence 60/4026) and ovaries were dissected out into 
glass embryo dishes containing 1ml of Leibovitz L-15 dissection medium 
supplemented with 3mg/ml BSA (#A9418, Sigma Aldrich Ltd). All dissections were 
done under a laminar flow hood.   
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2.1.3 Fine Dissection 
Any extra tissue surrounding the ovaries (such as the fallopian tube) was removed 
using insulin needles (BD Microfine Insulin Needles, 1ml U-100 29G, #037-7606) 
under a light microscope on a heated stage (heated to 37°C) and the bursa was 
removed. This was done in a laminar flow hood to ensure sterility. 
 
2.2 Newborn Mouse Ovary Culture 
2.2.1 Newborn ovary culture medium 
Alpha-MEM medium (Invitrogen, #22571/020) was used for all newborn ovary 
cultures. Aliquots of 50mls were stored at 4ºC and once opened, were used within 6 
days and then discarded. The osmolarity of each bottle was measured using an 
osmometer (Camlab, 026461 DBS) and adjusted to 285 mmOsm/kgH2O using sterile 
H2O (Sigma Aldrich Ltd, #W1515,). In a laminar flow hood, 3mg/ml BSA (A3311, 
Sigma Aldrich Ltd; this BSA was used as it is more refined than the one present in 
the L15) was added to the medium. The quantity of medium made up was 
determined as 1ml of media/ovary with 1ml extra added in case of loss during 
filtering. Once BSA was added and dissolved, the media was syringe filtered into 
sterile tubes (Greiner BioOne, #120190). 1ml of medium was pipetted into each well 
in a 24 well plate (Greiner BioOne, #662160) and a Whatman Nucleopore 
polycarbonate membrane (#WN/110414, Camlab) was placed on top of each well 
shiny side up using a pair of sterile watchmaker forceps. Plates were then incubated 
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in a humidified incubator at 37ºC and 5% CO2 in air for a minimum of 1 hour prior to 
use. 
2.2.2 Newborn ovary culture 
Each ovary, once finely dissected, was transferred using a glass pipette onto a 
Whatman Nucleopore membrane which was floating on top of 1ml alpha-MEM 
medium (Invitrogen) supplemented with 3mg/ml BSA (Sigma Aldrich) in a 24 well 
plate (Greiner Bio-one, #662160). Ovaries were randomly allocated into treatment 
groups. Culture plates were incubated in a humidified incubator at 5% CO2 in air and 
37°C for up to six days. 50% of medium was replaced every 48 hours. 
 
2.3 Chemotherapeutic agent stock solutions 
2.3.1 Cisplatin 
Cisplatin (cis-Diammineplatinum(II) dichloride, #P4394-25MG, Sigma Aldrich Ltd) 
was made up in sterile water (Sigma Aldrich Ltd, #W1515) in a class II fume hood to 
the concentration of 1mg/ml and pipetted vigorously until dissolved. Serial dilutions 
in sterile water were set up to produce a range of stock solutions including 500µg/ml 
and 100µg/ml. These were stored in eppendorfs which were parafilmed and wrapped 
in foil due to light sensitivity. These aliquots were kept at 4ºC for up to 6 weeks. 
2.3.2 Doxorubicin 
Doxorubicin hydrochloride (D1515-10MG, Sigma Aldrich Ltd) was made up in 
sterile water (W1515, Sigma Aldrich Ltd) in a class II fume hood to the 
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concentration of 1mg/ml. Serial dilutions in sterile water were set up to produce a 
range of stock solutions including 100µg/ml, 50µg/ml and 10µg/ml. These were 
stored in eppendorfs which were parafilmed and wrapped in foil due to light 
sensitivity. These aliquots were kept at 4ºC for up to 4 weeks. 
2.4 Histology 
2.4.1 Fixing and Processing 
Ovaries were removed from membranes using a glass pipette and washed in ice cold 
PBS (phosphate buffered saline) in a 24 well plate. They were fixed in Bouins or 
10% Formalin (Sigma Aldrich, #HT5014) for 75-90 minutes in a class II fume hood. 
Ovaries were then washed several times in 70% (v/v) ethanol and left overnight in 
70% (v/v) ethanol with eosin (approximately 1%) to stain. Ovaries were processed 
by machine (Sakura Tissue-Tek® VIP, Sakura Fintek UK Ltd, Thatchem UK) and 
embedded in paraffin. Ovaries were sectioned on a microtome (Leica UK) at 5µm 
thickness and mounted on poly-lysine coated glass slides (ThermoScientific, #12-
545-78).  
2.4.2 Haemotoxylin and eosin staining 
Sections were dewaxed in xylene for 20 minutes and rehydrated through decreasing 
concentrations of ethanol (100%, 95%, 90% and 70%) before being washed in 
running water. Slides were dipped in haemotoxylin (Thermoscientific, #6765004) for 
approximately 3 minutes before being washed in running water. Slides were acidified 
in acid alcohol (0.5% [v/v] HCl in 70% [v/v] ethanol) then washed in tap water 
before being placed in Scotch Tap Water Substitute (STWS, 0.2% NaHCO3, 2% 
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MgSO4 in dH2O) for 3 minutes. After another wash in tap water, slides were dipped 
in eosin (Sigma Aldrich, #E4382, 1% [w/v] solution) for 2 minutes and fixed in 
potassium aluminate for 2 minutes. After a further wash in tap water, slides were 
dehydrated through increasing concentrations of ethanol (70%, 90%, 95% and 100%) 
and placed in xylene to clear for 5 minutes. Slides were then mounted with glass 
coverslips using DPX (B&D) as a mounting solution.   
2.5 Follicle Counting 
Slides were photographed using a Leica microscope (Leica DMBL with Leica 
DFC480 camera, Leica UK). For counting, the sixth section of each ovary was 
photographed to prevent double counting. Images were analysed using Image J 
software and blind as to treatment group (with the ovaries assigned code numbers at 
fixation which were decrypted during statistical analysis). A follicle was counted if a 
germinal vesicle was present in the oocyte. A follicle was considered to be 
primordial if it consisted of an oocyte surrounded by one or a few flattened 
pregranulosa cells. A follicle was considered to be transitional if one or more of the 
surrounding granulosa cells were cuboidal. If all the surrounding granulosa cells 
were cuboidal and formed one complete layer around the oocyte, the follicle was 
considered to be primary. If there were two or more complete layers of cuboidal 
granulosa cells surrounding the oocyte, the follicle was considered to be secondary 
(Morgan et al, 2013).  
A follicle was considered healthy if: a) the oocyte was round and contained evenly 
stained cytoplasm; b) there were no pyknotic granulosa cells (or no more than 1 for 
primary follicles); and c) there was clear attachment between the oocyte and its 
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surrounding granulosa cells. Any follicle not considered healthy (not passing all 3 
criteria) was further categorized as having an unhealthy oocyte only; unhealthy 
granulosa cells only; or having both oocyte and granulosa cells unhealthy. An oocyte 
was considered to be of poor health if it exhibited any one of shrunken cytoplasm, 
heavy or uneven eosin staining or no attachment between oocyte and its surrounding 
somatic cells (Fig 2.1). A granulosa cell was considered to be pyknotic if it was 
shrunken and condensed. The assessment of the health of granulosa cells was 
dependent on follicle stage: for primordial and transitional follicles, a follicle was 
assessed as unhealthy if it contained any clearly pyknotic granulosa cell (out of the 3-
6 present); for primary follicles, a follicle was assessed as unhealthy if it contained 2 
or 3 or more clearly pyknotic granulosa cells (out of the 10-20 present). This criteria 
was chosen as, in control ovaries, it is rare to see any pyknotic granulosa cells in 











Fig 2.1. Examples of follicles determined as primordial, transitional and primary 
based on their morphology. Follicles were considered primordial if they consisted of 
an oocyte surrounded by one or a few flattened pregranulosa cells. Follicles were 
considered transitional if one or more of the surrounding granulosa cells were 
cuboidal. If all the surrounding granulosa cells were cuboidal and formed one 
complete layer around the oocyte, the follicle was considered to be primary. (A) A 
follicle with pyknotic granulosa cells (shown with black arrows). (B) Oocytes with 
shrunken cytoplasm and heavy eosin staining (shown with black arrows). 
Primordial Transitional Primary 
A B 
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2.6. Statistical Analysis 
For histological analysis, all the follicles in every sixth section of each ovary were 
counted and classified as described above. Ovaries were assessed with the counter 
blind as to treatment group, with the ovaries assigned code numbers at fixation which 
were decrypted during statistical analysis. The sum of the follicles in each category 
was multiplied by 6 to produce total numbers for each ovary analysed. The average 
of the total numbers was then quantified for all the ovaries in each treatment group. 
Graphpad prism software (Graphpad Software Inc, California USA) was used for all 
data analysis. One way ANOVAs determined if significant differences were present 
across treatments, followed by Bonferroni post hoc tests where ANOVA was 
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3.1.1 Known effects of cisplatin on follicles 
Cisplatin acts primarily through causing inter- and intra-strand DNA crosslinking, 
leading to adduct formation which can interfere with transcription and replication. 
These adducts, if not repaired appropriately by the cell, can lead to the activation of 
cell transcription pathways which culminate in the initiation of apoptosis (Siddik, 
2003). The effect of cisplatin on follicles within the ovary has only very recently 
being elucidated, with studies indicating that immature oocytes within follicles are 
highly susceptible to damage. In neonatal mouse ovaries, cisplatin administration 
leads to an upregulation of Abl (Abelson murine leukemia viral oncogene homolog 
1, Gonfloni et al, 2009), a non-receptor tyrosine kinase which is thought to act as a 
sensor of DNA damage. This in turn leads to an upregulation of TAp63 (Tumour 
protein p63), a member of the p53 family of proteins which is only expressed in the 
oocyte. The p53 family act as DNA repair proteins, which can initiate apoptosis if 
the level of DNA damage present is too high to be repaired (Smith and Suresh 
Kumar, 2010). Cisplatin treatment causes accumulation of Abl and TAp63 leading to 
extensive oocyte death (Gonfloni et al, 2009). The evidence from the literature to 
date is that the follicle class that is particularly susceptible to cisplatin within these 
experimental conditions appears to be the primordial follicle population (Kim et al, 
2013). The effect of cisplatin on more mature follicle classes is not known.  
 
3.1.2 Known effects of doxorubicin on follicles 
There are relatively few studies investigating the action of doxorubicin in the ovary, 
with the pharmacological mechanisms of action primarily being investigated in other 
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somatic cell populations; particularly in cardiomyocytes. In somatic cells in general, 
doxorubicin can interact with mitochondria (Pointon et al, 2010), leading to the 
release of cytochrome c into the cytosol. This in turn leads to activation of apoptotic 
cascades, including cleavage of the caspase family of proteins. There is also evidence 
that in the nucleus, doxorubicin can lead to an upregulation of p53 and hence 
apoptosis. The major problem with applying what has been identified in other studies 
to the ovary is that most of these studies use very high pharmacological doses of 
doxorubicin in primary cell lines, the results of which may not be therefore that 
applicable to serum level doses in whole tissue. Doxorubicin causes apoptosis in 
mature ovulated oocytes in vitro (Jurisicova et al, 2006; Perez et al, 1997); the effect 
on more immature oocytes maintained in follicles is less clear. It is also unclear if the 
drug is more toxic to oocytes or somatic cells when the whole follicle unit is 
exposed. An in vitro study using human ovary cortical strips identified DNA damage 
and apoptotic cell death in both the oocyte and granulosa cells (Soleimani et al, 
2011). However this study used much higher doses of doxorubicin (1-100µg/ml) than 
serum levels in patients. Preliminary experiments in this lab indicated that the 
primary cell type affected in neonatal mouse ovaries is the granulosa cells (George 
Liperis, Presented at SRF 2009).   
 
3.1.3 The mouse ovary as an in vitro model 
The sequence of events underlying follicle formation and folliculogenesis in humans 
has proven difficult to elucidate experimentally. Human ovarian tissue can be 
cultured but its use as a research model is more limited due to the scarcity of 
available material, ovarian size and ethical concerns regarding human embryo 
 55 
production. Therefore, mouse ovaries have been extensively used as an alternative 
culture model to examine the earliest stages of folliculogenesis in vitro. One 
advantage of using such a model is that the environment can be tightly controlled, 
allowing for the elucidation of key regulators and events during this process. 
Development in vitro from the primordial follicle stage through to fertilizable 
oocytes and live young has been achieved in the mouse (Eppig and O'Brien, 1996; 
O'Brien et al, 2003), indicating that in vitro culture can support oocyte development 
in a physiological manner. Although the mouse ovary model is very useful, there are 
some drawbacks. Mice are polyovular and have oestrous cycles of 4 days, in contrast 
to humans who are monoovular and have menstrual cyles of approximately 28 days. 
There is also comparatively little stromal tissue in the mouse ovary when compared 
to humans. 
 
The mouse ovary culture system used in the work detailed in this chapter supports 
follicle formation, growth initiation and development to the primary-secondary phase 
(Spears et al, 2003). In the first 3 days of culture, the predominant follicle class 
present is primordial. Over the six days most of these will activate so by the end of 
culture, the majority of follicles are transitional with around 30% classed as primary 
(Work carried out by Federica Lopes, Fig S1 in Morgan et al, 2013, Fig 3.1). As the 
population of follicles within this culture system is relatively homogenous with only 
the primordial or early growing classes present, this culture system will allow for 
determination of the effect of cisplatin and doxorubicin more precisely on the follicle 
reserve. Another advantage of using this culture system is that the whole ovary can 











Figure 3.1. The change in follicle distribution over a 6 day culture of newborn 
mouse ovaries. Work carried out by Federica Lopes, Fig S1 in Morgan et al, 2013. 
 
3.1.4. The bovine ovary as an in vitro model 
Other species are also utilised as models for human ovarian development including 
rat, sheep, pig, cow and baboon. In large mammalian species such as the cow, in 
vitro culture is more challenging due to the large size of the tissue and the increased 
density of stromal tissue. The time taken for a primordial follicle to mature to the 
preantral stage in the cow takes weeks or months in vivo, a process which takes only 
days in the mouse. The process of folliculogenesis in humans and large mammals 
however is accelerated in vitro so that which takes several months in vivo takes days 
in vitro (Telfer 1998). The impact of this accelerated development on follicles in 
terms of their health and their capacity to produce live offspring is presently unclear. 
The size of follicles is also species dependent, meaning that the culture of bovine 































most studies determining appropriate culture conditions for folliculogenesis were 
conducted initially in the mouse, it has proven difficult to apply these to the culture 
of bovine tissue, due to the differences in tissue and follicle size and the timing of 
follicle development. However, there is the argument that bovine tissue may be more 
appropriate as a model for the human ovary than the mouse. This is because the cow 
is more similar to humans in terms of being monovular, having folliculogenesis 
occur over a long time span and having denser stromal tissue. 
 
As it is not possible to culture whole ovaries from the cow as it is in the mouse, a 
different approach must be taken in vitro. If primordial and early growing follicles 
are isolated and placed into culture, they degenerate rapidly indicating they require 
the support of stromal cells. Therefore, culturing strips of ovarian cortex maintains 
this support (Hovatta et al, 1999), allowing widespread primordial follicle activation 
(Wandji et al, 1996) and development to the preantral stage. Further development 
can occur following mechanical isolation of follicles from cortical strips and 
individual culture thereafter (Telfer et al, 2008). These cultures appear to support the 
follicles fairly well, although no live offspring has been produced yet following 
culture in the cow, or indeed in any species other than the mouse.  
 
3.1.5 Aims 
The aim of the work described here was to determine the effect of cisplatin and 
doxorubicin on early ovarian follicles. Preliminary experiments to ascertain suitable 
doses for cisplatin were conducted in both newborn mouse ovaries and bovine 
cortical strips and results compared to examine any species-related differences. 
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3.2 Materials and methods 
3.2.1 Animals 
For the preliminary murine experiments, the mice used were the offspring from 
C57BL6 X CBA. This was changed to C57BL6 for subsequent experiments 
comparing the effect of cisplatin and doxorubicin due to low litter numbers available 
from the crosses. For the bovine cultures, ovaries were obtained from a local 
abbatoir. 
 
3.2.2. Experiment 3.1: Preliminary murine experiments with cisplatin 
Newborn mouse ovary culture 
Newborn mouse ovaries were dissected and cultured as described in Chapter 2. 
Medium was supplemented with cisplatin at the final concentrations 0, 0.05, 0.1 and 
0.2µg/ml for the full six days of culture. These doses were selected as preliminary 
experiments exposing individual preantral follicles in culture suggested that they 
were the lowest concentrations to show an effect (Cultures done by S Morgan). Four 
ovaries were analysed in each treatment group taken from two independent cultures. 
 
3.2.3. Experiment 3.2: Preliminary bovine cultures with cisplatin 
Bovine cortical strip culture 
Ovaries were obtained from a local abattoir and transported in Transporting Medium 
M199 (Hepes buffered, Invitrogen, UK) supplemented with pyruvic acid (25µg/ml), 
penicillin G (75µg/ml), streptomycin (50µg/ml) and amphotericin B (2.5µg/ml) (all 
chemicals from Sigma Aldrich Ltd, UK) at 30-35C, then sprayed with 70% ethanol 
to avoid contamination. In a laminar flow hood, cortical strips of approximately 1mm 
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thick were dissected from quiescent appearing areas of cortex i.e. areas containing no 
prominent follicles or corpus lutea. These were dissected using a scalpel and placed 
in dissection media [Leibovitz L15 medium (Invitrogen, UK) supplemented with 
sodium pyruvate (2mM), glutamine (2mM), BSA (#A3912, 3mg/ml), penicillin G 
(75µg/ml) and streptomycin (50µg/ml)]. 24 well flat-bottomed culture plates were set 
up with 300μl of control medium [McCoy’s 5a medium with bicarbonate 
supplemented with HEPES (20mM), BSA (A3912, 0.1% [w/v]), glutamine (3mM), 
penicillin G (0.1mg/ml), streptomycin (0.1mg/ml), transferrin (2.5µg/ml), selenium 
(4ng/ml), insulin (10ng/ml) and ascorbic acid (50µg/ml), all obtained from Sigma 
Aldrich Ltd, UK by Marie McLaughlin] in each well. Medium was also 
supplemented with cisplatin to produce final concentrations of 0, 0.1, 0.2 and 
0.4µg/ml. 150μl of medium was removed and exchanged with fresh medium every 
48 hours. After 6 days, strips were removed from culture and fixed in Bouins 
solution. Culture and dissection method taken from Telfer et al (2008). Twelve strips 
were analysed in each treatment group from two independent cultures. 
 
3.2.4. Experiment 3.3: The effect of cisplatin and doxorubicin 
Newborn mouse ovaries were dissected and cultured as described in chapter 2. The 
timing of drug exposure was modified to 24 hours on the second day of culture only. 
This shorter exposure time was chosen as it more closely models the drug exposure 
in patients. Following drug treatment, ovaries were transferred into a fresh plate with 
new membranes and control medium for the final 4 days of culture. The range of 
concentrations of cisplatin used here were: 0, 0.1, 0.5, 1 and 5µg/ml, whilst those of 
doxorubicin were: 0, 0.01, 0.05, 0.1 and 0.2 µg/ml. These drug concentrations were 
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increased from those used in previous experiments as the exposure window is shorter 
in this paradigm. Five ovaries were analysed in each treatment group with three 
independent cultures conducted for each drug. 
 
3.2.5 Histology 
Following culture, newborn mouse ovaries were fixed in Bouins fixative, processed 
and embedded in paraffin as described in Experiment 1. Ovaries were sectioned on a 
microtome at 5µm, stained with haemotoxylin and eosin and every 6
th
 section was 
photographed and counted. Follicles were assessed morphologically as described in 
Chapter 2 blind as to treatment. Follicle counts were corrected using the 
Abercrombie correction factor (Abercrombie, 1946). This correction factor takes into 
account the size of the average germinal vesicle and the thickness of the sections to 
correct for double counting. Oocyte diameters were measured using Image J 
software.  
 
Bovine cortical strips were fixed in Bouins for 24 hours, processed through 
increasing concentrations of ethanol and then placed in cedarwood oil to clear for 
24hours. This was removed with toluene, following which cortical strips were 
embedded in molten paraffin which was exchanged every hour for 3 hours to remove 
any remaining toluene before cooling. Strips were then sectioned on a microtome at 
5µm, mounted on poly-lysine coated slides and stained with haemotoxilyn and eosin 
as described in chapter 2. Every 12
th
 section was examined under a light microscope 
(chosen due to advice from Marie McLaughlin) and follicles were counted and 
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classified blind as to treatment. Follicles counted were expressed as percentages per 
cortical strip.  Follicle health was classified as described in chapter 2. 
 
3.2.6 Statistical analysis 
All data were analysed using Graphpad Prism (GraphPad Software, Inc, California 
USA). Where results were not normally distributed (as determined through 
Kolmogorov-Smirnoff tests for normality), log transformation was used to normalise. 
This was used to correct total follicle numbers in Experiment 3.3. One way ANOVA 
determined if significant differences were present across treatments, followed by 
Bonferroni post hoc tests where ANOVA was statistically significant. Post hoc tests 
determined the effect of treatment relative to its control. 
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3.3 Results 
3.3.1 Comparison of mouse and cow as model species 
3.3.1.1 Experiment 3.1:  Preliminary Murine Experiments with Cisplatin 
Newborn mouse ovaries were exposed to 0, 0.05, 0.1 and 0.2 µg/ml cisplatin for 6 
days in vitro and analysed histologically. These concentrations were chosen since 
prior experiments culturing individual preantral follicles suggested that they were the 
lowest concentrations to show an effect. The percentage of follicles classified as 
unhealthy was significantly higher following 0.1µg/ml cisplatin (Figure 3.2., 
p<0.001). At the highest dose, there was an increase in the percentage of follicles 
classified as unhealthy but this was not significant. This could be due to the low n 
number of ovaries in this treatment group. When follicle class was analysed, there 
was an increase in the number of transitional follicles classified as unhealthy in both 
0.1 and 0.2ug/ml cisplatin groups but this was not significant (Fig3.3A). Of the 979 
follicles which were classified as primordial, only 7 were classified as 
morphologically unhealthy and so these data are not shown in the figure. The only 
follicle type with a significant increase in the percentage classified as 
morphologically unhealthy were the primary follicles, which increased significantly 
following 0.1 and 0.2µg/ml cisplatin (Fig 3.3.B, p<0.01). As this class showed a 
significant increase in the percentage of morphologically unhealthy follicles, they 
was furthered analysed to determine which cell type was affected. The main reason 
that follicles were classified as unhealthy following cisplatin was due to the oocytes 
(Fig3.3.C). 
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3.3.1.2 Experiment 2: Preliminary Bovine Cultures with Cisplatin 
Bovine cortical strips were cultured in the presence of cisplatin and assessed 
morphologically to investigate if there was a similar effect to that observed in the 
mouse model described above. The concentration range was slightly increased due to 
the fact that there is denser stroma in bovine tissue which could affect the penetration 
of the drug into the tissue. Representative histological pictures are shown in figure 
3.4. The percentage of follicles classified as unhealthy increased significantly in all 
doses of cisplatin used (Figure 3.5.A, p<0.01).  
 
Virtually all follicles that were classified as unhealthy were classed as such due to 
morphologically unhealthy oocytes (of the 5996 total follicles counted, only 66 had 
unhealthy granulosa cells). When the distribution of follicle classes present in bovine 
cortical strips was compared to newborn mouse ovaries, there were more 
significantly fewer primordial and transitional follicles and a significantly higher 
percentage of primary follicles at the end of culture (Fig 3.6, p<0.05 except for 
primary follicles where p<0.01).  
 
As both the bovine and mouse cultures show similar results following cisplatin 
exposure and the mouse has a higher proportion of primordial follicles remaining at 
the end of culture, all subsequent experiments were conducted using the mouse 
model. This model was modified for the next experiments to shorten the exposure 
time of the drug used to 24 hours on the second day of culture only. This was to more 
closely model clinical conditions, where patients are exposed to a high dose bolus 
injection of the drug usually on an intermittent basis (Ansell, 2012).  
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3.3.2. Experiment 3: The effect of cisplatin and doxorubicin 
The effect of cisplatin noted in Experiments 3.1 and 3.2 was in contrast to previous 
experiments conducted in the lab examining the effect of doxorubicin, which showed 
morphological effects primarily in the granulosa cells of follicles (Murray and 
Spears, unpublished). Therefore, for the rest of the experiments here and in all 
subsequent experiments, cisplatin and doxorubicin were used in the same culture 
system and results compared. The concentration of cisplatin used was increased from 
the above experiments as the exposure time in this experiment was shorter. The 
concentrations of doxorubicin used were determined from previous preliminary dose 
response experiments in the lab (George Liperis, unpublished data). Both drugs were 
used in doses within the therapeutic range for patients, which are around 0.5-1 µg ml
-
1
 for cisplatin (Pfeifle et al, 1985; Urien and Lokiec, 2004) and about 0.02-0.6µg ml
-1
 
for doxorubicin (Barpe et al, 2010; Greene et al, 1983). Representative pictures of 
histological sections from each treatment group are shown in Fig 3.7. 
 
Follicles were assessed morphologically and classified into follicle stage and health. 
The total number of follicles counted for each treatment group is shown in Table 3.1. 
The proportion of follicles deemed morphologically unhealthy significantly 
increased with dosage for both cisplatin and doxorubicin (Fig 3.8.Ai and Bi). To 
assess whether drug treatment led to follicle loss, total follicle number was calculated 
from histological analyses and log transformed for normality. Both cisplatin and 
doxorubicin caused significant follicle loss, but with different patterns of dose 
response (Fig 3.8.Aii and Bii). Cisplatin induced significant loss of follicles only at 
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the highest concentration (5µg/ml; p<0.01), which induced poor health in almost all 
follicles (Fig 3.8.Ai). In contrast doxorubicin resulted in a significant decrease in 
follicle number even at a dose which induced poor health in only around 30-35% of 
follicles (0.05µg/ml; p<0.05; Fig 3.8.Bi). 
 
As both drug treatments led to increased numbers of unhealthy follicles, they were 
further categorized to see if a particular follicle class was affected by each drug. Both 
drugs caused a reduction in primordial follicle number to the point where, at the 
highest doses there were insufficient present to meaningfully analyse primordial 
follicle health (mean±sem number of primordial follicles in 5µg/ml cisplatin 
group=4±4, and in 0.2µg/ml
 
doxorubicin group=1±1, vs control=60±20; Fig 3.9.). 
However, further analysis was possible for transitional and primary follicles. 
Cisplatin caused a significant increase in the percentage of morphologically 
unhealthy transitional follicles only at the highest dose of cisplatin used (5µg/ml; 
p<0.001), whilst there were a significant percentage of unhealthy primary follicles at 
all doses (p<0.001; Fig. 3.10.A). In contrast, doxorubicin caused a significant 
increase in the percentage of both transitional and primary follicles classified as 
morphologically unhealthy at the second lowest dose (p<0.05 for transitional 
follicles, p<0.001 for primary follicles; Fig 3.10.B). 
 
In order to determine which specific follicular cell type was targeted by the two 
drugs, follicles were further classified as unhealthy due to: (a) the oocyte only; (b) 
granulosa cells only; or (c) both the oocyte and granulosa cells. In ovaries treated 
with cisplatin, unhealthy follicles were classified as such primarily due to oocyte 
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health (Fig 3.11.A), with significant increases in the percentage of follicles with 
morphologically unhealthy oocytes seen at all doses of cisplatin used (p<0.05). 
Doxorubicin, in contrast, primarily induced follicles classified as unhealthy due to 
the granulosa cell health (Fig 3.11.B), with significant increases in the percentage of 
follicles with morphologically unhealthy granulosa cells seen at the three highest 
doses (p<0.001). For both drugs, follicles in which both the oocyte and granulosa 
cells were unhealthy were rarely seen except at the highest dose (Fig 3.11.C; p<0.001 
for the two highest dose of both cisplatin and doxorubicin). 
 
During the analysis, it was noted that oocytes appeared larger in ovaries treated with 
doxorubicin, particularly at the higher doses. To assess this further, oocytes were 
measured in the ovaries treated with the highest dose of cisplatin and doxorubicin 
and compared to control (Fig 3.12.). There was a trend towards larger oocytes in 
doxorubicin treated ovaries; however this was not significant. Oocytes from primary 
follicles in cisplatin treated ovaries were, though, found to be significantly smaller 
than control (p<0.05). Follicle size was larger in doxorubicin cultures and smaller in 
cisplatin treated ovaries compared to the control; however this was not significant 
(Fig 3.12.ii). Nonetheless, it could be that the oocyte diameter is smaller in the 
primary follicles either because they are less developed or due to their poor health 
following cisplatin treatment. 
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 Total number of 
follicles counted 
Total number of 
follicles classified 
as healthy 
Total number of 
follicles classified 
as unhealthy (%) 
Control 1572 1513 59 (4) 
0.05µg/ml cisplatin 1788 1698 90 (5) 
0.1µg/ml cisplatin 1313 968 345 (26) 
0.2µg/ml cisplatin 973 824 149 (15) 
 
Table 3.1. Total number of follicles counted in newborn mouse ovaries cultured for 
6 days with cisplatin in each treatment group in Experiment 3.1 as well as the total 
number of these follicles classified as healthy or unhealthy (n=4 ovaries in each 
















































Figure 3.2. The percentage of murine follicles classified as unhealthy following 
cisplatin exposure. Bars denote mean±sem; n=4 for all groups except 0.2µg/ml 




















































































































Figure 3.3. The percentage of (A) transitional and (B) primary murine follicles 
classified as unhealthy following treatment with cisplatin. Primary follicles were 
further classified into damaged cell type (C): oocyte (blue check), granulosa cells 
(clear) or both (dark blue). Bars denote mean±sem, n=4 in all groups except 
0.2µg/ml where n=2, stars denote significant differences (**p<0.01). 
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Fig 3.4. Representative histological sections of bovine cortical strips cultured in 
control, 0.1µg/ml, 0.2µg/ml or 0.4µg/ml cisplatin. Scale bars represent 50µm. Black 
arrows indicate unhealthy oocytes. 
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 Total number of 
follicles counted 
Total number of 
follicles classified 
as healthy 
Total number of 
follicles classified 
as unhealthy (%) 
Control 1155 865 290 (25) 
0.1µg/ml cisplatin 1401 726 675 (48) 
0.2µg/ml cisplatin 1179 117 1062 (90) 
0.4µg/ml cisplatin 954 207 747 (78) 
 
Table 3.2. Total number of follicles counted in bovine cortical strips cultured for 6 
days in the presence of cisplatin as well as the total number of these follicles 















































Figure 3.5. Percentage of unhealthy follicles in bovine cortical strips following 
exposure to cisplatin, n=12 for all groups, bars denote mean±sem, stars denote 



































































Fig 3.6 Comparison of follicle distribution following six day culture for control 
treated murine (n=5) and bovine (n=12) tissue. Bars denote mean±sem.  
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Fig 3.7. Representative histological sections of mouse newborn ovaries cultured in 
increasing concentrations of cisplatin (left column) or doxorubicin (right column). 
Specifically, A and B) control, C) 0.1µg/ml cisplatin, D) 0.01µg/ml doxorubicin, E) 
0.5µg/ml cisplatin, F) 0.05µg/ml doxorubicin, G) 1µg/ml cisplatin, H) 0.1µg/ml 
doxorubicin, I) 5µg/ml cisplatin and J) 0.2µg/ml doxorubicin. Scale bars represent 
50µm. Solid black line arrows indicate follicles with unhealthy oocytes. Dashed line 




 Total number 
of follicles 
counted 
Total number of 
follicles classified 
as healthy 
Total number of 
follicles classified 
as unhealthy (%) 
Control 1620 1528 92 (6) 
0.1µg/ml cisplatin 1134 900 234 (21) 
0.5µg/ml cisplatin 1371 1028 343 (25) 
1µg/ml cisplatin 641 385 256 (40) 
5µg/ml cisplatin 123 10 113 (92) 
 
 Total number 
of follicles 
counted 
Total number of 
follicles classified 
as healthy 
Total number of 
follicles classified 
as unhealthy (%) 
Control 1574 1522 52 (3) 
0.01µg/ml doxorubicin 1667 1532 135 (3) 
0.05µg/ml doxorubicin 553 369 184 (33) 
0.1µg/ml doxorubicin 286 123 163 (57) 
0.2µg/ml doxorubicin 117 19 98 (84) 
 
Table 3.3. Total number of mouse follicles counted in each treatment group in 
Experiment 3.3 as well as the total number of these follicles classified as healthy or 

















































































































































Fig 3.8. (A) Cisplatin and (B) doxorubicin both lead to loss of murine follicle 
health and a reduction in follicle numbers. (i) Percentage of unhealthy follicles 
(green) and (ii) total number of follicles (purple) in each ovary. Bars denote 
mean±sem; n=5 for all groups, stars denote significant differences relative to control 


































































Figure 3.9. Number of primordial follicles (PMF) remaining following treatment 








































































































































































A: Cisplatin B: Doxorubicin
 
Figure 3.10.  Follicles were classified as morphologically unhealthy in cisplatin 
and doxorubicin treated mouse ovaries according to follicle type. Effect of (A) 
Cisplatin or (B) Doxorubicin on the percentage of transitional and primary follicles 
classified as morphologically unhealthy. Bars denote mean±sem; n=5 for all groups, 
stars denote significant differences relative to control (*p<0.05, **p<0.01, 
***p<0.001). 
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Figure 3.11. Cisplatin and doxorubicin affect different follicular cell types. Mouse 
ovaries were treated with cisplatin or doxorubicin and all unhealthy growing 
(transitional and primary) follicles were further categorized as unhealthy due to: (A) 
poor oocyte health; (B) poor granulosa cell health; or (C) both. Bars denote 
mean±sem; n=5 for all groups except for control where n=10, stars denote significant 



























































































































































































































































































































Figure 3.12. (i) Oocyte and (ii) follicle size of A) transitional and B) primary 
follicles. Bars denote mean±sem, n=5, stars denote significant differences from 




Initial experiments with cisplatin indicate in both the murine and bovine model that 
cisplatin causes follicle damage, with the oocyte appearing particularly susceptible. 
When cisplatin and doxorubicin are compared in the same culture model, the two 
drugs appear to target different cell types. 
 
3.4.1 Comparison of bovine and murine models 
When compared to the newborn mouse ovary, the follicle population within bovine 
cortical strips was different, with the vast majority of follicles activated by the end of 
the six day culture. Within the newborn mouse ovary culture, a high proportion of 
primordial follicles activated over the six days but this is not as widespread as in the 
bovine tissue. This is similar to other studies which have cultured bovine cortical 
strips (Fortune et al, 2000). The reason for such a widespread activation in bovine 
tissue is unclear but could be due to withdrawl of an inhibitory signal (which remains 
intact in the mouse whole ovary culture) or due to differences in the nutrient and 
oxygen exposure. In vivo, primordial follicles are maintained in the ovarian cortex 
which is poorly vascularized and so this increase in nutrient or oxygen exposure 
could lead to increased follicle activation (Wandji et al, 1997). 
 
Whilst the follicle population of the two culture systems was slightly different, there 
was still a detrimental effect on follicle health in the bovine tissue following cisplatin 
treatment, with a dose dependent increase in the number of unhealthy follicles. The 
percentage of follicles classified as unhealthy following drug treatment appears much 
higher in the bovine cortical strips when compared to similar concentrations of 
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cisplatin in the preliminary mouse culture, which could indicate that bovine follicles 
are more vulnerable to cisplatin-induced damage. However, the percentage of 
follicles which were classified as unhealthy in bovine tissue cultured in control 
medium is also higher than in the mouse, indicating that the follicles did not survive 
the culture process as well generally and so may help explain this discrepancy.   
 
In the bovine cultures, the oocyte was also the primary reason that follicles were 
classified as unhealthy; pyknotic granulosa cells were rarely seen. This indicates that 
the effect of cisplatin on oocytes noted here is not species specific, and may 
demonstrate a more general vulnerability of oocytes to cisplatin-induced damage. It 
is known that mouse oocytes are more sensitive to low doses of radiotherapy than 
other species (Adriaens et al, 2009); it is therefore interesting that the detrimental 
effect of cisplatin is similar in both species examine here. There is always the 
concern when using different species (such as the mouse) as a model for humans that 
results are not transferable due to species related differences; therefore to see similar 
results in both murine and bovine tissue is quite reassuring in terms of how 
applicable our model is. Ideally the next step would be to culture human tissue with 
cisplatin or doxorubicin to check if similar results are seen; this is currently being 
done in the lab.  
 
3.4.2 Comparison of cisplatin and doxorubicin  
Both cisplatin and doxorubicin have been linked to premature ovarian failure due to 
follicle loss; data presented here is consistent with this as there was a decrease in 
follicle number and an increase in unhealthy follicles following both drug treatments 
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when compared in the same murine ovary model. Both drugs were used in doses 
within serum range for patients which are around 0.5-1 µg ml
-1
 for cisplatin (Pfeifle 
et al, 1985; Urien and Lokiec, 2004) and about 0.02-0.6µg ml
-1
 for doxorubicin 
(Barpe et al, 2010; Greene et al, 1983). 
 
The stage of follicle loss affected following cisplatin treatment is predominantly the 
growing primary follicles in contrast to doxorubicin which equally affects both 
transitional and primary. Morphologically, it was difficult to assess the health of 
primordial follicles. By the highest doses of drugs, primordial follicle numbers were 
too low for a meaningful statistical assessment. Assessing the ovaries at an earlier 
point in culture may be a way around this, as the predominant follicle class in the 
first 3 days of culture is primordial (Federica Lopes, unpublished data, Fig 3.1). 
Throughout the six days, more primordial follicles are activated and so there is a shift 
in the class distribution. Primordial follicle numbers could be depleted here due to 
direct primordial follicle damage by the chemotherapeutic agents or due to an 
indirect effect; damage to more mature, growing follicles would lead to increased 
recruitment of primordial follicles out of the resting pool and hence to premature 
depletion of that resting follicle reserve (Meirow et al, 2010; Morgan et al, 2012).  
 
3.4.2.1 The effect of cisplatin 
Cisplatin causes cell death through DNA crosslinking and adduct formation. When 
the DNA damage is overwhelming, this activates cell signalling pathways 
culminating in apoptosis. Following cisplatin exposure, the primary reason for 
classifying a follicle as unhealthy was the oocyte, suggesting that cisplatin directly 
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targets the germ cell. This corroborates the preliminary data in both the murine and 
bovine models, which also observed oocyte specific damage. Given the importance 
of protecting the integrity of the germ line from DNA damage, it is perhaps logical 
that the germ cell may be particularly vulnerable to agents that cause overwhelming 
DNA damage. The sensitivity of the oocyte to cisplatin in particular could be 
explained by the diffuse chromatin in oocytes (Luciano et al, 2012). A study which 
exposed Hela cells to cisplatin and examined alterations in gene expression found 
that cisplatin inhibited expression of genes which were associated with more 
accessible chromatin (Jamieson and Lippard, 1999). The preferential site of ovarian 
toxicity being the oocyte may explain why follicle health was not reduced in follicles 
on initiation of growth (i.e. transitional follicles), but manifested at the slightly later 
primary stage. The fact that oocytes were significantly smaller in primary follicles at 
the highest dose is likely a reflection of their poor health; one of the major criteria for 
assessing oocyte health is shrunken cytoplasm. As discussed above, there is a larger 
percentage of primary follicles present in bovine cortical strips. If there is an 
increased vulnerability in follicles which have been activated to grow following 
cisplatin exposure, this may be another explanation of why the cortical strip cultures 
had such a high proportion of follicle death. 
  
3.4.2.2 The effect of doxorubicin 
Doxorubicin causes cell death through inhibition of topoisomerase enzymes and 
causing problems in DNA replication and transcription. Results here show that 
doxorubicin may directly target the granulosa cells, as the primary reason for 
assessing follicles as unhealthy was due to pyknotic granulosa cells. In contrast to 
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oocytes, granulosa cells are mitotically active, which may explain their vulnerability 
to these types of chemotherapy agents. Mature (MII) oocytes which are exposed to 
doxorubicin in vitro undergo apoptosis (Jurisicova et al, 2006; Perez et al, 1997) and 
oocytes collected from antral follicles and cultured are also highly susceptible to 
such damage (Bar-Joseph et al, 2010). As the oocytes examined here are not mature 
but contained within immature follicles, they may be less sensitive to doxorubicin. 
However, the model used here may be of more relevance to patients, as the oocytes 
contained in immature follicles are required to maintain long term fertility. A study 
in human primordial follicles treated in vitro to doxorubicin observed damage in both 
the granulosa cells and oocyte; however this study used much higher concentrations 
of doxorubicin than found in patient serum (Soleimani et al, 2011). The slightly 
larger oocyte size seen in doxorubicin treated ovaries, although not significant, could 
be a real effect, perhaps due to a dysregulation of oocyte growth by the granulosa 
cells. Increasing the n number would be useful here, to see if the result becomes 
significant. Due to the essential interaction between the oocyte and granulosa cells 
for each others growth and development, any problems in the granulosa cells could 
have a downstream effect on oocyte growth and health. 
 
3.4.3 Stromal effects 
Some research has suggested that chemotherapy may damage the stroma, and that 
this damage may have a detrimental downstream effect on follicle health (Marcello 
et al, 1990; Meirow et al, 2007). There was pyknosis of stromal cells evident in both 
the mouse and bovine models but this was inconsistent between treatment groups. 
Molecular analysis of cell death markers may be a more meaningful and practical 
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method of assessing any detrimental effects of chemotherapy on the ovarian stroma 
and will be discussed further in Chapter 4. 
 
3.4.4 Conclusion 
The data presented here indicate that cisplatin and doxorubicin cause ovarian follicle 
loss but target different cells. The molecular mechanisms through which these drugs 












MOLECULAR MECHANISMS BY WHICH CISPLATIN 
AND DOXORUBICIN INDUCE CELL DEATH 
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4.1 Introduction 
There are multiple potential pathways through which a cell can die, with the 
considerable cross-talk between these making dissecting specific mechanisms 
difficult. The ovary is the site of a large amount of cell death physiologically, with 
the vast majority of follicles dying through atresia. The exact molecular pathways 
involved in follicle atresia are not well understood, with some studies implicating 
apoptosis and others indicating autophagy. Chemotherapy could induce ovarian 




Apoptosis is perhaps the most well defined mechanism of cell death. The term 
programmed cell death was often previously used synonomously for apoptosis; 
however there is now more recent evidence that other cell death pathways such as 
necrosis and autophagy are also forms of programmed cell death. Apoptosis plays a 
significant role during development and is responsible for the removal of cells which 
are potentially harmful, senescent or no longer needed. Morphologically, it is 
characterised by membrane blebbing, cell shrinkage, chromatin condensation and 
DNA fragmentation. Apoptosis can be induced through pro-death signalling, a lack 
of growth factor signalling or anti-apoptotic signalling as well as stress inducers such 
as radiation. There is some evidence that apoptosis is involved in follicle loss 
following chemotherapy treatment (Perez et al, 1997) and a few specific signalling 
cascades have been investigated. One such is the ceramide pathway, which when 
suppressed can prevent oocyte apotosis (Morita et al, 2000).   
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4.1.1.2. Markers of apoptosis 
There are several markers which are often used to detect evidence of apoptosis. 
These include TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end 
labelling) assays, which detects DNA fragmentation, cleavage of the caspase protein 
family (traditionally Caspase 3) and cleavage of PARP-1 (Poly [ADP-ribose] 
polymerase 1).  
 
The PARP family of enzymes cause poly(ADP-ribosyl)ation, which is important for 
cell survival and the cell stress response. It is the process of adding long chains of 
ADP-ribose onto proteins as a form of post-translational modification. Proteins 
which are modified in this way include topoisomerases, histones, DNA polymerases 
and ligases. There are several members of the PARP family but by far the best 
characterised is PARP-1, which is activated predominantly in the presence of single 
and double strand DNA breaks (Virag et al, 2013). PARP-1 has been demonstrated 
to be essential for DNA repair during genotoxic stress in both PARP-/- mice (de 
Murcia et al, 1997) and cell lines (Trucco et al, 1998). When DNA damage is minor, 
PARP activates enzymatic machinery such as DNA polymerase and ligase, allowing 
repair of these breaks (Soldani and Scovassi, 2002). Where DNA damage is 
extensive, hyperactivation of PARP can lead to a large increase in poly(ADP-ribose) 
levels, an energy expensive process as it occurs at the expense of the cells NAD
+
 
(Nicotinamide adenine dinucleotide) supply (Burkle and Virag, 2013). The decrease 
in NAD
+ 
causes an imbalance in the NAD/NADH ratio which affects the activation 
of enzymes involved in respiration, as well as altering the redox state of the cell. The 
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cell will then try to restore the NAD pool by recycling nicotinamide with ATP 
(Adenosine triphosphate), meaning that excessive activation of PARP-1 depletes the 
pool of ATP and NAD
+
 (Boulares et al, 1999), affecting all energy-dependent 
processes in the cell. PARP-1 is cleaved during apoptosis, predominantly by the 
caspase family of proteins, in order to conserve the energy supplies of the cell.  
 
In work by others in this laboratory (Lopes and Spears), TUNEL staining was used to 
determine if there was an increase in DNA fragmentation in primordial follicles 
following treatment of ovaries with either cisplatin or doxorubicin. There was no 
significant increase in the number of cells labelled TUNEL positive (Fig 4.1), 
suggesting that apoptosis may not be involved in cisplatin or doxorubicin induced 
primordial follicle loss (Morgan et al, 2013, work done by Federica Lopes).  
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Fig 4.1 TUNEL-analysis to determine apoptosis in primordial follicles. (A): ovary 
section labelled with TUNEL reaction (green) and counterstained with DAPI (blue). 
Inset top- and bottom-right magnification images are of the respective framed areas, 
illustrating examples of TUNEL positive oocytes (white arrowheads) and TUNEL 
positive granulosa cell (white arrow) within follicles identified as at the primordial 
stage in (B). (B): section in (A) subsequently stained with haematoxylin and eosin. 
Inset sections in (A) correspond here to degenerated oocytes (black arrowheads) and 
degenerated surrounding granulosa cells (black arrow) within primordial follicles. 
Scale bar = 50 μm. (C) Total number of primordial follicles, and number of 
primordial follicles containing TUNEL-positive cells, in ovaries treated with 
cisplatin or doxorubicin. (D): TUNEL-positive primordial follicles further 
categorised into percentage in which the oocyte or the granulosa cells stained 
positive. Bars denote mean±sem; n=4-5 ovaries per treatment group; stars denote 























































































Autophagy is a form of programmed cell death which is highly conserved and tightly 
regulated. There is a basal level of autophagy present in all eukaryotic cells which 
helps maintain homeostasis, as it involves the degradation of cytoplasmic 
components leading to the production of metabolites for the cell. Autophagy is 
upregulated following amino acid starvation and other cellular stresses. If autophagy 
is inhibited, there is evidence that this can lead to alternative cell death pathways 
such as apoptosis. Dysregulation of autophagy has been linked to various diseases 
such as cancer (Kondo et al, 2005) and neurodegeneration. At the molecular level, it 
involves organelles and components of the cytoplasm being engulfed in 
autophagosomes (double membraned vacuoles), which then fuse with lysosomes and 
are degraded (Choi et al, 2010).  
 
There are over 30 genes which have been identified as playing an important role in 
autophagy; some of which are essential for it to occur. These include Beclin1, Ulk1 
(unc-51 like autophagy activating kinase 1), Atg7 (Autophagy-related protein 7), and 
Atg13 (Autophagy-related protein 13). Beclin1 promotes the formation of the 
autophagosome, allowing for cytoplasmic components to be sequestered and 
degraded. It also interacts with the canonical apoptosis pathway, by interacting with 
the anti-apoptotic Bcl-2 family of proteins (Liang et al, 1998). Ulk1 is responsible 
for phosphorylating Beclin1, allowing for formation of the autophagosome and is 
essential for the induction of autophagy in mammals (Russell et al, 2013). Atg13 is 
also essential for autophagy induction, at least in part due to its ability to enhance 
Ulk1 activity (Alers et al, 2011). Atg7 is required for expansion of the 
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autophagosome (Mehrpour et al, 2010) and in the ovary, a null mutant mouse for 
Atg7 lacks any discernable germ cells by postnatal day 1 (Gawriluk et al, 2011), 
indicating its importance in germ cell survival (Summarised in Fig 4.2.). 
 
Autophagy is essential in the Drosophila melanogaster ovary for the process of 
oogenesis to successfully occur (Barth et al, 2011). In the mouse ovary, autophagy 
appears to be an important cell survival mechanism for germ cells, as mice deficient 
in Becn1 or Atg7 have a significant reduction in the number of primordial follicles 
present perinatally (Gawriluk et al, 2011). This suggests that autophagy may be 
important in regulating germ cell nest breakdown and/or primordial follicle 
formation. In a toxicology test investigating the ovotoxicity of cigarette smoke, 
autophagy was found to be the key mechanism of follicle loss following such 





Fig 4.2. Brief summary of autophagy. Ulk1 is the main gene responsible for the 
induction of autophagy, its activity being enhanced by Atg13. Through Bcln1 and 




Another process of programmed cell death is necrosis, which involves characteristic 
cell changes including increased membrane permeability and nuclear degeneration 
(de Bruin et al, 2002). Necrosis was not considered to be a form of programmed cell 
death until recently; previously, it was considered to be more of an ‘accidental’ or 
passive response to cell injury. The mechanisms of necrosis and apoptosis have 
massive overlap, with many key players involved in both processes. Necrosis can be 
induced by cytokines such as Tumour necrosis factor (TNF) and FasL, ischemia, 
oxidative stress or DNA damage (Proskuryakov et al, 2003). The reason that a cell 
enters into necrotic cell death rather than apoptosis is not clear but is likely related 
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mainly to the energy status of the cell (Eguchi et al, 1997) as well as the cell type and 
its environment. Apoptosis is an ATP-dependant process, whilst an energy 
deficiency such as a large reduction in cell ATP can lead to the alternative necrotic 
pathways. The importance of necrosis in the ovary is not as well defined as apoptosis 
but has been linked to the process of ovulation in sheep (Murdoch et al, 1999).  
 
Due to the massive overlap between necrotic and apoptotic intracellular pathways, it 
is difficult to solely identify the activation of necrosis. Most experimental techniques 
rely heavily on the morphological differences between the two, as necrosis causes 
cells to swell and the membrane to become more permeable (Proskuryakov et al, 
2003). This is in contrast to apoptosis which causes cells to shrink and nucei to 
condense. Work by others in the laboratory (Zukowska, Lopes and Spears, 
uupublished data) using propidium iodide absorption (to demonstrate increased 
membrane permeability) as a marker for necrosis found no significant increase 
following drug treatment, suggesting that this is not a key mechanism of cisplatin or 
doxorubicin induced follicle death.  
 
4.1.4 Aims 
Given that the classes of chemotherapy drugs are all linked to an array of different 
mechanisms, it is likely that different drugs could induce a variety of specific cell 
death pathways, meaning that the effect on the ovary could be very drug specific. 
The aim of the work in this chapter was to compare the molecular actions of cisplatin 
and doxorubicin and to determine if different pathways are activated. As preliminary 
 99 
experiments indicated that necrosis may not be involved, work concentrated on 
autophagy and apoptosis. 
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4.2 Materials and methods 
4.2.1 Animals 
C57BL6 newborn female mice were used for all experiments.  
 
4.2.2 Culture of newborn ovaries. 
Newborn mouse ovaries were cultured as described in Chapter 2. The culture time 
was shortened to 2 days, so that ovaries were cultured in control medium for 24 
hours, exposed to either cisplatin or doxorubicin for a further 24 hours and then 
removed from culture.  Ovaries were then washed in cold PBS (Phosphate buffered 
saline, Invitrogen # 10010-015, pH7.4) and snap frozen in eppendorfs on dry ice. For 
Westerns assessing the time course of cleaved PARP expression, ovaries were 
removed from culture after 4, 8, 12 or 24 hours of cisplatin exposure (following the 
initial 24 hours of culture). Each time point had a control and a treated group.  
 
For qPCR analysis, 3 ovaries were pooled in each treatment group to create 1 
sample. This is because preliminary experiments indicated that fewer ovaries 
provided too small a yield of RNA. Three samples were then analysed which were 
taken from 3 independent cultures. For Western blot analysis, 2 ovaries were pooled 
in each treatment group to create 1 sample and to ensure sufficient protein yield. For 
the time course experiments, 2 samples from different cultures were analysed. For 





4.2.3 RNA extraction 
RNA was extracted from ovaries using an RNeasy mini kit (Qiagen UK, #74104) 
and according to manufacturer instructions (Summarised in Fig 4.3). On column 
DNA digestion was included to remove any genomic DNA contamination. From one 
eppendorf which contained 3 ovaries of the same treatment group pooled, 30µl of 
RNA containing water was eluted.  
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Fig. 4.3. Summary of protocol for RNA extraction using RNeasy mini kit. 
 
The concentration of RNA eluted was assessed using a Nanodrop 2000 
(Thermoscientific, UK). The average concentration of RNA expected was 
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approximately 20-30µg/µl. If the concentration of RNA was too low, the sample was 
discarded. The quality of eluted RNA was assessed by running 1µl of each sample on 
a 1% (w/v) agarose gel. 
 
4.2.4. RNA gel 
A 1% (w/v) agarose gel was made containing SYBRsafe staining dye (1µl in 50mls, 
Invitrogen, #S33102). The gel was prepared by dissolving 0.5g agarose (SeaKem® 
LE agarose, #50002, Stratech Scientific UK) in 50mls 1% TBE buffer. Solution was 
microwaved and topped up with dH2O until completely dissolved. Samples were 
added to a loading dye (6x, #R0611, Thermoscientific), separated using 
electrophoresis and examined using a UV transilluminator at 254nm. Two clear 
bands representing 18s and 28s ribosomal RNA were considered good, any smeared 
samples were discarded. 
 
4.2.5. cDNA synthesis 
cDNA was synthesised using the Quantitect Reverse Transcription kit (Qiagen, 
#205311) and according to manufacturers instructions. RNA was incubated with 
gDNA Wipeout Buffer to remove any genomic DNA contamination. The RNA was 
incubated in a mixture of primers, reverse transcriptase enzyme, Mg
2+
 and dNTPs for 
15 mins at 42ºC. Alongside, a sample of RNA was incubated with the same mix 
without reverse transcriptase enzyme present. This was to provide an additional 
control for qPCR analysis (called –RT control). All samples were then heated to 
95ºC for 3 minutes to inactivate the reverse transcriptase enzyme. Samples were then 
stored at -80ºC until needed (summarised in Fig 4.4).  
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Fig 4.4. Flow diagram of cDNA synthesis protocol using the Quantiscript Reverse 
Transcription Kit. 
 
4.2.6. Primer design 
For every cDNA which was analysed by real time PCR, primers had to be designed. 
cDNA sequences were obtained from the NCBI Nucleotide Database 
(http://www.ncbi.nlm.nih.gov/nuccore/), including alternatively spliced isoforms. 
The gene region which was chosen to design primers was common to all 
alternatively spliced isoforms and when possible, spanned exon exon junctions, to 
help eliminate the amplification of contaminating genomic DNA during PCR. 
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Once the gene region was chosen, this was imported into the online primer design 
software Primer3 (http://frodo.wi.mit.edu/). Primers were selected on the following 
criteria: 
1. Were 18-25 base pairs long (ideally 20) 
2. Amplified a region of up to 250 base pairs 
3. Had low scores on primer-primer self and inter- complementarity tests 
4. Had a GC% ratio of around 50% 
5. An annealing temperature range of 55-60º 
 
Each primer sequence was then checked in the NCBI database BLAST algorithm to 






Forward primer Reverse primer 
Becn1 5’AGCCTCTGAAACTGGACACG 5’TGGCGAGTTTCAATAAATGG 
Ulk1 5’TGGGCAAGTTCGAGTTCTCT 5’TTGATTTCCTTTCCCAGCAG 
Atg7 5’CCTGCACAACACCAACACAC 5’CGAAGGTCAGGAGCAGAAAC 
Atg 13 5’TTTTGCCCTCAAGACTGTCC 5’GACAGGGCCTTCTTTGCTTC 
 
Table 4.1. Primer sequences designed for qPCR analysis 
 
4.2.7. Quantitative PCR 
The relative amount of cDNA in an ovary sample was quantified using the 
QuantiTect SYBR Green Real-Time PCR Kit (Qiagen, #204143) and according to 
manufacturer’s instructions.  
 




SYBR Green 10 
RNase free H2O 7 
cDNA 1 
Reverse Primer 1 
Forward Primer 1 
 
Table 4.2. Reaction mix details for Real Time qPCR analysis  
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Reaction mixes (Table 4.2) were made up in sterile PCR tubes and mixed thoroughly 
by pipetting (#TC50851, lids #TC50803, BioRad). The relative amounts of any 
genes quantified were normalised against the housekeeping gene Gapdh 
(Glyceraldehyde 3-phosphate dehydrogenase), using the sense 
5’GGGTGTGAACCACGAGAAAT and the antisense 
5’CCTTCCACAATGCCAAAGTT primers (Primers designed by P Filis). Gapdh 
was selected as a housekeeping control as it is a well-established one and preliminary 
experiments indicated that it had a constant expression between samples tested. In 
each experimental run, a sample of cDNA from control, cisplatin and doxorubicin 
treated ovaries were run in triplicate for the gene being examined and Gapdh. 
Additionally a water and a –RT control was included for each gene. Alongside this, a 
standard curve for each gene would be run using 5-fold dilutions of highly 
concentrated cDNA from adult mouse ovaries.  
  
4.2.8. qPCR analysis 
The values for each triplicate analysis were averaged and normalised to the 
housekeeping gene values, to make one value per experimental run. Each gene was 
analysed in 3 separate runs, with a different ovary sample used in each i.e. an n of 3 
for each gene analysed. ANOVA was used to determine if groups were significantly 
different followed by Bonferroni post hoc tests. 
 
4.2.9. Protein extraction. 
20µl of protein lysis buffer (50nM HEPES buffer, 10% [v/v] Triton X, 50mM NaCl, 
Protease inhibitor cocktail [#11697498001, half a tablet in 10mls] and protease 
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inhibitors [I, #P0044, 1% (v/v) and II, #P5726, 1% (v/v)], H2O; all purchased from 
Sigma Aldrich Ltd except for Protease inhibitor cocktail which was purchased from 
Roche Diagnostic Ltd, UK) was added to snap frozen ovaries. Ovaries were then 
homogenised using a sterile pestle and centrifuged then at 4ºC for 20 minutes at 
13000rpm. 10µl of supernatant was removed and frozen at -20ºC until use. Protein 
extracts were denatured by boiling them for 5 minutes at 95ºC in 1:1 Laemmli buffer 
(Sigma-Aldrich, #127K6052) and loaded into a 7% (v/v) polyacrylamide gel.  
   
4.2.10. Western blotting 
7% (v/v) polyacrylamide gels (Resolving gel: 7% (v/v) Acrylamide/bis acrylamide 
(Sigma Aldrich, #A3699), 0.1% SDS [Sodium dodecyl sulphate], 375mM Tris HCl, 
0.15% Ammonium persulfate and 0.0004% TEMED [N,N,N′,N′-
Tetramethylethylenediamine], Stacking gel: 4% Acrylamide/ bis acrylamide, 0.1% 
SDS, 125mM Tris HCl, 0.15% Ammonium persulfate and 0.004% TEMED, pH 6.8) 
were made to separate proteins in the samples by electrophoresis. 10µl of each 
sample (approximately 10µg protein per lane) was loaded and run at room 
temperature in the presence of Running Buffer (50mM Tris HCl, 350mM glycine, 
0.2% SDS[w/v]) at constant ampere (15mA/gel)  until proteins were well separated. 
Alongside the samples, 5µl of a molecular weight ladder (Thermoscientific UK, 
Pageruled Plus Prestained Ladder #26619, range 10-250kDa) was loaded to allow 
easier identification of proteins by molecular size. 
 
Resolved proteins from the gel were transferred onto nitrocellulose membranes 
(BioRad UK, #162-0115) in the presence of Transfer buffer (25mM Tris HCl, 
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200mM glycine, 20% [v/v] Methanol) for 1 hour at 200mA at 4ºC. The nitrocellulose 
membranes were then washed in a plastic box with a protein staining solution (1% 
[w/v/] Amido Black, 5% [v/v] acetic acid, 10% [v/v] Methanol) to confirm good 
protein transfer and separation. Membranes were then washed repeatedly in water to 
remove staining.  
 
Membranes were then incubated for 1 hour in Blocking solution (5% powdered milk 
(w/v), PBS [pH 7.3, 160mM NaCl, 3mM KCl, 8mM Na2HPO4, 1mM KH2PO4], 
0.1% [v/v] TWEEN), with the primary antibodies (PARP, Cell Signalling #9542, 
1:1000 and βactin, Abcam UK #8227, 1:5000) then added into the solution. This was 
incubated overnight at 4ºC, then washed 3x 5mins in washing buffer (1x PBS with 
0.1% TWEEN), probed with Alexafluor® 750 Goat anti-rabbit secondary antibody 
(Invitrogen UK, A-21039) at room temperature for 1 hour, washed again in wash 
buffer 3x 5mins and dried. The fluorescent signal was detected by scanning the 
membranes with Odyssey Infrared Imaging Scanner by LiCor (LiCor BioSciences 
Ltd) according to manufacturer’s instructions. 
 
4.2.11 Statistical Analysis 
Measurements of protein band size were taken using LiCor Odyssey software and the 
size of the Cleaved PARP (89kDa) band was divided by the size of the β actin band 
for each lane. The means of 3 independent samples per treatment group was 
calculated and any statistically significant differences were assessed by one way 
ANOVA, followed by Bonferroni post hoc tests. All statistical tests were carried out 
using Graphpad Prism. 
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4.3. Results 
4.3.1 Expression of autophagy-associated genes 
Quantitative PCR analysis was used to detect mRNA expression of autophagy genes, 
Ulk 1, Atg7, Atg13 and Becn1, following 24 hours of exposure to 0, 5µg/ml cisplatin 
or 0.2µg/ml doxorubicin. These concentrations were selected as they are the highest 
used previously and were therefore considered to be the most likely to show an 
effect. No expression of Ulk1, Atg7 or Atg 13 was detected. Expression of Becn1 was 
detected but no increase was seen following drug-exposure, in fact expression 
significantly decreased following both cisplatin and doxorubicin (Fig 4.5). These 
results indicate that autophagy is unlikely to be a key mechanism in the action of 
cisplatin or doxorubicin. Furthermore, the decrease in Becn1 expression suggests that 
apoptosis may be important. Subsequent experiments therefore examined the 
expression of cleaved PARP, as an indicator of apoptosis. 
 
4.3.2 Cleaved PARP protein expression 
Western blots were used to detect cleaved PARP protein expression (representative 
blots shown in Fig 4.6). A preliminary experiment was undertaken to determine the 
peak of cleaved PARP expression following cisplatin treatment. This was due to 
concerns that solely using a single time point of 24 hours of drug exposure could lead 
to missing the peak of expression of cell death markers. However, results indicate the 
expression of cleaved PARP is highest at 24 hours over the analysed time period (Fig 
4.7). Subsequent experiments therefore used 24 hours of exposure to either cisplatin 
or doxorubicin. At 24 hours, cisplatin caused a dose-dependant increase in cleaved 
PARP expression with significant differences detected at 1 and 5µg/ml (Fig 4.8A). 
 111 
There was a significant increase in cleaved PARP expression following doxorubicin 
treatment; however this was not as robust an increase as in the cisplatin treated 
ovaries (Fig 4.8B). Overall, results here indicate that cisplatin and doxorubicin are 


























































Figure 4.5. mRNA expression of Becn1 relative to Gapdh. Bars denote mean±sem, 




Figure 4.6. Representative Western blots showing Cleaved PARP and β-actin 
protein expression in ovaries following exposure to increasing concentrations of A) 
cisplatin or B) doxorubicin for 24 hours. 
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Figure 4.7. Protein expression of cleaved PARP over 24 hours in ovaries treated 

































































































Figure 4.8. Protein expression of cleaved PARP in newborn mouse ovaries treated 
with A) cisplatin or B) doxorubicin relative to βactin. Bars denote mean±sem, stars 





4.4.1 Cell death is unlikely to occur via autophagy  
Autophagy is a process of cell death which is being increasingly implicated as having 
a crucial role in the ovary. No expression of autophagy genes Ulk1, Atg7 or Atg13 
was detected and expression of Becn1 significantly decreased following drug 
exposure. Results here therefore indicate that autophagy is not an important 
component of either cisplatin- or doxorubicin-induced ovarian cell death. There are 
over 30 genes which have all been identified as being involved in autophagy; the 
genes selected for analysis here have all been shown to be indispensable for 
autophagy to occur (Mehrpour et al 2010): it is therefore unlikely that autophagy is a 
major player as none of the genes tested increased in expression.  
 
Autophagy and apoptosis interconnect, with each process negatively regulating the 
other to produce a balancing act allowing for cell survival. Key to this balance is 
Beclin1 (Marquez and Xu, 2012), a protein which is essential for autophagy to occur. 
Beclin1 promotes the formation of the autophagosome, allowing for cytoplasmic 
components to be sequestered and degraded. Beclin1 can however bind to Bcl-2 
family members (Liang et al, 1998), which are anti-apoptotic proteins, inhibiting the 
formation of the autophagosome and thus preventing autophagy. The significant 
reduction in Becn1 seen here could therefore be an indication of increased apoptosis 
(Takacs-Vellai et al, 2005). A recent study found that in human melanoma cells, 
cisplatin downregulated Beclin1 protein expression, with a concurrent increase in the 
expression of apoptosis markers including caspase 3 (Del Bello et al, 2013). A good 
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extension to this work would be to confirm that the downregulation seen here in 
Becn1 mRNA levels also occurs at the protein level, using Western blotting. 
 
No expression of Ulk1, Atg7 and Atg13 was detected here. The fact that none of these 
genes were expressed in either control or treated tissue is likely due to too low a level 
of expression for accurate detection. This is because the genes should be 
constitutively expressed in this tissue as they are all essential for mammalian 
autophagy (Mehrpour et al, 2010). Pooling more ovaries into each sample could be a 
way of getting around this problem, as a product was detected at the top of the 
standard curve for these genes (also indicating that the sensitivity of the assay was 
the problem rather than primer failure). This would however mean that a very large 
number of newborn ovaries would have to be pooled to detect a result, which may 
not be technically that feasible, or to use an amplification kit in order to increase the 
cDNA concentration in my samples. A better alternative would probably be to 
investigate protein expression in future, through either Western blotting or 
immunohistochemistry. 
 
4.4.2 Apoptosis is likely to be involved in cell death 
As the expression of Becn1 indicates that apoptosis may be involved in ovarian cell 
death following drug exposure, the expression of cleaved PARP was examined. 
PARP-1 causes ADP-ribosylation of key proteins such as histones and ligases to 
facilitate DNA repair, an energy dependant process which occurs at the expense of 
the cells NAD
+
 and ATP supply (Burkle and Virag, 2013). The cleavage of PARP-1 
is often used as a marker for apoptotic cell death. 
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There is evidence that PARP can feed into autophagic, necrotic and apoptotic cell 
death pathways (Shen and Codogno, 2012). Which cell death pathway is activated 
appears to be dependent on the energy status of the cell, the cell type and the extent 
to which the cell is injured. As autophagy is induced in situations of cell starvation, a 
change in energy homeostasis in the cell such as that caused by increased PARP 
activation could potentially lead to an increase in cell autophagy (Shen and Codogno, 
2012). Autophagy appears to be induced by PARP activation as a protective 
mechanism to aid cell survival (Shen and Codogno, 2012). Necrosis is also an energy 
dependant process, and so there is evidence that when there is a large increase in the 
amount of ADP-ribose and subsequent drop in the amount of ATP, cell death by 
necrosis occurs (De Vos et al, 2012). When there is a large amount of DNA damage 
present, PARP-1 can be cleaved. This is thought to occur in order to prevent the 
massive energy loss that ensues when PARP is overactivated. This cleavage often 
occurs through caspase enzymes such as caspase 3 and is therefore considered to be 
part of the apoptosis mechanism. Although there is some evidence that PARP 
cleavage is not essential to the process of apoptosis, it is generally considered one of 
the hallmarks of apoptotic cell death (Koh et al, 2005). PARP cleavage can occur 
during necrosis (Shah et al, 1996), however the fragments formed are different sizes 
to those detected here. There was a large increase in expression of cleaved PARP 
detected here following the two highest doses of cisplatin treatment, with a much 
smaller but still significant increase following the highest dose of doxorubicin. This 
suggests that cisplatin and doxorubicin are causing ovarian cell death through 
apoptosis although with different patterns of expression for each drug. 
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It is interesting that TUNEL staining, also considered a hallmark of apoptosis, did 
not increase significantly in primordial follicles following either drug treatment. It 
could be that using the time point of 24 hours is not appropriate for TUNEL 
detection, and that the peak of expression was earlier or later than this time point. A 
time course experiment would potentially be a good way of checking this. An 
alternative explanation could be that TUNEL was used to examine primordial 
follicles, whereas here cleaved PARP was used to detect whole ovary apoptosis; the 
difference seen may therefore be due to an increase in stromal cell apoptosis which 
was not quantified in the TUNEL analysis. 
 
4.4.3 Conclusion 
Data here shows that apoptosis rather than autophagy is likely to be the mechanism 
through which cisplatin and doxorubicin cause ovarian cell death. The next step is to 
try and identify the cell type which is expressing these markers, and compare 
expression between the two drugs. Work in Chapter 5 will therefore explore cell 













CELL LOCALISATION OF APOPTOSIS 
 121 
5.1. Introduction 
Apoptosis is a well-defined mechanism of programmed cell death, characterised by 
distinct morphological changes including cell shrinkage, DNA fragmentation and 
membrane blebbing. The mechanism of apoptosis is complex, tightly regulated and 
involves an energy-dependant molecular cascade. One of the earliest studies 
describing morphological changes in cells consistent with apoptosis (here called 
chromatolysis) was in 1885, which described cells in rabbit ovarian follicles with 
fragmented nuclei (Flemming, 1885; Majno and Joris, 1995).  The term apoptosis to 
describe programmed cell death was first used in 1971 in a study which described 
cells in the liver shrinking and showing chromatin condensation (Kerr, 1971). Since 
then, apoptosis has been found to be essential during development, as well as cell 
clearance when cells are considered harmful or senescent. Aberrant apoptosis has 
been linked to several diseases including cancer and neurodegeneration.  
 
5.1.1 Cleaved PARP 
PARP is a DNA repair protein which is cleaved during apoptosis. It is activated in 
response to DNA damage, allowing for the post-transcriptional modification of 
proteins essential for DNA repair (Soldani and Scovassi, 2002). If there is large scale 
DNA damage, PARP is hyperactivated leading to massive depletion of cell energy 
stores (Boulares et al, 1999), and so PARP can be cleaved during apoptosis in order 
to preserve this energy. Results from Western blotting in Chapter 4 indicated that 
cisplatin and doxorubicin cause a significant increase in cleaved PARP protein 




The most heavily investigated members of the apoptotic signalling pathway are the 
caspase family of proteins. There have been at least 14 members of the caspase 
family identified in humans, which are constitutively expressed in virtually all cell 
types in the body (Kohler et al, 2002). They function primarily as proteases, cleaving 
proteins which are either important for cell function or whose cleavage will initiate 
further death signalling (Hengartner, 2000). There are many different signals which 
can initiate caspase-3 mediated apoptosis, with considerable crosstalk between the 
downstream processes. Disruption of mitochondrial function plays an important role, 
which includes loss of transmembrane potential and the release of cytochrome c into 
the cytosol (Skulachev, 1998). Once released, cytochrome c forms a complex with an 
adaptor protein Apaf-1 (Apoptotic protease activating factor 1) and caspase-9 
(Hengartner, 2000). The activation of caspase 9 allows for the downstream 
activation/cleavage of other members of the caspase family including caspase-2, 3 
and 7 which then cleave downstream target proteins (Fiandalo and Kyprianou, 2012). 
The mitochondrial pathway is often activated by DNA damage, primarily through 
upregulation of p53 (Levine et al, 2006) which in turn upregulates factors such as 
Bax. Bax is a pro-apoptotic member of the Bcl-2 family and can directly interact 
with the mitochondria, to induce changes in membrane potential and hence 
cytochrome c release (Murphy et al, 1999). An alternative pathway for capase-3 
activation is the extrinsic binding of a death signal (e.g. Fas) which leads to the 
activation of caspase-8 (Kaufmann et al, 2012) which subsequently cleaves caspase-
3. One of the substrates that caspase-3 cleaves is PARP which is also used as a 
marker of apoptosis. One of the problems with studying caspase family activity is 
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that there is a large amount of functional redundancy between family members, 
allowing for different caspase’s to compensate for each other’s loss.  
 
The best understood caspase in terms of its function in apoptosis is caspase-3. 
Caspase-3 knockout mice are born at a low frequency, die within a few weeks and 
they have ectopic masses of cells in the brain indicating a decrease in cell death 
during brain development (Kuida et al, 1996). Caspase-3 appears to be essential for 
certain aspects of apoptosis to occur, including DNA fragmentation and membrane 
blebbing as MCF-7 breast carcinoma cells which are lacking functional caspase-3 are 
killed by inducers of apoptsis but without these morphological changes (Janicke et 
al, 1998).  In the ovary, caspase-3 is required for granulosa cell apoptosis during 
follicle atresia (Matikainen et al, 2001). It is expressed in oocytes (Exley et al, 1999) 




H2AX is a histone protein which is randomly distributed throughout the DNA (Altaf 
et al, 2007). When there is a double strand DNA break, H2AX is phosphorylated 
becoming γH2AX (Rogakou et al, 1998). This phosphorylated protein then acts as a 
recruiter of DNA repair proteins. Foci of γH2AX proteins form, which can therefore 
be used as a sensitive marker for DNA double strand breaks (Pilch et al, 2003). 
Following DNA repair, γH2AX is dephosphorylated. There is some evidence that 
double strand DNA breaks are involved in chemotherapy-induced ovarian cell death, 
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with cyclophoshamide causing a significant increase in oocytes expressing γH2AX 
(Petrillo et al, 2011). 
 
5.1.4 Aim 
Work in the previous chapter indicated that both cisplatin and doxorubicin lead to 
apoptosis in the ovary. The aim of these experiments was to localise expression of 
apoptosis markers to different cell types in ovaries treated with cisplatin or 
doxorubicin. 
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5.2 Materials and methods 
5.2.1 Animals 
C57BL6 females were used for all experiments. 
 
5.2.2 Newborn ovary culture 
Newborn ovaries were dissected and cultured as described in chapter 2. Ovaries were 
cultured for 24 hours and then exposed to control medium, cisplatin or doxorubicin 
for a further 24 hours. As preliminary experiments using Cleaved PARP in 
immunohistochemistry indicated that the drug dosages used in qPCR and Western 
analysis in Chapter 4 caused damage too widespread to easily quantify, drug 
concentrations were reduced. The final concentration of cisplatin used was 0.5µg/ml; 
the final concentration of doxorubicin was 0.05µg/ml. Ovaries were washed in PBS 
and fixed immediately after the end of the period of drug exposure. Six ovaries in 
each treatment group were analysed from three independent cultures. 
 
5.2.3 Histology 
Ovaries were fixed in 10% (v/v) buffered formalin (Sigma Aldrich) for 
approximately 90 minutes then washed in 70% (v/v) ethanol. Formalin was used 
instead of Bouins for fixing tissue as experiments indicated that Bouins fixative 
caused non-specific staining following immunohistochemistry. They were then left 
overnight in 70% (v/v) ethanol with eosin, processed, embedded and sectioned as 
described in Chapter 2.  
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5.2.4. Immunohistochemistry using DAB staining 
This was used to detect Cleaved PARP (New England Biolabs UK, #9544) and 
Cleaved Caspase 3 (#9661). 
 
Slides were dewaxed in xylene and rehydrated in decreasing concentrations of 
ethanol. Slides were then washed in water and boiled in 0.01M sodium citrate buffer 
for 20 minutes in a microwave, ensuring that slides were always covered in liquid. 
Slides were cooled before being washed in wash buffer (1xPBS [pH 7.3, 160mM 
NaCl, 3mM KCl, 8mM Na2HPO4, 1mM KH2PO4] with 0.1% [v/v] Triton X). They 
were then incubated for 30 minutes in 3% H2O2/90% methanol, to reduce 
endogenous peroxidase background staining. Slides were then washed in wash buffer 
and incubated for 1 hour in blocking solution (20% Normal Goat serum/5% bovine 
serum albumin/PBS). Primary antibodies were then diluted 1:200 in blocking 
solution and applied to all slides except one, which was the negative control. Slides 
were incubated in a humidified chamber overnight at 4ºC.  
 
Slides were washed in wash buffer and incubated for 1 hour in a 1:200 secondary 
antibody solution (Goat anti-rabbit biotinylated antibody, Dako UK # E043201-8) 
diluted in blocking solution. Slides were then washed and incubated for 30mins in 
ABC kit (Avidin Biotin Kit, Vectastain, #PK6100, Vector Labs UK). Slides were 
washed in wash buffer and incubated in DAB solution (3,3'-Diaminobenzidine, 
Vector UK, #SK4100) until brown staining appeared (up to 10 minutes). The 
reaction was quenched in H2O, slides were dipped in haemotoxylin for 20 seconds, 
then washed in H2O. Slides were then placed in STWS (0.2% [w/v] NaHCO3, 2% 
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[w/v] MgSO4 in dH2O) for 1 minute, washed and then dehydrated in increasing 
concentrations of ethanol. The ethanol was cleared in xylene for 5 minutes and then 
slides were mounted with DPX and glass coverslips. 
 
5.2.4.1. Counting and analysis 
Two non-adjacent sections more than 50µm apart were taken from the middle of 
each ovary and used for immunohistochemical analysis for each antigen examined. 
Photomicrographs were taken using a Leica microscope. Sections were analysed 
blind as to treatment. Any distinct cells which were stained brown were counted and 
the cell type was identified morphologically. Image J was used to measure the area of 
each section. The number of brown cells was then adjusted to the area and the 














Fig 5.1. Example of section analysis of a murine ovary. Image J software was used to 
draw a line around each section and calculate the area of that section in µm
2
. This 
was converted to mm
2
 and the number of cells counted was divided by this value. 
 
5.2.5 Immunofluorescence 
Fluorescence was used for the detection of γH2AX (Abcam UK, #22551), using the 
Vector Mouse On Mouse kit (Vector, #BMK-2202) according to manufacturers 
instructions. This kit was chosen due to a high amount of background staining when 
conventional immunofluorescent staining was used. Slides were dewaxed and 
antigen retrieved as described in section 5.2.4. They were then incubated for 30 
minutes in 3% (v/v) H2O2/90% (v/v) methanol, to reduce endogenous peroxidase 
background staining which is an extension of that described in the kits instructions. 

















solution (Vector labs, M.O.M. blocking solution [2 drops of stock solution to 2.5ml 
PBS]). Slides were then washed and incubated for 5 minutes in M.O.M. diluent 
solution (600µl of kit Protein Concentrate stock solution to 7.5ml PBS). This was 
then tipped off slides and a primary antibody solution was applied (γH2AX, 1:200 in 
diluent solution) for 30 minutes. Slides were then washed and biotinylated secondary 
antibody solution (M.O.M. kit) was applied for 10 minutes. Slides were washed and 
a solution containing streptavidin 488 fluorescent antibody (Alexafluo®r, Invitrogen 
UK, #S11223) diluted 1:200 in diluent solution was applied for 5 minutes, keeping 
slides in the dark. Slides were then washed, keeping them in the dark, and then a 
solution of DAPI counterstain (Invitrogen, #D3571, 1:10000 in H2O) was applied for 
20 minutes. Slides were then washed and mounted using Vectashield (Vector, #H-
1400) to reduce photobleaching and glass coverslips. Slides were photographed using 
a Leica A6000 fluorescent microscope.  
  
5.2.6. Statistical Analysis   
The number of stained cells was adjusted for area and the average of two sections per 
mouse ovary was calculated. Six ovaries were analysed like this per treatment group 
for Cleaved PARP and Cleaved Caspase 3 staining. All data was analysed using 
Graphpad Prism software. One way ANOVAs determined if significant differences 
were present across treatment groups, followed by Bonferroni post hoc tests where 
ANOVA was statistically significant. 
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5.3. Results 
5.3.1 Cleaved PARP 
Expression of the apoptosis marker cleaved PARP was analysed in control, cisplatin 
and doxorubicin treated ovaries, example images of which are shown in Fig. 5.2. 
Two sections were analysed and averaged per ovary, 6 ovaries were analysed per 
treatment group. The number of cells expressing cleaved PARP was adjusted for area 
and compared (Fig 5.3A); there was a significant increase in the number of cleaved 
PARP positive cells in doxorubicin treated ovaries. The number increased following 
cisplatin treatment, however this was not significant (p=0.06). When cell type 
affected was broken down into oocytes (Fig 5.3B) or somatic cells (Fig 5.3C), the 
number of positively stained oocytes did not increase significantly following either 
drug treatment. There was a significant increase in the number of positive somatic 
cells following doxorubicin treatment. When somatic cells were broken down further 
into either granulosa cells (Fig 5.4A) or stroma (Fig 5.4B), there was a significant 
increase in the number of both cell types staining positive for cleaved PARP.  
 
5.3.2 Cleaved Caspase-3 
Expression of cleaved caspase-3 was analysed in control, cisplatin and doxorubicin 
treated ovaries, example images of which are shown in Fig. 5.5. Two sections were 
analysed and averaged per ovary, 5 ovaries were analysed per treatment group. When 
the number of cells which stained positive for cleaved caspase 3 was analysed, there 
was no significant increase following either cisplatin or doxorubicin treatment (Fig 
5.6A). When cell type affected was broken down into oocytes (Fig 5.6B) or somatic 
cells (Fig 5.6C), there was a non-significant increase in the number of positive 
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oocytes following cisplatin treatment. When somatic cells were broken down further 
into either granulosa cells (Fig 5.7A) or stroma cells (Fig 5.7B), there was a 
significant increase in the number of granulosa cells stained positive for cleaved 
caspase-3 following doxorubicin treatment. In contrast to cleaved PARP analysis, 
there was no significant increase in stromal cell expression. 
 
Analysis of the stromal cells was more challenging than with cleaved PARP, with 
some vessel-like structures identified with positive cleaved caspase-3 staining; when 
these were counted there was a significant increase in the number following 
doxorubicin treatment when compared to control (Fig 5.8). As these have a similar 
phenotype to blood vessels, double immunofluorescence was used to see if there was 
co-localisation of cleaved caspase-3 with CD31, an endothelial marker. There were 
many problems optimising the experimental protocol for this and it was not 
sufficiently optimised in time.  
 
5.3.3 γH2AX  
Sections from ovaries treated with control, cisplatin and doxorubicin were stained for 
γH2AX (Fig 5.9). Etoposide-treated ovaries (material supplied by Agnes 
Stefansdottir) were used as a positive control, as it is well established that etoposide 
causes double strand DNA breaks (Smart et al, 2008). There were a lot of problems 
with high background staining in preliminary experiments, possibly due to the fact 
that the primary antibody was raised in mouse. These were overcome to some extent 
through use of a Mouse on Mouse blocking kit (Vector), however due to these 
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technical problems, there was not time for a detailed analysis of γH2AX expression 
in the cisplatin- or doxorubicin- treated ovaries. 
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Figure 5.2. Representative immunohistochemistry images of cleaved PARP 
expression in A) control, B) cisplatin or C) doxorubicin treated mouse ovaries. Inset 
shows negative control. Solid line arrows show positively stained oocytes as 
determined by their morphology. Dashed arrow shows a cluster of stained stromal 


















































































































































Figure 5.3. Number of cleaved PARP positive A) cells, B) oocytes and C) somatic 
cells in ovaries treated with 0.5µg/ml cisplatin or 0.05µg/ml doxorubicin. Bars 


























































































































Figure 5.4. Number of cleaved PARP positive A) granulosa cells and B) stromal 
cells in ovaries treated with 0.5µg/ml cisplatin or 0.05µg/ml doxorubicin. Bars 






Figure 5.5. Representative immunohistochemistry images of cleaved caspase-3 
expression in A) control, B) cisplatin or C) doxorubicin treated newborn mouse 
ovaries. Inset shows negative control. Solid line arrows show positively stained 
oocyte as determined by its morphology. Dashed arrows show stained stromal cells. 

























































































































Figure 5.6. Number of cleaved caspase 3 positive A) cells, B) oocytes and C) 
somatic cells in newborn mouse ovaries treated with 0.5µg/ml cisplatin or 0.05µg/ml 




































































































Figure 5.7. Number of cleaved caspase 3 positive A) granulosa cells and B) stromal 
cells in newborn mouse ovaries treated with 0, 0.5µg/ml cisplatin or 0.05µg/ml 
doxorubicin. Bars denote mean±sem, n=5 for each treatment, stars denote significant 
























































Figure 5.8. A) Example of Cleaved caspase 3 expression in the stroma which 
resembles a vessel as highlighted by the black arrow (structure classified as single 
vessel), B) number of possible vessels stained positive for cleaved caspase 3 in 
ovaries treated with 0, 0.5µg/ml cisplatin or 0.05µg/ml doxorubicin. Bars denote 






Figure 5.9. Expression of γH2AX (green) in newborn mouse ovaries (nuclei stained 
blue) treated with (A) control, (B) cisplatin, (C) doxorubicin and (D) etoposide 








Apoptosis markers cleaved PARP, cleaved caspase-3 and γH2AX, were used to 
determine cell localisation of apoptosis in newborn mouse ovaries cultured with 
cisplatin or doxorubicin. Results here suggest that both drugs induce apoptosis, with 
different patterns of cellular expression. Doxorubicin causes apoptosis in ovarian 
somatic cells; cisplatins action is less clear. 
 
5.4.1 Cisplatin 
There was no significant increase in the number of cells expressing cleaved PARP or 
cleaved caspase-3 following cisplatin treatment. However, the near-to-significant p 
value for cleaved PARP analysis (p=0.06) could well indicate that this could become 
significant if the sample size was increased. Clearly, increasing the n number to 
determine if this is the case or not, is important future work. Although the results 
were not significant and so no firm conclusions can be drawn, there were some 
interesting trends. The increase in the number of oocytes positive for cleaved 
caspase-3 in particular, although not significant, is notable and so extending the 
study with a larger sample size could yield a more significant result. Alternatively, 
the concentration of cisplatin used could be slightly increased. Cell localisation of 
apoptosis markers TUNEL and γH2AX in another study following cisplatin 
treatment indicated that cisplatin targets the oocyte; there was a much higher 
concentration of cisplatin used in this study than used here (6µg/ml compared to 0.5 
µg/ml used here) (Gonfloni et al, 2009). Therefore, increasing the concentration of 
cisplatin used could potentially lead to more significant results. Nonetheless, the 
concentrations used here are in serum range (Pfeifle et al, 1985; Urien and Lokiec, 
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2004), which causes damage and follicle loss and so it could be that using a different 
time point or an alternative method of detection will yield significant results.  
 
There is a discrepancy between results in Chapter 4 and here, with Chapter 4 
demonstrating a large scale, robust increase in cleaved PARP expression following 
cisplatin treatment. This increase was however only significant at 1 and 5µg/ml 
cisplatin and so again, the smaller concentration which was used here may account 
for this difference.  
 
5.4.2 Doxorubicin 
Doxorubicin induced a significant increase in the number of granulosa cells which 
express the apoptosis markers cleaved PARP and cleaved caspase-3. This 
corroborates results in Chapter 3, which saw a significant increase in the percentage 
of follicles with pyknotic granulosa cells. This suggests that granulosa cells are 
particularly sensitive to doxorubicin treatment and is consistent with other reports 
(Ben-Aharon et al, 2010; Roti Roti et al, 2012). The reason that granulosa cells are 
so sensitive to doxorubicin could be related to the fact that they are so mitotically 
active; doxorubicin interferes with cellular replication and transcription. This damage 
to the granulosa cells could cause indirect germ cell death and hence follicle loss.   
 
There was a significant increase in the number of cleaved PARP positive stromal 
cells following doxorubicin, indicating that doxorubicin also causes apoptosis in the 
stroma. Most studies which have investigated the effect of chemotherapy on the 
ovary concentrate on direct follicle action; few describe stromal specific effects. One 
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ultrastructural study of ovarian biopsies in girls who underwent treatment for 
leukaemia found moderate to severe signs of stromal damage as well as capillary 
changes (Marcello et al, 1990). A recent study investigating the action of 
doxorubicin on the ovary found that cell death (as analysed by neutral comet assay 
which detects DNA breaks) appeared first in the stroma, with expression appearing 
in the granulosa cells, then the oocytes over time (Roti Roti et al, 2012). Toxic insult 
to the stromal cells could have detrimental effects on the follicles in the ovary and be 
an indirect method through which follicle loss could occur.  
 
The ‘vessel’ structures observed also showed significantly increased expression of 
cleaved caspase-3 following doxorubicin treatment. Their morphology suggests that 
they could be blood vessels; unfortunately this could not be confirmed due to 
technical difficulties. Vasculature changes have been suggested as an additional 
mechanism by which chemotherapy could cause follicle loss through local ischemia 
(Meirow et al, 2007). The morphology of these ‘vessels’ is similar to that described 
in a study which used doxorubicin in human cortical pieces (Soleimani et al, 2011). 
There, immunostaining for the endothelial marker CD31 found a significant 
reduction in vessel density following doxorubicin treatment.  
 
It is notable however that these structures were identified here with cleaved caspase-
3 staining only and not with cleaved PARP. It could be that these are some sort of 
artefact of this antibody’s staining. This may also explain why there is no significant 
difference in positive stromal cells following cleaved caspase-3 in contrast to cleaved 
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PARP; as the staining was less distinct, the counting of positive stromal cells may 
have been less accurate than in the cleaved PARP analysis.    
 
The difference in expression of cleaved PARP and cleaved caspase-3 is intriguing, as 
they are both used to identify apoptosis. As well as antibody-related staining 
problems, there are other possible explanations for this. Apoptosis is a molecular 
cascade, involving signals which are expressed transiently. This could mean that the 
difference seen here may be related to the fact that a single time point of 24 hours 
was used for analysis.  
 
5.4.3 γH2AX 
γH2AX is a marker for DNA double strand breaks (Pilch et al 2003). Although, there 
was not time to perform a full analysis, preliminary results are interesting and worth 
pursuing. In both cisplatin and doxorubicin treatment, there appears to be a slight 
increase in cells (predominantly oocytes) with γH2AX foci. As these images are 
fluorescent, it is slightly more difficult to determine cell type based solely on their 
morphology. It would therefore be worth immunostaining for γH2AX in conjunction 
with a cell specific marker in future (e.g. vasa/MVH [Mammalian vasa homologue] 
for oocytes [Castrillon et al 2000]). There also appears to be a huge increase in 
expression of γH2AX in the etoposide treated ovaries when compared to the other 
treatment groups. This is expected, as etoposide is a well-known inducer of DNA 
breaks (Tanaka et al 2007). What is perhaps more suprising is the difference in 
expression following etoposide treatment when compared to cisplatin or doxorubicin. 
Although these results are preliminary, this may suggest that DNA double strand 
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breaks are not actually that important a mechanism of cisplatin or doxorubicin-
induced cell death. Cisplatin has been shown previously to induce an increase of 
γH2AX foci in oocytes, however this was following a much higher dosage of 
cisplatin (6µg/ml compared to 0.5 µg/ml used here) (Gonfloni et al, 2009). In 
primary granulosa cell cultures, doxorubicin induces DNA double strand breaks as 
assessed by comet assay (Roti Roti and Salih, 2012). In the whole ovary, doxorubicin 
in another study caused an increase in γH2AX expression in primordial follicles 
following 24 hours of exposure; however the dosage used here was high (20mg/kg) 
(Roti Roti et al, 2012). To put this dosage into perspective, rats treated with 6mg/kg 
of doxorubicin have a peak plasma concentration of doxorubicin of 1.7µg/ml 
(Rahman et al, 1986), the ovaries here were exposed to 0.05 µg/ml which is in the 
human serum range (Greene et al, 1983). It could therefore be that the other studies 
are detecting an increase in DNA double strand breaks following these drugs because 
they are using higher, more pharmacological concentrations of cisplatin or 
doxorubicin. 
 
5.4.4. Future Work 
As well as completing the work described above, there are other directions which 
this research could take. Now that it has been determined that apoptosis is likely to 
be the key mechanism through which these drugs are causing ovarian cell death and 
the differences in cellular localisation, it is important to consider why these different 
cells are more vulnerable to each drug. Finding how the drugs initiate apoptosis in 
each cell type will potentially allow for treatments to be designed that can block 
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these cell effects. Potential pharmacological treatments for preventing ovarian 
damage will be discussed further in Chapter 6. 
 
5.4.5 Conclusion 
Cell localisation of apoptosis induced by cisplatin and doxorubicin in the ovary was 
investigated. Results here show that doxorubicin causes apoptosis in the somatic 
cells of the ovary, particularly in the granulosa cells. Cisplatins action and cell 
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Due to the increasing number of women affected by POF as a result of chemotherapy 
treatment, preservation of fertility (now termed oncofertility) is a question of 
growing importance. The established options currently available to women and girls 
for fertility preservation include cryopreservation of oocytes, ovarian tissue and 
embryos for women with life partners (Wallace et al, 2005). The ideal solution 
would be if the ovary could be directly protected from any toxic effects of 
chemotherapy drugs, thus preserving fertility and alleviating symptoms which are 
associated with premature menopause.  
 
6.1.1. Current options to protect fertility 
6.1.1.1 Cryopreservation 
The most reliable method of preserving fertility remains the cryopreservation of 
embryos as embryos are less vulnerable to cryopreservation-induced damage than 
oocytes (Blumenfeld et al, 2008). There are, however, several disadvantages to this 
option: it is not an option for very young patients who do not ovulate or do not have 
a partner, for some older patients it will be reliant on a sperm donor (which can 
present legal and ethical issues) and for all it requires time for an IVF cycle which 
the patient may not have (Tao and Valle, 2008). There is also the concern that IVF 
may be detrimental for patients who have estrogen-sensitive tumours. Oocyte 
cryopreservation has resulted in pregnancies (Kuleschova et al, 1999; Selvaraj et al, 
2009) but overall this technique is still fairly experimental (Qiao et al, 2013). 
Cryopreservation of ovarian cortex and its reimplantation following treatment is an 
option available to females of all ages. For the young patient, cryopreservation of 
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ovarian cortical tissue collected laparoscopically is extremely promising with the 
birth of twenty live infants reported so far following reimplantation of frozen-thawed 
tissue (Donnez et al, 2012). Ovarian tissue cryopreservation has the potential 
advantages of preservation of a large number of oocytes within primordial follicles, it 
does not require hormonal stimulation when time is short, and is appropriate for the 
pre-pubertal girl.  Disadvantages include the need for an invasive procedure, and the 
uncertain risk of ovarian contamination in hematological and other malignancies 
(Rosendahl et al, 2010b; Shaw et al, 1996). As well as the small size of the tissue, 
reimplantation following cyropreservation or vitrification causes substantial follicle 
loss (Abir et al, 2011) which also limits the lifespan of the tissue and so can never 
replace long term fertility or protection from symptoms of the menopause. 
 
6.1.1.2 GnRH agonists/antagonists 
Although the effectiveness of administering GnRH agonists to prevent chemotherapy 
induced ovarian damage has yet be fully proven, this is, in places, a widely used 
clinical treatment. These agonists are used to suppress the hypothalamic-pituatry-
gonadal axis, thereby returning the ovary to a more quiescent state (Sonmezer and 
Oktay, 2004). The hypothesis that this suppression could protect the ovary is based 
on observations that prepubertal girls appear less susceptible than older women to the 
damaging effects of chemotherapy on fertility (Ortin et al 1990). However, these 
observations could be a result of the larger follicle reserve in prepubertal patients, as 
well as difficulties in assessing the follicle reserve in young patients (Brougham et al 
2012). Reduction of the follicle reserve in these patients will also manifest many 
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years after therapy, which may account for the difference between these and older 
women, rather than the prepubertal environment being in itself protective.  
 
The mechanism by which GnRH agonists are thought to protect the ovary is unclear. 
One hypothesis is that it restricts blood flow to the ovary, allowing less of the 
chemotherapeutic agent access to the ovarian reserve. A rat model system has shown 
that following GnRH agonist treatment, there is a decrease in ovarian vascular 
permeability and density (Kitajima et al, 2006), however the relevance of ovarian 
blood flow to human physiology remains disputed. It has also been hypothesised that 
GnRH agonists could act directly on the ovary. This seems unlikely to be responsible 
for a long term protective effect, as GnRH receptors are only present in preovulatory 
follicles and the corpus luteum (Choi et al, 2006), neither of which would be present 
in the quiescent ovary. GnRH agonists have a protective effect against doxorubicin 
directly on granulosa cells in vitro (Imai et al, 2007) but these granulosa cells were 
taken from mature follicles which express GnRH receptors. GnRH agonists have 
been shown to cause an inhibition of follicular recruitment (Ataya et al, 1989), 
however any direct effect of them on smaller follicle classes remains unclear.  
 
There have been several clinical studies investigating the efficacy of GnRH agonists 
in protecting the ovarian reserve, with conflicting conclusions being drawn as many 
such studies are not randomised, have small patient numbers, occasionally lack 
controls and are often case studies (Beck-Fruchter et al, 2008). Two large-scale 
randomised multicentre clinical trials were published in 2011, but unfortunately these 
had conflicting results. In the PROMISE-GIM6 study, a significant reduction in 
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chemotherapy-induced ovarian failure was found following GnRH agonist 
administration (Del Mastro et al, 2011). However, following GnRH treatment, the 
GBG 37 ZORO study did not find a statistically significant reduction in 
chemotherapy-induced POF (Gerber et al, 2011). While the outcome measures of 
both studies were primarily menstrual function with limited endocrine analysis, it is 
unclear why different results were found. Both assessed POF after a relatively short 
time (PROMISE-GIM6 study after one year; the ZORO study after six months) and 
there remains a need for long term follow up, to fully determine whether GnRH 
agonists are having a lasting protective effect on the ovary. 
 
6.1.2 Potential protective treatments 
Directly protecting the ovary from damage induced by chemotherapeutic agents 
would be the ideal method through which fertility could be preserved. There are 
several key requirements which this potential protective treatment would have to 
fulfill. It could not interfere with the anti-cancer action of the chemotherapy agent it 
was protecting against. It would also have to be non-toxic in itself, both to the ovary 
and to the patient in general. Finally it would have to have no negative effects on the 
competence of the oocytes it was protecting. Several potential treatments currently 
under investigation are discussed below. 
 
6.1.2.1 Ceramide 
Ceramide is a sphingosine-based lipid signalling molecule which, when produced in 
high levels in cells, can lead to apoptosis (Morita and Tilly, 2000). When the 
ceramide pathway is manipulated by adding sphingosine-1-phosphate (S1P), a 
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downstream antiapoptotic metabolite of ceramide, mature oocytes are protected in 
vitro from doxorubicin-induced cell death (Perez et al, 1997). Rodents treated in vivo 
with S1P have a decrease in primordial follicle death following chemotherapy 
exposure (Hancke et al, 2007) and there is no discernible genomic damage in the 
offspring of rodents given such ovarian protection against irradiation (Paris et al, 
2002). Primates which were exposed to radiation alongside an S1P analogue 
demonstrated a protective effect on ovarian function (Zelinski et al, 2011); whether 




AS101 (ammonium tri-chloro(dioxoethylene-O,O’-)tellurate) was developed as a 
potential immunomodulatory treatment (Sredni et al, 1987). It has been shown to 
protect against hematopoietic damage and alopecia induced by cyclophosphamide, 
carboplatin and etoposide (Kalechman et al, 1991; Sredni et al, 1995). AS101 
appears to function through stimulating the secretion of cytokines such as IL-1 and 
the inhibition of IL-10 (Hayun et al, 2007). IL-10 is essential for tumour cell 
proliferation, meaning that AS101 has anti-tumour properties in itself as well as 
increasing the efficacy of chemotherapy agents used in conjunction with it (Sredni et 
al, 2004). IL-10 inhibition also leads to a downstream activation of Akt, a serine-
threonine kinase which has been shown to be an important suppresser of male germ 
cell apoptosis following radiotherapy (Rasoulpour et al, 2006). AS101 has been used 
in conjunction with cyclophosphamide in male mice and it was found that AS101 
caused a significant reduction in sperm DNA fragmentation and seminiferous tubule 
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damage as well as a partial rescue of fertility when compared to cyclophosphamide 
alone (Carmely et al, 2009). A recent study in the ovary suggests that AS101 can 
protect against cyclophosphamide-induced follicle loss, primarily through reducing 
primordial follicle activation (Kalich-Philosph et al, 2013).    
 
6.1.2.3 Dexrazoxane 
Dexrazoxane is a chemoprotectant which has been investigated as a method for 
blocking doxorubicin-induced cardiotoxicity (Swain et al, 1997) and is currently 
approved for clinical use as such. There is also some evidence that dexrazoxane may 
be effective against etoposide-induced toxicity in bone marrow and nervous system 
tumours (Attia et al, 2009; Hofland et al, 2005). There are two mechanisms through 
which dexrazoxane can potentially act. The first is through an interaction with 
topoisomerase II enzyme. Doxorubicin interacts with topoisomerase II, allowing it to 
bind to DNA but preventing it from resealing DNA breaks (Burden and Osheroff, 
1998). Dexrazoxane binds to a different site on the topoisomerase enzyme and 
prevents it from binding onto DNA altogether (Hasinoff and Herman, 2007), whether 
doxorubicin is present or not. This means that doxorubicin is unable to induce DNA 
damage. The other mechanism by which dexrazoxane may work is that it is 
metabolised in the cell to an EDTA derivative. This derivative chelates iron which 
could reduce oxidative stress (Vile and Winterbourn, 1990). Importantly, 
dexrazoxane use in conjunction with doxorubicin does not prevent the anti-tumour 
activity of doxorubicin in breast cancer (Marty et al, 2005) nor does it lead to 
secondary malignancies in pediatric cases of leukaemia (Barry et al, 2008). One 
study so far has used dexrazoxane on granulosa cell cultures and found a reduction in 
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DNA damage with co-treatment when compared to doxorubicin alone (Roti Roti and 
Salih, 2012). However, another study has found dexrazoxane treatment alone causes 
increased germ cell apoptosis in foetal human ovaries (Poulain et al, 2012). The 
effectiveness of this treatment on preserving the follicle reserve in whole postnatal 




Tamoxifen is a chemotherapeutic agent introduced in the 1970s and is primarily used 
for the treatment of estrogen receptor positive breast cancer (Jordan, 2003). It 
functions as a selective oestrogen receptor modulator and is anti-estrogenic in 
mammary tissue. As it is extensively used clinically both alone and in combination 
with other chemotherapy agents, it would be an ideal protective agent as its safety 
has already been established. In rats treated with cyclophosphamide, there was a 
decrease in primordial and total follicle number, an effect which was rescued 
following co-treatment with tamoxifen (Ting and Petroff, 2010). Tamoxifen also 
reversed the detrimental effect of cyclophosphamide on neonatal survival in this 
study (Ting and Petroff, 2010). A randomized trial which followed women one year 
after CMF (Cyclophosphamide, methrotrexate and 5-fluouracil) treatment for breast 
cancer found no significant increase in the percentage of menstruating women 
following tamoxifen co-treatment (n=60) when compared to CMF alone (n=63) 
(Sverrisdottir et al, 2009). The efficacy of tamoxifen as a means to protect the 




Amifostine, also known as Ethyol or WR-2721, is a thiol prodrug which was 
designed to function as a protective agent in normal tissue against radiation-induced 
damage (Kouvaris et al, 2007). It functions primarily as a scavenger of free radicals 
and is selective, as it concentrates more rapidly in normal cells than tumours (Citrin 
et al, 2010). It is also considered to be a broad spectrum chemoprotective agent and 
effective against cisplatin-induced nephrotoxicity and ototoxicity (Fouladi et al, 
2008; Hartmann et al, 2000). Importantly, co-treatment of patients with amifostine 
and cisplatin does not decrease the efficacy of cisplatin (Korst et al, 1998). In male 
rats treated with cisplatin, amifostine co-treatment conferred partial protection 
against cisplatin-induced testicular damage and germ cell death (Lirdi et al, 2008). 
However, whilst amifostine has a partial protective effect on the seminiferous 
epithelium of male rats against doxorubicin exposure, long term fertility was not 
improved and there was increased early embryo loss suggesting that the quality of 
the sperm DNA was compromised (Vendramini et al, 2012; Vendramini et al, 2010). 
One study has examined amifostine in the ovary against cyclophosphamide treatment 
in female mice and found a decrease in apoptosis markers such as TUNEL in 
cotreated ovaries when compared to cyclophophamide treatment alone. These mice 
were superovulated three weeks following treatment and reassuringly, the ovulation 
rates, fertilisation rates and embryo development up to the 4 cell stage were rescued 
in the co-treated group when compared to cyclophosphamide-only treatment 




The ability of antioxidants to act as chemoprotectants is currently garnering massive 
research attention. This is because chemotherapy agents such as doxorubicin and 
cyclophosphamide have shown to cause negative side effects such as cardiotoxicity, 
at least in part, through oxidative stress (Schimmel et al, 2004). For example, 
curcumin, a dietary supplement commonly known as tumeric, has been shown to 
reduce the negative side effects of cyclophosphamide on the lungs and kidney 
through its antioxidant and anti-inflammatory properties (Arafa, 2009; Venkatesan 
and Chandrakasan, 1995). Pretreatment with curcumin in males reduced sperm 
abnormalities following exposure to metronidazole (Singh et al, 2013). The ability of 
curcumin to protect the ovary against chemotherapy-induced damage is currently 
unclear.  
 
Mesna (sodium 2-mercaptothanesulfonate) is an antioxidant which has been used to 
prevent haemorrhagic cysts, an adverse side effect often associated with 
cyclophosphamide treatment (Freedman and Ehrlich, 1984). It has been used in one 
study in rats to determine if it can prevent cisplatin-induced ovarian damage and it 
was determined that cisplatin reduces the number of AMH positive follicles and 
serum AMH levels, an effect which was prevented by mesna cotreatment, indicating 
that mesna may protect small growing follicles (Yeh et al, 2008). However, this is 
the only endpoint utilised by this study and so the ability of mesna to protect the 
ovary needs to be explored further.  
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Selenium and selenium-containing compounds are also being explored as potential 
chemoprotectants. Co-treatment with selenium has been found to have a protective 
effect against cisplatin damage in the kidney of rats through a decrease in oxidative 
stress (Ognijanovic et al, 2012). Selenium nanoparticles have recently been used to 
protect the testis against cisplatin in a rat in vivo model, with a significant 
improvement in sperm quality, spermatogenesis and serum testosterone levels with 
cotreatment (Rezvanfar et al, 2013). The effectiveness of selenium as a 
chemoprotectant in the ovary has not yet been established, although it has recently 
been shown to be effective against ischemia-induced damage in rat ovaries (Bozkurt 
et al, 2012).  
 
6.1.2.5 Imatinib 
Imatinib mesylate was the first receptor tyrosine kinase inhibitor to pass clinical 
trials. It is now the primary treatment for chronic myeloid leukeumia due to its 
inhibition of BCR-ABL (Fausel, 2007; Pytel et al, 2009) and is also effective against 
gastrointestinal stromal tumours (Eisenberg and Pipas, 2012). It selectively inhibits 
the tyrosine kinases Abl, c-kit and PDGF receptor (Steeghs et al, 2006). A study 
which used imatinib alongside cisplatin found a significant reduction in follicle death 
when compared to cisplatin alone (Gonfloni 2009). A later study published 
conflicting results, finding no protective effect of imatinib (Kerr et al, 2012). The 
difference in these two studies can potentially be explained by the differing drug 
concentrations used. The later study also found imatinib to be detrimental to follicle 
health alone although other recent evidence shows no significant damaging effect to 
either follicles or spermatagonia when imatinib was used at serum levels (Schultheis 
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et al, 2012). The ability of imatinib to protect the ovary against other 
chemotherapeutic agents including doxorubicin is currently unknown.  
 
6.1.3 Aims 
The aim of the work detailed in this chapter was to determine if imatinib can protect 
the ovary from cisplatin or doxorubicin induced damage. 
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6.2 Materials and Methods 
6.2.1. Animals 
C57Bl6J females were used for all experiments detailed here as described in Chapter 
2. 
 
6.2.2 Imatinib stock solution 
Imatinib mesylate (Catalogue number CAYM13139, Cayman Chemicals through 
VWR International) was made up in sterile water (Sigma Aldrich, W1515) in a class 
II fume hood to the concentration of 3mg/ml. This was aliquoted out in 10µl 
quantities and frozen at -20ºC. Stocks were replaced every 6 months. 
 
6.2.3. Newborn ovary culture 
Newborn ovaries were dissected and cultured for 6 days as described in Chapter 2 
and 3. For the cultures containing imatinib mesylate, imatinib was added to produce 
a final concentration of 3µg/ml. This concentration was chosen due to preliminary 
dose test results (Sampurna Ghosh and Norah Spears, unpublished results). Cisplatin 
or doxorubicin exposure was limited to Day 2 of culture as in previous experiments, 
with imatinib present throughout Days 1-3 of culture to maximize any potential 
protective capacity of the drug. Cisplatin was added to produce a final concentration 
of 0.5µg/ml, while doxorubicin was added to produce a final concentration of 
0.05µg/ml. These mid-range doses were chosen as both induced the appearance of a 
similar percentage of unhealthy follicles (around 30%), without causing the extensive 
damage to the ovary found after exposure to the highest doses. After the 3 days of 
imatinib exposure, ovaries were moved into drug free culture for a further 3 days 
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(Days 4-6) with 50% of medium changed every other day. Seven ovaries were 
analysed in each treatment group which were taken from 4 independent cultures. 
6.2.4. P4 ovary culture 
P4 (Postnatal day 4) mouse ovaries were collected and dissected in the same way as 
the newborn ovary culture method. They were cultured in the same drug 
concentrations and conditions as described above. Five ovaries were analysed in each 
treatment group taken from 3 independent cultures.  
6.2.5. Histology 
Ovaries were collected at the end of culture and fixed in 10% buffered formalin 
solution. They were processed, embedded and sectioned as described in chapter 2. 
For the newborn ovaries, every 6
th
 section was stained with haematoxylin and eosin 
then analysed. For the P4 ovaries, every 12
th
 section was stained and analysed. This 
was because the P4 ovaries are larger than the newborn ovaries and so fewer sections 
were sampled. Follicles were analysed as described in Chapter 2. 
6.2.6. Statistical analysis. 
All data were analysed using Graphpad Prism. One way ANOVA determined if 
significant differences were present across treatments, followed by Bonferroni post 
hoc tests where ANOVA was statistically significant. Post hoc tests determined the 
effect of treatment relative to its control.
 161 
6.3 Results 
6.3.1. Newborn ovary cultures 





imatinib and cisplatin or  
imatinib and doxorubicin.  
Representative pictures of sections are shown in Fig 6.1. Total number of follicles 
counted in each treatment group is shown in Table 6.1. Imatinib treatment alone led 
to a small reduction in the percentage of unhealthy follicles when compared to 
control, although this was not significant (Fig 6.2A). There was a significant 
reduction in the percentage of follicles classified as unhealthy when imatinib was 
added in conjunction with cisplatin when compared to cisplatin treatment alone (Fig 
6.2A). Imatinib tended to lead to a reduction in the percentage of unhealthy follicles 
present during exposure to doxorubicin (9% reduction), but this was not significant. 
The total number of follicles present was significantly higher in imatinib treatment 
when compared to control (Fig 6.2B). The same trend occurred in the cisplatin- 
(p=0.38) and doxorubicin- (p=0.54) treated cultures but was not significant (Fig 
6.2B).  
 
The significant difference in follicle number found in the cultures of newborn ovaries 
could be due to either an increase in follicle survival and/or an effect on follicle 
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formation, as there is still some formation occurring in the first three days postnatal 
life (Pepling and Spradling, 2001). This also occurs in culture (Federica Lopes, 
unpublished results) and therefore during the window of imatinib exposure. The 
experiment was repeated by culturing 4 day old ovaries (P4) as follicle formation 
should have finished by this point. This would mean that any effect of imatinib found 
would have to be due to an effect on follicle survival. 
 
6.3.2. P4 cultures 
P4 ovaries were cultured as described above, representative pictures of which are 
shown in Fig 6.3. Total number of follicles counted in each treatment group is shown 
in Table 6.2. Imatinib treatment alone had no significant change on the percentage of 
follicles classified as unhealthy when compared to control (Fig. 6.4A). There was a 
reduction in the percentage of follicles classified as unhealthy when imatinib was 
added in conjunction with cisplatin when compared to cisplatin treatment alone, 
however this was not significant. There was no significant difference in the number 
of follicles present in the imatinib-treated group compared to the control, indicating 
that the difference in follicle number seen in the newborn ovary cultures is likely due 
to an effect on follicle formation (Fig 6.4B). 
 
Follicle distribution was also examined in both the newborn and P4 ovaries to see if 
there was any change (Fig 6.5). This is because tyrosine kinase signalling has been 
heavily implicated in primordial follicle activation (Nilsson et al, 2006; Nilsson and 
Skinner, 2004). For clarity, the doxorubicin and the doxorubicin and imatinib 
cotreatment groups are not shown (similar but not significant trends seen as shown in 
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Fig 6.5). Imatinib treatment alone caused a significant decrease in the percentage of 
follicles in newborn ovaries classified as primary compared to control. Imatinib co-
treatment with cisplatin caused a similar significant decrease in the percentage of 
follicles in newborn ovaries classified as primary compared to cisplatin treatment 
alone (Fig 6.5A). There was a corresponding but non-significant increase in the 
percentage of primordial follicles (PMF) in the imatinib group compared to control 
as well as in the imatinib cotreatment group when compared to cisplatin alone. There 
were no significant differences in the follicle distribution when examined in the P4 




Figure 6.1. Representative photomicrographs of haemotoxylin and eosin stained 
sections from newborn mouse ovaries treated with (A) control, (B) 3µg/ml imatinib, 
(C) 0.5µg/ml cisplatin, (D) cisplatin and imatinib co-treatment, (E) 0.05µg/ml 
doxorubicin and (F) doxorubicin and imatinib co-treatment. Scale bars represent 
25µm. Black arrows indicate pyknotic granulosa cells. 
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as unhealthy (%) 
Control 633 559 74 (11) 
3µg/ml imatinib 1525 1425 100 (7) 
0.5µg/ml cisplatin 891 639 252 (28) 
Cisplatin and imatinib 
co-treatment 
1237 1153 84 (7) 
0.05µg/ml doxorubicin 703 535 168 (24) 
Doxorubicin and 
imatinib co-treatment 
1032 864 168 (16) 
 
Table 6.1. Total number of follicles counted in newborn mouse ovaries cultured in 
the presence of absence of imatinib (n=7 ovaries in each treatment group) as well as 




























































































Fig 6.2. Control, cisplatin-treated (0.5g/ml) and doxorubicin-treated (0.05g/ml) 
cultured newborn mouse ovaries were cultured for six days in the presence or 
absence of imatinib. (A): Percentage of unhealthy follicles; (B): Total number of 
follicles. Bars denote mean±sem; n=7 for all groups, stars denote significant 
differences relative to control (**p<0.01). 
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Fig 6.3. Photomicrographs of haemotoxylin and eosin stained sections from P4 
mouse ovaries treated with (A) control, (B) 3µg/ml imatinib, (C) 0.5µg/ml cisplatin, 
(D) cisplatin and imatinib co-treatment, (E) 0.05µg/ml doxorubicin and (F) 
doxorubicin and imatinib co-treatment. Scale bars represent 50µm. Solid black line 
arrows indicate unhealthy oocytes. Dashed black line arrows indicate follicles with 
pyknotic granulosa cells. 
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 Total number of 
follicles counted 








Control 1095 1003 92 (8) 
3µg/ml imatinib 721 669 52 (7) 




415 319 96 (23) 
0.05µg/ml 
doxorubicin 




259 160 99 (38) 
 
Table 6.2. Total number of follicles counted in P4 mouse ovaries cultured in the 
presence of absence of imatinib (n=5 ovaries in each treatment group) as well as the 
















































































































Fig 6.4 Control, cisplatin-treated (0.5g/ml) and doxorubicin-treated (0.05g/ml) P4 
mouse ovaries were cultured for six days in the presence or absence of imatinib. (A): 
Percentage of unhealthy follicles; (B): Total number of follicles. Bars denote 
mean±sem; n=5 for all groups. 
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Fig 6.5. Follicle distribution in (A) newborn and (B) P4 murine ovaries comparing 
control medium to imatinib treatment and cisplatin treatment to cisplatin and 
imatinib cotreatment over six days of culture. Bars denote mean±sem, n=5, stars 














































































A: Culture of newborn ovaries
B: Culture of P4 ovaries
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6.4 Discussion 
Imatinib mesylate was used in conjunction with cisplatin and doxorubicin, to 
determine if imatinib could protect the ovary from chemotherapy-induced follicle 
damage. Results here indicate that imatinib is effective against cisplatin- but not 
doxorubicin-induced follicle loss. Imatinib also increases follicle number, which is 
likely due to an effect on follicle formation. 
 
6.4.1. Imatinib’s protective effect 
Recent work has suggested that the imatinib can reduce the toxic effect of cisplatin 
on the ovary through its inhibition of c-Abl (Gonfloni et al, 2009). Results here 
provide evidence of a reduction by imatinib of the adverse effect of cisplatin on 
follicle health. This protection is specific, with no significant protection found 
against doxorubicin-induced damage. The effect is clearer in the newborn ovaries 
than in the P4 ovaries, potentially due to a larger sample size in the newborn 
experiments. This is in contrast to (Kerr et al, 2012), who did not find a significant 
protective effect of imatinib against cisplatin-induced damage, possibly due to the 
difference in drug dosages between the two studies (10µM imatinib, 20µM cisplatin 
in (Kerr et al, 2012); 5.09µM imatinib and 1.67 µM cisplatin here). The fact that the 
adverse effects of cisplatin were inhibited by imatinib but not those of doxorubicin is 
further evidence that these drugs act on the ovary via different mechanisms. 
 
Imatinib is thought to provide ovarian protection against cisplatin damage by 
inhibiting c-Abl, a tyrosine kinase which promotes accumulation of p63, which in 
turn activates cell death following high levels of DNA damage (Gonfloni, 2010; 
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Gonfloni et al, 2009). c-Abl is ubiquitously expressed in both the nucleus and 
cytoplasm of cells and has recently been implicated to be an important component in 
the response to DNA damage (Shaul and Ben-Yehoyada, 2005). Inhibition of c-Abl 
prevents a subsequent accumulation of TAp63, high levels of which is essential for 
cisplatin-induced oocyte death (Kim et al, 2013). 
 
In addition, imatinib treatment alone did not have a deleterious effect on the ovary, in 
agreement with some recent work (Maiani et al, 2012; Schultheis et al, 2012) 
although in contrast to another study (Kerr et al, 2012). Kerr et al (2012) used a 
higher concentration of imatinib, which may explain the discrepancy (10µM 
compared to 1µM in Maiani et al (2012) and approximately 5µM here). The 
concentration used here is the same as that used by another very recent study (Kim et 
al, 2013), which also found this to be the most effective and non-damaging 
concentration to use. 
 
6.4.2. Imatinib and follicle formation 
Imatinib treatment alone in newborn ovaries caused a significant increase in the 
number of follicles present. There were two potential explanations for this. The first 
is that imatinib is a pro-survival factor for follicles in itself. The second is that it has 
a stimulatory effect on follicle formation. Follicle formation still continues in vivo 
through to postnatal day 3, which spans the drug exposure window (Pepling and 
Spradling, 2001; Smitz and Cortvrindt, 2002). Culture of P4 ovaries showed no 
significant increase in the number of follicles present indicating that it is likely that 
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imatinib caused the increase in follicle number in newborn ovaries through an effect 
on formation.  
 
Imatinib inhibits tyrosine kinases including Abl, c-kit and platelet derived growth 
factor receptor (PDGF-R) and so it is likely that the effect on follicle formation is 
mediated through one of these factors. Relatively little is known about the action of 
tyrosine kinase’s on follicle formation (Pepling, 2006). Addition of SCF (Stem Cell 
Factor also known at Kit ligand) to hamster ovaries accelerates follicle formation and 
conversely inhibition of SCF decreases follicle formation (Wang and Roy, 2004). As 
imatinib inhibits c-kit which is the receptor for SCF, the opposite effect to that seen 
here would be expected. A study which injected an antibody that selectively inhibited 
c-kit in mouse ovaries, found no evidence of an effect of c-kit on follicle formation 
(Yoshida et al, 1997). One way of establishing which tyrosine kinase is responsible 
for this effect on follicle formation would be to culture newborn ovaries with 
imatinib and each of these factors to see if the effect is reversed.  
 
6.4.3 Imatinib and follicle recruitment 
One of the major events that tyrosine kinases have been implicated in within the 
ovary is follicle activation. Kit ligand and PDGF have both shown to upregulate the 
transition from primordial follicle to primary (Nilsson et al, 2006; Nilsson and 
Skinner, 2004) and inhibition of c-kit has been demonstrated to prevent primordial 
follicle activation (Yoshida et al, 1997). There was a significant decrease in the 
percentage of primary follicles in cisplatin- and imatinib- treated newborn ovaries 
when compared to cisplatin- treatment alone. There is also a non- significant increase 
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in the number of primordial follicles in the cisplatin- and imatinib-treated group 
compared to cisplatin alone which could suggest a decrease in primordial follicle 
recruitment. In contrast, this effect is not seen in P4 ovaries. This could be due to the 
reduced n number which was used in the P4 experiment (carried out at the end of the 
PhD). Another potential explanation is that, although inhibition of c-kit has been 
demonstrated to be important for preventing primordial follicle development, the 
timing of inhibition is crucial, with a significant effect only seen within the first 5 
days post-partum (Yoshida et al, 1997).  
 
As cyclophosphamide has recently been demonstrated to cause increased recruitment 
of primordial follicles, and AS101 co-treatment leading to a concurrent decrease 
(Kalich-Philosph et al, 2013), whether imatinib could have an impact on follicle 
activation is worthy of consideration. Aside from examining the follicle distribution, 
there are other methods to evaluate this. Using immunohistochemical markers for 
members of the PI3K/PTEN/Akt pathway for example, which have recently been 
demonstrated as important for follicle activation (Jagarlamudi et al, 2009). 
 
6.4.4. Imatinib as a clinical treatment  
Imatinib is currently used to treat chronic myeloid leukemia as well as 
gastrointestinal stromal tumours (Fausel, 2007; Patel, 2013). Its use in conjunction 
with cisplatin has not been tested clinically and there is concern that it could affect 
the anti-tumour activity of cisplatin. This needs to be tested as this would limit 
imatinibs clinical use as a protective agent. 
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Another concern is that whilst imatinib may protect oocytes from cisplatin-induced 
loss, the oocytes may still be damaged. Instead of preventing cisplatin-induced DNA 
damage, imatinib may be preventing the ovary from clearing oocytes which are 
damaged by inhibiting the activation of cell death pathways. A recent study has 
shown that cisplatin-induced DNA damage in oocytes remains present following 
imatinib co-treatment (Kim et al, 2013). Whether or not oocytes have the ability to 
repair this kind of DNA damage remains to be seen but failure to do so could have 
downstream effects on fertilisation and embryo viability.  
 
6.4.5. Conclusion 
Imatinib mesylate confers specific ovarian protection against cisplatin- but not 
doxorubicin- induced early follicle damage. Imatinib also appears to have an effect 

















7.1. Summary of Results 
Chemotherapeutic agents lead to follicle loss and premature ovarian failure in 
premenopausal women; this thesis set out to determine specific mechanisms through 
which this occurs. Cisplatin is an alkylating-like chemotherapeutic agent which is 
considered to be moderately ovotoxic and is commonly used in premenopausal 
women for the treatment of ovarian, bladder and cervical cancer. Initial experiments 
compared the action of cisplatin in two different model species, the mouse and the 
cow. Both models demonstrated an increase in the percentage of unhealthy follicles 
following treatment and these follicles were classified as unhealthy due to poor 
oocyte morphology. Similar results were found in both species and due to the high 
number of primordial follicles in the mouse ovary, it was decided that subsequent 
experiments would be conducted using the mouse. 
The major aim of this project was to establish the ovarian cell type and follicle 
classes affected by chemotherapy agents. To do this, neonatal mouse ovaries were 
cultured in vitro, exposed to cisplatin and examined histologically. It was determined 
that cisplatin caused an increase in the number of follicles classified as unhealthy and 
total follicle loss. Follicles which were classified as unhealthy primarily had 
morphologically unhealthy oocytes, suggesting that cisplatin acts directly on the 
germ cell (Fig 7.1). This effect was initially seen in the primary follicles, indicating 
that the growing follicles may be more vulnerable to cisplatin-induced toxicity. The 
action of cisplatin was compared within the same experimental system to another 
chemotherapeutic drug, doxorubicin, which is also commonly used in premenopausal 
women for the treatment of breast cancer and Hodgkins lymphoma. The effect of 
doxorubicin was different, with follicles classified as unhealthy primarily due to the 
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presence of pyknotic granulosa cells. The follicle class affected was also more 
general than cisplatin (Fig 7.1). The difference in these two drugs indicates that these 
two drugs are likely to be affecting the ovary through different mechanisms. 
 
 
Fig 7.1. Summary of the different mechanisms through which cisplatin and 
doxorubicin cause follicle loss. Cisplatin acts primarily on the oocyte of the growing 
primary follicles, leading to oocyte death and follicle loss.  The follicle class affected 
is more general following doxorubicin exposure, with the site of action primarily the 
granulosa cells. The stromal cells and possibly the blood vessels are also damaged 
following doxorubicin treatment. It is unclear whether either drug directly causes 
primordial follicle loss or if there is an increase in primordial follicle activation after 
exposure (as indicated by the dashed lines). 
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The molecular mechanism through which these two drugs act was then investigated. 
Results indicate that the primary action of both of the drugs is apoptosis, with both 
causing an increase in the protein expression of cleaved PARP, a marker of 
apoptosis. The expression of cleaved PARP was examined by immunohistochemistry 
and indicted that doxorubicin causes apoptosis in the somatic cells, including the 
granulosa cells and the stroma. Further examination with cleaved caspase-3, another 
marker of apoptosis, demonstrated increased granulosa cell apoptosis following 
doxorubicin exposure. These results fit well with the histological data and altogether 
demonstrate that doxorubicin causes follicle damage through apoptosis of the 
somatic cells. The molecular results for cisplatin were less clear, although cleaved 
PARP protein levels significantly increase indicating cisplatin also causes apoptosis. 
A potential apoptosis pathway through which cisplatin and doxorubicin could act is 
described in Fig 7.2. 
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Fig. 7.2. Potential mechanism by which cisplatin and doxorubicin could cause cell 
death. Cisplatins initiation of apoptosis is dependent on cAbl, which is inhibited by 
imatinib. Doxorubicin may act through ATM, which provides an alternate route of 
activating TAp63, thereby explaining why imatinib co-treatment fails to rescue 
doxorubicin-induced damage. Through TAp63 activation (and potentially p53), both 
drugs cause apoptotic cell death. Dashed lines indicate potential activations, red 
arrows indicate cleavage activation. 
Protecting the ovary directly from damage induced by chemotherapeutic agents 
would be the ideal solution for preventing premature ovarian failure. Imatinib 
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mesylate is a chemotherapeutic agent which has been used in other laboratories as a 
protective treatment against cisplatin (Gonfloni et al, 2009; Kim et al, 2013), 
although its effectiveness is controversial. Results here demonstrate that imatinib has 
a protective effect against cisplatin treatment only, with no protection conferred 
against doxorubicin-induced toxicity (potential mechanism outlined in Fig 7.2). An 
interesting side effect of imatinib treatment was an increase in the total number of 
follicles present in the ovary. Further experiments culturing postnatal day-4 ovaries 
with imatinib removed this difference, indicating that this difference in follicle 
numbers in the newborn ovary cultures is almost certainly due to an effect on follicle 
formation. Imatinib is a tyrosine kinase inhibitor, and so this result highlights an 
importance for tyrosine kinase signalling in follicle formation, with, relatively little 
known about this at present.  
The results of this thesis overall demonstrate that two chemotherapeutic agents 
commonly used in premenopausal women, cisplatin and doxorubicin, have different 
effects on the mouse ovary. Cisplatin causes oocyte-specific damage, whilst 
doxorubicin in contrast causes apoptosis of the granulosa cells as well as increased 
stromal death. Furthermore, the putative protective agent imatinib has a protective 
effect against cisplatin but not doxorubicin. These results suggest that different 
chemotherapeutic agents will act through a variety of mechanisms on the ovary and 
so any protective treatment may have to be designed in a patient specific manner. 
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7.2. Future Work and Considerations 
7.2.1. Extending the mouse in vitro model 
The mouse ovary has proven to be an invaluable tool for research into human 
folliculogenesis. In terms of in vitro culture, the mouse is the best defined ovarian 
model available with live offspring produced from cultured primordial follicles 
(O'Brien et al, 2003). Other advantages of using the mouse as a model include high 
material availability and the ease at which the mouse can be genetically manipulated, 
allowing for the role of specific genes to be determined. The material available is 
also extremely similar as it is from mice which are the same age, from the same 
inbred line and raised in the same environmental conditions. However, when using 
the mouse as a model, it is important to consider species differences and limitations. 
The human ovary is larger, with much more stromal tissue than the mouse. In 
contrast to the monovular humans, the mouse is polyovular, with a short oestrous 
cycle and a short period of folliculogenesis. There are some issues with using human 
ovarian tissue experimentally, the first of which is limited tissue availability. Also, 
whilst there have been great advances in the culture of human ovarian tissue and 
follicles, this is still not a well-defined experimental model (Telfer and Zelinski, 
2013). Overall, I think that the work described here has produced a good model for 
the initial investigation of chemotherapy drug toxicology but that it has limitations. 
Therefore, some of this work should be repeated using human ovarian tissue, to 
ensure the removal of species differences in their response to chemotherapeutic 
agents. As tissue availability is such an issue, using another model species which is 
more closely related to humans than mice, is also an option for further extending this 
work. One possibility would be to use a non-human primate model. The non-human 
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primate ovary is the closest model to humans, as it has a protracted period of 
folliculogenesis in vivo as well as a long follicular stage in the menstrual cycle 
(Gougeon, 1996; Telfer and Zelinski, 2013).  
The work presented in this thesis was also solely in vitro. Whilst this is a valuable 
tool, as it allows for more specific evaluation of direct drug actions on the ovary, 
there are other factors to consider in patients. The amount of drug which an ovary is 
exposed to in vivo is difficult to extrapolate solely from serum dosages, as the blood 
supply to the ovary is more limited, and less well defined, than that of other organs. 
Interactions with the hypothalamic-pituitary axis are also a consideration as any 
detrimental effect of chemotherapy on the brain could have a downstream negative 
effect on the ovary. However, whilst hypopituitarism (leading to a decrease in 
gonadotrophin secretion) has been reported following cranial irradiation, it is not 
currently linked to chemotherapy treatment (Darzy and Shalet, 2005). The in vitro 
environment does mimic the in vivo one to an extent, as healthy offspring can be 
produced in the mouse following oocyte culture. However, it is only to an extent, and 
there are many factors and interactions in the ovary which are still unclear. The 
advantage of using the in vitro neonatal culture system used in this thesis is that the 
follicle population present is fairly uniform and so more specific effects of drug 
treatment can be established. It is difficult to expose these ovaries in vivo due to the 
general toxicity of chemotherapy agents on neonatal mice and so in vivo experiments 
would have to utilise adult females. Using adult females as an in vivo model is useful 
for determine the effect of chemotherapy on long term fertility but less so for 
determining specific mechanisms of drug action due to the heterogeneity of the 
follicle population in these mice. Therefore, a good extension to the work in this 
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thesis, which focused on more specific drug actions, would be to confirm the long 
term effect on fertility of chemotherapeutic agents in vivo using adult mice.   
Another factor which this model has not yet taken into account is drug combinations. 
It is rare that a patient is ever exposed to a single drug treatment, instead most agents 
are used as combination therapy. Utilising commonly used combinations for 
premenopausal women such as CMF (cyclophosphamide, methotrexate and 5-
fluouracil) is another logical next step, as this will be more reflective of the clinical 
conditions. As cisplatin and doxorubicin here targeted different cell types in the 
ovary, their use in combination could potentially have more than additive effects. 
This is now being explored by others in the laboratory.      
7.2.2 Protective treatments 
The use of protective agents which could directly shield the ovary from the damaging 
effects of chemotherapy agents is gathering increasing research attention. Imatinib is 
perhaps now the most studied and appears, at least in some studies including this 
one, to be effective against cisplatin administration (Gonfloni et al, 2009; Kim et al 
2013). With any putative protective treatment there are a number of clinical concerns 
which will need to be addressed. A major concern with imatinib, and potentially 
some of the other putative treatments, is that rather than preventing the damage that 
chemotherapy agents are inducing in oocytes, it is instead preventing them from 
dying from this damage. This would mean that, unless the oocyte is able to repair this 
damage itself, any detrimental effects would persist and would potentially be 
conferred to the embryo and hence the offspring. This is obviously far from ideal and 
so another approach would be to try and prevent the drug causing damage in the first 
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place. Such approaches could involve preventing cellular uptake (presumably 
difficult as cisplatin and doxorubicin appear to enter the cell through passive 
diffusion) or preventing the drug from entering the nucleus and causing DNA 
damage.  
There are of course concerns that the protective agent would negatively interact with 
the anti-cancer ability of the chemotherapy drugs, something which would absolutely 
need to be established before their clinical use. Targeting the protective agent to the 
ovary would be one way of hopefully minimising this eventuality. So far the majority 
of studies investigating protective agents have done so either in vitro or, if in vivo, 
using injection/IV and thus serum exposure. One approach to more directly target the 
ovary would be to use an implant located adjacent to the ovary, an approach which 
has been successfully tried in one study in primates (Zelinski et al, 2011). 
Nanoparticles are a method which is being investigated to target chemotherapy to 
tumour sites and could potentially therefore be utilised to localise a protective agent 
to the ovary. One way to use these is to load magnetic nanoparticles with a drug, 
which can be localised to a specific area of the body on application of an external 
magnetic field (Deok Kong et al, 2012; Lee et al, 2013).  
7.2.3. Mutagenesis, epigenetics and transgenerational changes 
Cisplatin and doxorubicin have both been shown to cause an increase in the number 
of unhealthy follicles and follicle loss (Chapter 3). However, at doses equivalent to 
those seen in patients, there are still follicles remaining following exposure to either 
drug which look morphologically healthy. It is important to consider if the oocytes of 
primordial follicles which remain after drug treatment are healthy and capable of 
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correct embryonic development, as these are the oocytes which represent the germ 
cell reserve in patients. It is generally unlikely for patients to opt to become pregnant 
during or immediately after treatment, and therefore it is this follicle reserve which is 
the most likely to produce offspring.  
 
Chemotherapeutic agents are mutagenic to somatic cells, causing abnormalities 
including chromosomal breaks, gene mutations and aneuploidy (Degrassi et al, 
2004). This is highlighted by the incidence of secondary malignancies in patients 
following treatment (Borgmann et al, 2008). There is concern that these agents could 
also have similar effects on the germ cells which could influence fertilisation, 
viability of pregnancies and problems with the offspring including malformations. 
There is also the possibility that these agents compromise the cytoplasmic 
competence of the oocyte as well as the DNA. Most of the information on germ cell 
mutagenesis is derived from animal studies, the majority of which have been 
conducted using males rather than females. This is because when a female is treated 
with a chemical agent, any embryonic lethality could be due to problems induced on 
the uterus or other aspects of their reproductive physiology, rather than specifically 
mutagenesis on oocytes. The majority of studies in humans reassuringly show no 
increase in foetal abnormalities in the offspring of parents who underwent 
chemotherapy treatment (Sanders et al, 1996; Signorello et al, 2012; Winther et al, 
2012), although chromosomal damage and aneuploidy has been detected in the 
sperm of male survivors (Brandriff et al, 1994; Genesca et al, 1990). DNA-damaged 
spermatozoa can however still fertilize oocytes and achieve full-term pregnancies 
(Ahmadi and Ng, 1999; Gandini et al, 2004). In general, the main limitation of the 
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human studies is that there is little information about the type or dosage of treatment 
which the patient received (Winther and Olsen, 2012). Current studies also 
concentrate on major abnormalities, meaning that more subtle changes which could 
be occurring, such as altered methylation patterns or changes in transcription, are not 
being detected.  
 
Cyclophosphamide and other alkylating agents are the most researched drug class in 
terms of their effect on fertility. An increase in abortions and foetal malformations 
was found in female mice which were treated with cyclophosphamide and 
subsequently mated, with the malformation rate 10 fold higher in treated groups 
when compared to the control (Meirow et al, 2001). A third of conceptions which 
were from oocytes exposed at the earliest stages of growth were malformed (Meirow 
et al, 2001). In males, cyclophosphamide alters the sperms chromatin structure as 
well as the sperm head protein composition (Codrington et al, 2007). Mating of 
cyclophosphamide-treated male rats to females leads to an increase in pre- and post- 
implantation embryo loss and an increase in malformed and growth retarded foetuses 
(Trasler et al, 1986). 
 
7.2.3.1 Cisplatin and doxorubicin as mutagens 
There is surprisingly little information on the capacity of cisplatin or doxorubicin to 
act as germ cell mutagens. Cisplatin causes dominant lethal mutations in female 
mice, resulting in increased early embryonic mortality (Witt and Bishop, 1996). 
Another study examining the effect of cisplatin on mature MII oocytes in vivo found 
treatment lead to a marked increase in aneuploidy (Higson et al, 1992). In male mice, 
 188 
cisplatin induces chromosomal aberrations in spermatocytes (Choudhury et al, 2000). 
Male rats treated with subclinical doses of cisplatin and subsequently mated had an 
increase in pre- and post-implantation embryo losses and a significant number of 
malformed or growth retarded foetuses (Seethalakshmi et al, 1992). Doxorubicin has 
been identified as a female specific inducer of dominant lethal mutations, particularly 
in preovulatory oocytes in female mice (Arnon et al, 2001). A small but significant 
increase in chromosome translocations was detected in spermatogonial stem cells in 
mice following doxorubicin exposure (Meistrich et al, 1990). 
  
7.2.3.2 Protective treatments and mutagenesis 
The ability of imatinib to protect the follicle population against cisplatin induced 
damage has been previously discussed (Chapter 6). Whilst there is evidence here and 
in two other studies that imatinib may help alleviate cisplatin-induced toxicity, there 
is no evidence presently on whether the germ cells which appear to have been 
protected are actually healthy (Gonfloni et al, 2009; Kim et al, 2013). Exploring the 
developmental competence of oocytes which have been protected by agents such as 
imatinib will be a useful tool, to determine if these treatments are truly conferring a 
protective effect.  
 
7.2.3.3. Epigenetic modifications 
The ability of chemotherapeutic agents and other drugs to create epigenetic 
modifications is not well described, especially in the germ line. It is logical to expect 
that, as chemotherapy drugs cause DNA damage and alterations in DNA structure, 
this could have an impact on epigenetic modifications and gene imprinting. 
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Curcumin, a dietary agent which is a putative protective agent against 
cyclophosphamide-induced POF, is an inhibitor of DNA methyltransferase leading to 
DNA hypomethylation (Teiten et al, 2013). Sorafenib, another tyrosine kinase 
inhibitor primarily used for kidney cancers, also produces anti-tumour effects 
through epigenetic changes including histone modifications (Zhang et al, 2013). In 
terms of germ cells, cyclophosphamide exposure in males which were subsequently 
mated leads to disturbed methylation and changes in chromatin structure in the 
zygote (Barton et al, 2005). If changes such as these are not repaired, this could 
result in aberrant embryogenesis. The ability of chemotherapeutic agents to modify 
female germ cell epigenetics is currently unclear and therefore a huge potential 
research area.   
7.2.3.4. Transgenerational effects 
Transgenerational effects are also a concern, whether they are attributable to DNA 
damage, cytoplasmic changes or epigenetic modifications. Cyclophosphamide 
treatment in male rats leads to cerebral changes and behavioural deficits in the first 
and second generation of progeny as well as increased postnatal mortality and 
learning deficits in the third generation (Auroux et al, 1990; Dulioust et al, 1989). 
After paternal exposure to cyclophosphamide, mitomycin C or procabazine in mice, 
genomic instability is elevated in the bone marrow and germ line of progeny (Glen 
and Dubrova, 2012). Transgenerational effects of doxorubicin have been reported 
following exposure in female mice, with an increase in neonatal death, physical 
malformations and chromosomal abnormalities in the fourth and sixth generation 
(Kujjo et al, 2011) 
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7.2.3.5. Proposed experimental model 
In human patients, it is the primordial follicle reserve which is the most important 
consideration for mutagenesis experiments as it is these follicles that will provide the 
germ cells for possible offspring. Exposing primordial follicles to chemotherapy 
agents and then later investigating their developmental competence would therefore 
be the most applicable model to determine if chemotherapy has a mutagenic effect on 
germ cells. Within the experimental design of previous chapters, primordial follicles 
in neonatal mouse ovaries were exposed in vitro to chemotherapeutic agents and in 
that culture, they develop to the primary/secondary stage. Developmental 
competence can only be explored if mature, fertilisable oocytes could be obtained 
from these primary/secondary follicles. One way of achieving this would be to use 
the culture system designed by Eppig and colleagues in which oocyte-granulosa cell 
complexes are obtained from cultured whole neonatal ovaries and then matured using 
a different culture paradigm. Maturing primary follicles to fertilisable oocytes in the 
mouse is an experimental technique which has been established in other laboratories 
(Eppig and O'Brien, 1996; O'Brien et al., 2003) but not in our own. Preliminary 
experiments using this technique have been unsuccessful in our laboratory and so a 
new experimental approach is being undertaken. Grafting of newborn ovaries into 
adult mice is being explored in our laboratory as a potential alternative approach for 
maturing primordial follicles following exposure to chemotherapeutic drugs. 
Grafting of ovarian material has proven to be a useful tool, with ovarian material 
from various species being xenografted into immunodeficient mice (Gosden et al., 
1994; Senbon et al., 2005) as well as transplantation of mouse ovarian material back 
into mice, and its subsequent successful development (Li et al., 2010). Autografting 
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of cryopreserved ovarian tissue in women is used clinically and live births have been 
reported (Donnez et al., 2012). The location of grafting is a consideration, with the 
bursal cavity, the kidney capsule and subcutaneous sites all described (Bols et al., 
2010). The location of the grafted material may directly influence how many oocytes 
are recovered as well as their quality (Yang et al., 2006). The kidney capsule is an 
attractive prospect as it  provides a good blood supply (Gosden et al., 1994) and there 
is evidence that more oocytes are recovered from grafts under the kidney capsule 
when compared to subcutaneous locations (Hernandez-Fonseca et al., 2004). 
For oocyte recovery, animals will be treated with hCG eight hours before collection 
of the ovaries (Li et al., 2010). Large follicles will then be punctured and the oocyte-
cumulus complexes collected for IVF. Utilising embryo transfer, blastocysts could be 
used to produce offspring which could be monitored for epigenetic modifications and 
other abnormalities. Subsequent mating of these animals could provide information 
on any transgenerational changes caused by the chemotherapeutic agents. 
A very recent study utilised a similar technique in order to explore if imatinib could 
protect oocytes from cisplatin induced damage and exposed neonatal ovaries before 
grafting them under the kidney capsule (Kim et al, 2013). However, this study did 
not go as far as the experiment proposed here and attempt to fertilise the oocytes, and 
so fully examine their competence. An experimental system such as the one 
described here could potentially be a useful tool to examine the effects of various 
chemotherapeutic agents on the competence of oocytes when exposed at the 
primordial stage, as well as determining the ability of protective treatments to 
successfully prevent any damage. In my opinion, this is the most important next step 
following the work undertaken in this PhD thesis.   
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7.2.4. Targeted chemotherapy treatments and personalized medicine 
New drug treatments which are more effective anti-cancer agents than those 
described in this thesis and which are better tolerated by patients are in high demand 
and the subject of much research. A more personalized approach to cancer treatment 
is becoming a reality, with the sequencing of various cancer genomes meaning that 
new drugs and regimes can be tailored specifically to the patient (Yarden et al, 
2013). As our knowledge of cancer biology increases, drugs that specifically exploit 
the differences and vulnerabilities of tumour cells can be developed. The 
identification of novel mutations and biochemical changes in tumour cells also opens 
up the possibility of directly localising drug action to the cancer itself. As discussed 
above, emerging technologies such as nanoparticles could also aid in the more 
specific localisation of a chemotherapy agent to a tumour site. The model which has 
been used here could remain a useful tool, in investigating the adverse effects of new 
drug treatments on female fertility as they become available. However, it could be 
that with more targeted treatment, adverse side effects such as POF will not be such a 
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The effect of cisplatin on the ovary. 
Stephanie Morgan, Richard Anderson and Norah Spears. 
Centre for Integrative Physiology and *Centre for Reproductive Health, University 
of Edinburgh 
Presented at Fertility, 2010. 
Treatment of premenopausal women with chemotherapeutic agents can lead to germ 
cell loss and hence premature ovarian failure, but the exact mechanism by which this 
loss occurs is not well understood. Cisplatin is a DNA cross-linking agent commonly 
used in the treatment of lymphomas, sarcomas and germ cell cancers. Cisplatin was 
administered to several in vitro ovary culture models to identify the precise sequence 
of events which ultimately lead to germ cell loss. The earliest stages of follicle 
development (primordial, transitional and primary) were examined using newborn 
mouse ovaries cultured in vitro. After 24 hours in the presence of cisplatin, newborn 
ovaries exhibited a significant increase in protein expression of the apoptosis marker 
cleaved PARP, detected by Western blotting. After 6 days in the presence of varying 
concentrations of cisplatin, histological examination showed follicles with oocyte-
specific damage: furthermore only primary stage follicles were affected (up to 45% 
compared with 7% in controls). Bovine ovaries were also cultured since they, like 
human ovaries, have dense stromal ovarian tissue. Bovine cortical strips cultured in 
vitro for 6 days with varying doses of cisplatin showed oocyte-specific cell death, 
similar to the murine data. We have found using a variety of other drugs that other 
chemotherapeutic agents (doxorubicin, docetaxel) initially damage granulosa cells, 
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with germ cell loss a downstream consequence; the results here indicate that in 
contrast, cisplatin selectively acts on the oocyte. 
 
 v 
The effect of cisplatin and doxorubicin on the ovary 
Stephanie Morgan, *Richard Anderson and Norah Spears 
Centre for Integrative Physiology and *Centre for Reproductive Health, University 
of Edinburgh 
Presented at Reproductive Function and Dysfunction, 2011. 
Chemotherapy treatments cause germ cell loss, and hence premature ovarian failure, 
in premenopausal women, but the precise mechanism by which this occurs is 
unclear. Cisplatin is a DNA cross-linking agent commonly used in the treatment of 
lung, ovarian and bladder cancers, while the anthracycline doxorubicin is commonly 
used to treat breast cancer and leukaemia. Here, cisplatin and doxorubicin were 
administered to an in vitro ovary culture model to identify the precise sequence of 
events occurring in the ovary which ultimately leads to germ cell loss. The earliest 
stages of follicle development (primordial, transitional and primary) were examined 
using newborn mouse ovaries cultured in vitro.  Ovaries were cultured for 6 days in 
total and exposed to either drug in varying doses during Day 2 of culture. In 
cisplatin-treated ovaries, histological examination showed follicles with oocyte-
specific damage: furthermore only primary stage follicles were affected (up to 98% 
compared with 13% in controls, p<0.001). In contrast, doxorubicin treatment caused 
damage specifically to granulosa cells and affected all stages of follicle present. 
Apoptosis in tissue was examined by determining expression of cleaved PARP by 
Western blotting, with tissue collected at the end of Day 2 of culture. Both drug 
treatments significantly increased expression of cleaved PARP but the effect of 
cisplatin was over 4-fold greater. These data indicate that cisplatin and doxorubicin 
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cause follicle loss through different mechanisms, suggesting that treatment of 
chemotherapy patients to try to prevent ovarian damage may need to be targeted to 
the drug(s) involved. 
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Cisplatin and Doxorubicin cause ovarian cell death through apoptosis not 
autophagy. 
Stephanie Morgan, Richard A. Anderson and Norah Spears. 
Centre for Integrative Physiology and *Centre for Reproductive Health, University 
of Edinburgh 
Presented at the Society for the Study of Reproduction meeting, 2013  
Chemotherapy treatment in premenopausal women has been linked to follicle loss 
and premature ovarian failure but the precise mechanisms of this are unclear. 
Cisplatin is a DNA cross-linking agent commonly used in the treatment of ovarian, 
lung and bladder cancers, while the anthracycline doxorubicin is commonly used to 
treat leukaemia and breast cancer. The aim of this work was to compare the action of 
these two drugs in an in vitro ovary culture model and to establish the molecular 
mechanism underlying cell damage. Newborn mouse ovaries were cultured for 24 
hours before being exposed in vitro to 5µg/ml cisplatin or 0.2µg/ml doxorubicin for a 
further 24 hours. Quantitative PCR analysis of these ovaries showed no expression of 
autophagy genes Atg7, Atg13 or Ulk1. In addition, expression of Beclin1 was reduced 
with both drug treatments (4-fold reduction for cisplatin when compared to control, 
p= 0.003, 2 fold reduction for doxorubicin, p=0.015, n=3). To provide further 
evidence that apoptosis rather than autophagy was the predominant cell death 
pathway, immunohistochemical analysis was carried out for two apoptosis markers: 
cleaved PARP and cleaved caspase 3. The drug concentration was reduced for this 
analysis to 0.5µg/ml cisplatin and 0.05µg/ml doxorubicin, as at the higher doses, the 




 staining positive for cleaved PARP following doxorubicin treatment 
(Mean=332+57 for doxorubicin compared to 173+20 for control, p=0.005, n=6). 
Analysis of the affected cell types showed that doxorubicin caused a significant 
increase in the number of stromal (Mean= 273+60 compared to 118+19 in control, 
p=0.009) and granulosa cells (Mean= 30+6 compared to 11+3 in control, p=0.011) 
staining positive, but there was no change in the number of oocytes expressing 
cleaved PARP indicating that doxorubicin causes follicle loss primarily through 
apoptosis of ovarian somatic cells. The expression of cleaved caspase 3 also revealed 
a significantly higher number of granulosa cells/mm
2
 staining positive following 
treatment with doxorubicin (Mean= 65+20, compared to 8+4 in control, p=0.05, n=5) 
but as with cleaved PARP there was no change in oocyte expression. Cisplatin 
caused a non-significant increase in somatic cells/mm
2
 staining positive for cleaved 
PARP (Mean= 238+23 compared to 173+20 in control, p=0.063, n=6) and there was 
no significant increase in the number of oocytes staining positive for either cleaved 
PARP (Mean= 104+23 compared to 73+8 in control, p=0.271) or cleaved caspase 3 
(Mean=55+11 compared to 32+7 in control, p=0.246) following cisplatin treatment, 
although there was a trend towards an increase for both markers. This work shows 
that doxorubicin causes ovarian cell damage through apoptosis rather than 
autophagy, and that the primary site of cell damage is the somatic cells, rather than 
the oocyte. The locus and mechanism of follicle loss with cisplatin is unclear from 
these data, but it appears to be through different pathways to doxorubicin. 
 
 
